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Abstract 
 Constitutive activation of NF-κB is a common feature of many human 
tumors. In fact, it predisposes normal cells to neoplastic transformation. Mainly 
by inhibiting apoptosis, NF-κB overturns the balance between proliferation and 
apoptosis towards malignant growth. Therefore, targeting NF-κB for cancer 
therapy is one of the new challenges of modern tumor biology. 
Since very little was known about the role of NF-κB in thyroid 
oncogenesis, we focused on the model of thyroid carcinomas. We showed that 
NF-κB is strongly activated in human thyroid neoplasias, particularly in 
anaplastic carcinomas. To investigate the oncogenic activity of NF-κB in 
thyroid, we analyzed its activity in thyroid transformed cell lines, recapitulating 
different steps in thyroid oncogenesis. In this experimental system we showed 
a constitutive NF-κB activity, even though at different levels, and a different 
resistance to drug-induced apoptosis, which directly correlated with levels of 
NF-κB activation. The stable expression of a super-repressor form of IκBα 
(IκBαM), blocking NF-κB activity, in the human  anaplastic thyroid carcinoma 
cell line FRO (FRO-IκBαM), led to an enhanced sensitivity to drug-induced 
apoptosis. Moreover, while FRO parental cells (FRO-Neo) were able to form 
colonies in soft-agar and to induce tumor growth in nude mice, FRO-IκBαM 
cells lost both these properties. To obtain insights into mechanisms sustaining 
the anti-apoptotic effect of NF-κB, we analyzed JNK activity in FRO and 
FRO-IκBαM clones. FRO cells showed a barely detectable JNK activity, 
whereas JNK activation was completely restored in FRO-IκBαM clones. In 
addition, FRO-IκBαM clones treated with a specific JNK inhibitor, SP600125, 
rescued their resistance to apoptosis induced by chemotherapeutic agents. 
These results provide evidence that NF-κB plays a pivotal role in thyroid 
carcinogenesis, maintaining the transformed phenotype and inducing resistance 
to drug-induced apoptosis, at least partially through the inhibition of JNK. 
Because of the importance of sustained activation of NF-κB in 
oncogenesis, we then focused our efforts on the molecular mechanisms down-
regulating NF-κB activation. Classical activation of NF-κB is dependent on the 
phosphorylation of the inhibitory sub-unit IκBα by a multimeric-, high 
molecular weight-complex, called IκB kinase (IKK)-complex. This is 
composed of two catalytic sub-units, IKKα and IKKβ , and a regulatory sub-
unit, NEMO/IKKγ, that is essential for activation of IKKs and NF-κB. The 
mechanisms regulating activation of the IKK-complex are not fully understood 
so far. In the last few years, we isolated novel interactors of the IKK-complex, 
by using a combined genetic and biochemical approach. Here, we studied the 
mechanism of NF-κB inhibition by ABIN-1 (A20 Binding Inhibitor of NF-
κB), a known interactor of the NF-κB inhibitor A20. We found that both 
ABIN-1 and A20 inhibit NF-κB at level of the IKK-complex and that A20 
blocks activation of NF-κB by de-ubiquitinating NEMO/IKKγ. Importantly, by 
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using RNA-interference technology, we showed that ABIN-1 and A20 co-
operate in inhibiting NF-κB at level of NEMO/IKKγ. Altogether these data 
indicate that ABIN-1 physically links A20 to NEMO/IKKγ and promotes the 
A20-mediated de-ubiquitination of NEMO/IKKγ, thus resulting in inhibition of 
NF-κB. 
The strong constitutive NF-κB activity in anaplastic thyroid carcinomas, 
besides to represent a novel diagnostic tool, makes it a molecular target for 
developing novel therapeutic strategies which, interfering with NF-κB activity, 
could potentiate the effects of well-established chemotherapeutic agents. In this 
scenario, ABIN-1 and A20 represent examples of signal-specific mediators of 
NF-κB activation, which could be targeted for therapeutic strategies intended 
to interfere with sustained activation of NF-κB in tumor progression. 
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Background 
I – Introduction 
 In addition to marshalling immunity and inflammation, NF-κB controls 
cell survival. Activation of NF-κB antagonizes apoptosis or programmed cell 
death (PCD) and the anti-apoptotic activity of NF-κB plays a pivotal role in 
various aspects of oncogenesis, including transformation, proliferation, 
invasiveness, metastasis formation and angiogenesis (Kucharczak et al. 2003). 
Actually, NF-κB activity has been found altered in many types of human 
tumors from either haematological or solid origin, such as melanomas (Amiri 
and Richmond 2005), and breast (Kalaitzidis and Gilmore 2005), prostate 
(Sweeney et al. 2004), ovarian (Mabuchi et al. 2004), pancreatic (Sclabas et al. 
2005), colon (Kojima et al. 2004) and thyroid carcinomas (Visconti et al. 
1997). The role of NF-κB in solid tumors has been well documented in several 
studies performed on primary tumors and neoplastic cell lines derived from 
different human tissues (Pacifico and Leonardi 2006). These studies show that 
the inhibition of constitutive NF-κB activity blocks the oncogenic potential of 
neoplastic cells by sensitizing tumor cells to chemotherapeutic drug-induced 
apoptosis, decreasing the highly proliferative rate which characterizes 
transformed cells, and inhibiting tissue invasiveness and metastatic potential of 
highly malignant cells (Karin et al. 2002). 
Genes encoding NF-κB-family members are frequently rearranged, 
amplified or mutated in human cancers, and most oncogene products are 
capable of activating NF-κB. These alterations deregulate the ability of NF-κB 
to control both expression and function of a wide spectrum of genes involved 
in the control of cell cycle, apoptosis, cell growth, and tissue invasiveness. 
Further, since it is generally accepted that chronic inflammation contributes to 
the genesis of many solid tumors, it has been recently shown that activation of 
NF-κB is a crucial mediator of inflammation-induced tumor growth and 
progression in animal models of inflammation-associated cancer (Greten et al. 
2004, Pikarsky et al. 2004). Thus, all these evidences show that the control of 
apoptosis by NF-κB is central to oncogenesis. 
II – The family of NF-κB transcription factors 
NF-κB is an ubiquitously expressed family of transcription factors that 
control the expression of numerous genes involved in immune and 
inflammatory responses. NF-κB also regulates the expression of genes outside 
of the immune system and, hence, can influence multiple aspects of normal and 
disease physiology. In mammals, the NF-κB family consists of five members: 
p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). NF-
κB1 and NF-κB2 are synthesized as large precursors, p105 and p100, that are 
post-translationally processed to the DNA-binding sub-units p50 and p52, 
respectively. All NF-κB proteins carry a N-terminus conserved 300-amino acid 
Rel-homology domain (RHD) that contains a nuclear localization sequence 
(NLS) and is responsible for dimerization, interaction with IκBs, and binding 
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to DNA. Although p50 and p52 lack a transcription activation domain, such a 
domain is present in RelA, RelB and c-Rel. The NF-κB proteins form 
numerous homo- and heterodimers that are associated with specific biological 
responses, depending on their ability to regulate target gene transcription 
differentially. For instance, p50 and p52 homodimers function as repressors, 
whereas dimers that contain RelA or c-Rel are trancriptional activators. RelB 
can be both an activator and a repressor, forming only hetero-dimers with 
either p50 or p52 (Hayden and Ghosh 2004; Fig.1). 
In most cell types, NF-κB homo- or heterodimers are retained in the 
cytoplasm by IκBs, which are a specific family of inhibitors binding to the 
RHD and interfering with NF-κB NLS function. These proteins contain 6–7 
ankyrin repeats that mediate binding to the RHD. Binding of NF-κB to IκB 
results in costant shuttling of IκB:NF-κB complexes between the nucleus and 
the cytoplasm, although the steady-state localization of these complexes is in 
the cytosol, thereby maintaining NF-κB in an inactive state. The dynamic 
balance between cytosolic and nuclear localization is altered upon IκB 
degradation, because it exposes the previously masked NLS, resulting in 
predominantly nuclear localization of NF-κB (Hayden and Ghosh 2004; Fig.1). 
III – The classical pathway of NF-κB activation 
Two major signaling pathways lead to translocation of NF-κB dimers 
from the cytoplasm to the nucleus: the classical and the alternative pathways. It 
is well established that the former pathway is essential for innate immunity, 
whereas the latter has been uncovered more recently and has been shown to 
play a crucial role in lymphoid organ development and adaptive immunity 
(Bonizzi and Karin 2004). 
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In the classical 
pathway, proinflammatory 
cytokines, such as tumor 
necrosis factor α (TNF-α) and 
pathogen-associated molecular 
patterns (PAMPs), working 
through different receptors 
belonging to the TNF receptor 
(TNFR) and Toll-like receptor 
(TLR)-interleukin-1 (IL-1) 
receptor (IL-1R) 
superfamilies, cause activation 
of the IκB kinase (IKK) 
complex. In cells the IKK 
activity can be purified as a 
700–900-kDa complex, and 
has been shown to contain two 
kinase subunits, IKKα (IKK1) 
and IKKβ (IKK2), and a 
regulatory subunit, NEMO 
(NF-κB essential modifier) or 
IKKγ (Ghosh and Karin 2002). 
The activated IKK complex, 
acting predominantly through 
IKKβ in a NEMO/IKKγ-
dependent manner, catalyzes the phosphorylation of the inhibitory sub-unit IκB 
on specific serine residues (e.g. Ser32 and 36 of IκBα). Phosphorylated IκBs 
are recognized by the ubiquitin ligase machinery, leading to their lysine (K)-
48-linked polyubiquitination (e.g. Lys21 and 22 of IκBα) and subsequent 
degradation by the proteasome. The freed NF-κB dimers (in this pathway most 
commonly the p50-RelA dimer) translocate to the nucleus, where they bind to 
specific sequences in the promoter or enhancer regions of target genes and 
activate transcription. NF-κB can then be down-regulated through a feedback 
pathway whereby newly synthesized IκBs proteins bind to nuclear NF-κB and 
export it out to the cytosol (Karin and Ben-Neriah 2000; Fig.2).  
IV – Ubiquitination and NF-κB signaling pathway 
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Figure 2. The classical pathway of NF-kB activation.
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Ubiquitin conjugation 
has been most prominently 
associated with protein 
degradation through a 
proteasome-dependent 
pathway, but it is becoming 
increasingly evident that 
ubiquitination plays a key 
role in the signal transduction 
pathway leading to activation 
of NF-κB (Chen 2005, Liu et 
al. 2005). Recent reports 
have shown that 
ubiquitination is crucial for 
activation of the IKK 
complex. Studies of TNFR 
and IL-1R signaling led to 
the discovery that TRAFs, a 
family of proteins 
characterized by the presence 
of a RING-finger domain and 
coiled-coil domain, are 
important mediators of signal transduction through TNFRs (Hsu et al. 1996). 
One TRAF-family member, TRAF6, promotes ubiquitin conjugation to itself 
and NEMO/IKKγ through its RING-finger domain. However, instead of 
inducing conventional K-48-linked polyubiquitination, TRAF6 induces the 
formation of a K-63-linked polyubiquitin chain (Sun et al. 2004). Importantly, 
K-63-linked polyubiquitination of NEMO/IKKγ does not lead to its 
degradation through a proteasome dependent pathway, rather it results in 
activation of the IKK complex, and the subsequent phosphorylation and 
degradation of IκB (Zhou et al. 2004). Thus, K-63-linked ubiquitination of 
NEMO/IKKγ is an important step for the activation of IKKs and NF-κB 
following various receptors, such as TCR, TNFR, IL-1R and TLR (Boone et al. 
2004, Tang et al. 2003, Zhou et al. 2004; Fig.3).  
The key feature of the ubiquitination system is that ubiquitin can be 
rapidly removed by deubiquitinating enzymes (DUBs), which serve to switch 
off the ubiquitin signal. Notably, ubiquitination shares this feature with protein 
phosphorylation: both modifications are recognized by specific protein 
domains, providing a mechanism for translation of the ubiquitin- or phospho-
specific signal to down-stream effectors (Hicke et al. 2005). Two DUBs have 
recently been shown to be important in suppressing NF-κB activation at a step 
upstream of IKK. One of these DUBs is the cylindromatosis tumor suppressor 
CYLD, which inhibits IKK and NF-κB activation by cleaving K-63-linked 
polyubiquitin chains on several proteins, such as TRAF2, TRAF6 and 
NEMO/IKKγ (Kovalenko et al. 2003). Another DUB that acts in the NF-κB 
Figure 3. K-63-linked ubiquitination regulates NF-κB 
activation (Liu et al. 2005).
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pathway is A20, an NF-κB-induced protein that inhibits NF-κB in a negative-
feedback loop. The central role played by A20 in terminating NF-κB activation 
is demonstrated by the evidence that A20-/- mice develop severe inflammation 
and cachexia, are hyper-sensitive to both LPS and TNF, and consequently die 
prematurely (Lee et al. 2000). A20 contains a novel ovarian tumor (OTU)-type 
DUB domain at the N-terminus, and several zinc-finger in the remainder of the 
protein. The OTU domain disassembles K-63-linked ubiquitin chains from 
RIP, an essential mediator of the proximal TNFR-1 signaling complex, thereby 
suppressing IKK activation. Moreover, after K-63 chains are removed, A20 
functions as an ubiquitin ligase through its zinc-finger domains to assemble K-
48-linked polyubiquitin chains on RIP, targeting it for proteasomal degradation 
(Wertz et al. 2004). Furthermore, A20 terminates TLR-induced NF-κB 
signaling, by cleaving ubiquitin chains from TRAF6 (Boone et al. 2004; Fig.4). 
V – The role of NF-κB in oncogenesis 
According to Hanahan and Weinberg (2000), six essential alterations in 
cell physiology characterize a tumor cell: self-sufficiency in growth, 
insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis and metastasis. Many of the genes 
able to mediate such effects are under transcriptional control of NF-κB 
(Aggarwal 2004). Activity and expression of Cyclin D1 (Guttridge et al. 1999), 
CDK2 kinase (Perkins et al. 1997), and c-myc (Kim et al. 2000), which are 
involved in the control of cell cycle and are altered in several types of cancer 
are under control of NF-κB. Expression and function of numerous cytokines, 
that funtion as growth factors for tumor cells, are NF-κB-dependent. Among 
them are: IL-1β, a growth factor for acute myeloid leukemia (AML); TNF, a 
growth factor for Hodgkin’s lymphoma, cutaneous T cell lymphoma and 
gliomas; interleukin (IL)-6, a growth factor for multiple myeloma (Pahl 1999). 
Some growth factors, such as epidermal growth factor (EGF), or growth factor 
receptors, such as HER2, able to promote growth of solid tumors, activate NF-
κB (Biswas et al. 2000). Tissue invasion and metastasis, two crucial events of 
Figure 4. The deubiquitinating and E3 ubiquitin ligase activities of A20 in terminating NF-κB signaling
(Liu et al. 2005).
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tumor progression, are caused by NF-κB-dependent genes, including matrix 
metalloproteinases (MMPs; Farina et al. 1999), urokinase type of plasminogen 
activator (uPA; Novak et al. 1991), IL-8 (Kunsch and Rosen 1993), the 
adhesion molecules VCAM-1, ICAM-1 and ELAM-1 (Van de Stolpe et al. 
1994) and chemokine receptors such as CXCR4 (Helbig et al. 2003). NF-κB 
activity is also involved in the regulation of angiogenesis, an essential step for 
tumor growth and invasiveness. For instance, vascular endothelial growth 
factor (VEGF), which is the main member of angiogenic factor family, is under 
transcriptional control of NF-κB (Kiriakidis et al. 2003). Finally, altered 
expression of genes involved in regulation of apoptosis, which is a feature of 
neoplastic cells, is often due to deregulated NF-κB activity. By promoting cell 
survival, these genes lead to the maintaining of cell transformed state and are 
responsible for the resistance to chemotherapeutic drugs. All these evidences 
highlight the crucial role of altered NF-κB in promoting neoplastic 
transformation. As a consequence, inactivation of NF-κB in different cell lines 
derived from tumors displaying high constitutive NF-κB activity leads to the 
loss of their tumorigenic potential due to either an increased susceptibility to 
drug-induced apoptosis and/or a decrease of their proliferative rate. Moreover, 
in some cases, blocking NF-κB activity inhibits the metastatic potential of 
cancer cells or reduces the tumor size. 
VI – Thyroid carcinomas and NF-κB 
Thyroid carcinomas are the most common neoplasias of endocrine 
system (Figge 1999). Four types of thyroid cancer comprise more than 98% of 
all thyroid tumors: papillary thyroid carcinoma (PTC), follicular thyroid 
carcinoma (FTC), both of which may be summarized as differentiated thyroid 
carcinoma, medullary thyroid carcinoma (MTC) and undifferentiated 
anaplastic thyroid carcinoma (ATC; Sherman 2003). PTC, FTC and ATC 
derive from the thyroid follicular epithelial cells, while MTC derives from the 
parafollicular C-cells (Gimm 2001). PTC is the most common malignant 
thyroid neoplasm in countries with sufficient iodine diets and comprises up to 
80% of all thyroid malignancies. FTC is more common in regions with 
insufficient iodine diets and represents approximately 10-20% of all thyroid 
malignancies. The overall 5-10 year survival rate of patients with PTC is about 
80-95%, while that of patients with FTC is about 70-95%. The incidence of 
MTC is not well known because epidemiologic studies are rare. Generally, it is 
believed that MTC comprises about 5-10% of all thyroid malignancies (Ball et 
al. 1996, Gimm 2001, Sherman 2003). ATC is one of the most aggressive 
human malignancies, with a very poor prognosis. Although rare, accounting for 
up to 10% of clinically recognized thyroid cancers, the overall median survival 
is limited to months (Gimm 2001, McIver et al. 2001, Sherman 2003). Surgery, 
radiotherapy and chemotherapy, based primarily on doxorubicin and cisplatin 
treatment, do not meaningfully improve survival of ATC patients (McIver et al. 
2001, Tennvall et al. 1994). Novel therapeutic approaches are therefore needed. 
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Very little is known about the role that NF-κB plays in thyroid 
physiology. On the other hand, there is weak evidence that NF-κB may be 
important in RET-mediated carcinogenesis, by maintaining the transformed 
phenotype of thyroid cell lines (Visconti et al. 1997). However, the role that 
NF-κB plays “in vivo” in human thyroid neoplasia has not been fully 
investigated. 
VII – The control of programmed cell death by NF-κB 
Apoptosis is critical for maintenance of normal homeostasis together 
with other important processes such as proliferation and differentiation. 
Defects in apoptosis contribute to tumor pathogenesis and progression in 
several ways, such as allowing neoplastic cells to survive beyond their normal 
lifespan, providing protection against hypoxia as tumor mass expands, 
promoting angiogenesis and invasiveness during tumor progression, and 
allowing tumor cells to become resistant to radio- and chemotherapy. They also 
promote resistance to immune system, given that many of the weapons used by 
cytolytic T-cells and NK cells for killing tumor cells depend on the integrity of 
the apoptotic machinery. Thus, de-regulated apoptosis is a fundamental aspect 
of the biology of cancer. 
The first indication that suppression of apoptosis is an important NF-κB 
function came from the evidence that relA-/- mice died during embryonic 
development as a result of massive liver apoptosis. The massive liver 
apoptosis, which is also displayed by mice lacking IKKβ or NEMO/IKKγ, is 
mediated by TNF-α and is completely suppressed in TNF-α or TNFR1 
knockout mice (Li and Verma 2002). Further experiments showed that NF-κB 
is a critical regulator of apoptotic response in different physiological and 
pathological contexts. The survival of peripheral B cells in response to antigen 
depends on B-cell receptor (BCR)-mediated activation of NF-κB and the 
induction of anti-apoptotic target genes (Bendall et al. 1999). The full 
activation of naïve T cells via T-cell receptor (TCR) leads to NF-κB activation 
and consequent cell survival via induction of anti-apoptotic genes (Jamieson et 
al. 1991). A link between NF-κB and apoptosis has also been demonstrated in 
the regulation of innate immune response, which plays a fundamental role in 
the detection and elimination of pathogens (Naumann 2000). The inhibition of 
NF-κB activity in mouse xenograft models of chemo-resistant tumors provokes 
tumor regression by sensitizing them to chemotherapeutic drug treatments 
(Greten and Karin 2004). Consistent with this work, NF-κB inhibition in many 
human tumor-derived cell lines induces spontaneous apoptosis and/or 
sensitizes them to killing by TNF-α, TRAIL or anti-cancer drugs. 
Mechanisms for NF-κB-mediated protection from apoptosis are 
essentially based on its ability to activate the transcription of a number of genes 
capable of suppressing cell death (Kucharczak et al. 2003, Pacifico and 
Leonardi 2006; Fig.5). Among them are: 1) pro-survival members of the 
mammalian Bcl-2 gene family, Bcl-xL and Bfl-1/A1, which suppress the 
release of pro-apoptotic cytochrome c and Smac/Diablo from mitochondria, 
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thereby blocking programmed cell death in response to TNF-α and 
chemotherapeutic drugs (Boise et al. 1993, Wang et al. 1999); 2) the cellular 
inhibitors of apoptosis c-IAP1, c-IAP2, TRAF1 and TRAF2, the zinc-finger 
protein A20, and c-FLIP, all of them able to suppress cell death induced by 
TNF-α, death receptors or anti-cancer drugs (Deveraux et al. 1998, Yeh et al. 
2000, Wang et al. 1998); 3) the anti-apoptotic protein XIAP, that inhibits the 
processing of procaspase-9 and the activities of caspase-7 and -3 (Tang et al. 
2001), and GADD45β, belonging to the GADD45 family of factors involved in 
cell cycle control and DNA repair (De Smaele et al. 2001), both of them 
implicated in NF-κB-mediated suppression of pro-apoptotic JNK signaling in 
response to TNF-α. A similar mechanism of action is displayed by Ferritin 
Heavy Chain (FHC) that controls ROS production, responsible, in turn, to 
mediate the sustained activation of JNK and, thus, its pro-apoptotic activity 
(Pham et al. 2004). All these anti-apoptotic proteins may work in a coordinated 
manner to interfere with apoptosis at multiple steps along with the apoptotic 
signaling cascade, thus promoting tumor progression. 
VIII – JNK signaling in programmed cell death 
JNK1/2/3 are the downstream components of one of the major 
mitogen-activated protein kinase (MAPK) cascades, also comprising the 
extracellular signal-regulated kinase (ERK1/2) and p38(α/β/γ/δ) cascades 
(Chang and Karin 2001, Davis 2000, Johnson and Lapadat 2002). By and large, 
activation of JNK (and p38) is associated with the induction of apoptosis. In 
contrast, activation of ERK is linked to cell growth and survival (Chang and 
Karin 2001, Davis 2000, Johnson and Lapadat 2002, Tournier et al. 2000). 
Actually, jnk1-/- and jnk2-/- mouse embryonic fibroblasts (MEFs) exhibit a 
severe defect in the apoptotic response to stress (Tournier et al. 2000). JNK is 
Figure 5. NF-κB controls the transcription of a number of genes interfering with different
steps in the apoptotic process (Pacifico and Leonardi 2006). 
 18
also required for TNFR-induced killing (De Smaele et al. 2001, Javelaud et al. 
2001, Tang et al. 2001), as the JNK1 and JNK2 double deletion virtually 
abrogates this killing (Deng et al. 2003). Yet, precisely how JNKs activate the 
apoptotic signaling is unknown. However, from different experimental 
evidences it seems clear that the duration of JNK activation affects its role in 
apoptosis. Interestingly, it is the sustained (and not the acute) induction of JNK 
that has been linked to PCD. This has been recently demonstrated by different 
groups showing that NF-κB is able to inhibit TNF-α-induced apoptosis by 
negatively regulating the sustained activation of the JNK pathway. They have 
also shown that the negative regulation of JNK activity exerted by NF-κB is 
mediated by GADD45β, XIAP, and FHC, all of them under the transcriptional 
control of NF-κB (De Smaele et al. 2001, Pham et al. 2004, Tang et al. 2001). 
However, the prolonged JNK activation alone may not be sufficient to induce 
apoptosis (Tang et al. 2001). In contrast, some studies have indicated that JNK 
may also contribute to cell survival (Davis 2000). Thus, the dual role of JNK in 
both apoptotic and anti-apoptotic signaling pathways suggests that the function 
of JNK is complex and that the physiological response most likely reflects a 
balance between the ability of JNK to signal both apoptosis and cell survival. 
IX – NF-κB as target for cancer therapies 
All the evidences reported above clearly show that NF-κB is a key 
player in cancer. Thus, researchers have focused their efforts in looking for 
drugs able to suppress NF-κB activity in malignant cells. NF-κB activation 
could be blocked at different levels targeting various components of its 
signaling cascade, such as the IKK complex, the IκB inhibitory proteins, the 
p65 subunit of the transcriptionally active heterodimer, and/or the proteasome. 
Therefore, an increasing number of compounds able to block NF-κB, by 
inhibiting one or more molecules involved in its signaling pathway, have been 
tested and have shown to suppress the growth of those cancer cells whose 
tumorigenicity depends on NF-κB activity (Karin et al. 2002). Many of these 
drugs have given promising results in preclinical models for NF-κB-dependent 
solid tumors (breast, lung, colon, bladder, ovary, pancreas and prostate 
cancers), but their clinical efficacy has shown to be poorly appreciable. At 
present, the only pharmacological inhibitors of NF-κB activation approved for 
clinical use are represented by proteasome inhibitors for treatment of some 
haematological malignancies, such as multiple myeloma, or adult T-cell 
leukemia, for whose pathogenesis it has been clearly demonstrated the key role 
of NF-κB (Nasr et al. 2005, Richardson et a. 2004). 
One of the most problematic aspects of a cancer therapy based on 
inhibition of NF-κB activity is represented by the difficulty to find compounds 
which block the oncogenic activity of NF-κB without interfering with its 
physiological roles in immunity, inflammation and cellular homeostasis. 
Unfortunately, most of the drugs analyzed so far also affect other cellular 
signaling pathways involved in the regulation of apoptosis and proliferation 
other than inflammatory and immunological response, thereby determining a 
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number of highly toxic side effects. To this end, all the efforts are now 
concentrated on the ability to identify novel NF-κB targets specifically 
activated in tumors, but not in normal cells, or agents that block the prosurvival 
effectors of NF-κB, rather than NF-κB itself. 
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Aims of the Study 
NF-κB family of transcription factors is deeply involved in the control 
of cell survival. Activation of NF-κB antagonizes apoptosis or programmed 
cell death and the anti-apoptotic activity of NF-κB plays a pivotal role in 
various aspects of oncogenesis, including transformation, proliferation, 
invasiveness, metastasis formation and angiogenesis. 
Very little is known about the role of NF-κB in thyroid oncogenesis. It 
has been shown that NF-κB may be important in RET-mediated 
carcinogenesis, by maintaining the transformed phenotype of thyroid cell lines 
(Visconti et al. 1997). Thus, the first aim of this study has been to analyze the 
oncogenic activity of NF-κB in specimens from human thyroid carcinomas and 
in thyroid transformed cell lines reproducing in vitro the human thyroid 
neoplasias. Further, our efforts have focused on gaining an understanding of 
the precise mechanism(s) by which NF-κB promotes thyroid transformed cell 
survival and chemoresistance. 
Because of the importance of sustained activation of NF-κB in 
promoting neoplastic transformation, the second aim of the present study has 
been to identify novel molecules involved in switching off NF-κB signaling 
pathways and dissect their inhibitory mechanisms. 
However, our ultimate aim has been to uncover unknown pieces in the 
NF-κB puzzle that can be exploited as molecular targets for developing novel 
therapeutic strategies, which, interfering with NF-κB activity, could potentiate 
our weapons against tumors. 
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Materials and Methods 
I – Cell cultures and biological reagents 
NPA is a cell line derived from human papillary thyroid carcinoma 
(Ludwig et al. 2001), FRO is derived from human anaplastic thyroid carcinoma 
(Fagin et al. 1993), and WRO is derived from human follicular thyroid 
carcinoma (Estour et al. 1989). These cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma) supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 1% 
glutamine. FRO cells were transfected with the empty expression vector 
pcDNA3.1-FLAG (Invitrogen; FRO-Neo) or with pcDNA3.1-FLAG encoding 
a mutant form (S32A/S36A) of IκBα (FRO-IκBαM; De Smaele et al. 2001). 
NPA cells were transfected with the empty expression vector pcDNA3.1-
FLAG (NPA-Neo) or with pcDNA3.1-FLAG vector encoding human IKKβ 
(NPA-IKKβ; Leonardi et al. 2000a). Stable transfected clones were selected 
and maintained in the presence of 200 µg/ml geneticin (Sigma). HEK293 cells 
were maintained as described above. 
Anti-ABIN-1 polyclonal antibodies were generated in rabbits, by using 
a recombinant peptide encompassing amino acids 380-636 of human ABIN-1. 
Other antibodies used for this study were: FLAG epitope (Sigma), p65 and 
A20 (BD Pharmingen), JNK1/2 and p-JNK1/2 (Cell Signaling), HA epitope, 
p65, NEMO/IKKγ, IKKβ, IκBα and Tubulin (Santa Cruz Biotechnologies). 
The following reagents were also used: cisplatin and doxorubicin (kindly 
provided by S. Pepe) used at different concentrations as indicated in the 
experiments; anisomycin (Sigma) 10 µg/ml; SP600125 (Biomol Research 
Laboratories) 10 µM; human TNF-α (Peprotech) 2,000 units/ml. 
Human ABIN-1 was amplified by PCR from a human liver c-DNA 
library (BD Clontech) and cloned into pcDNA3.1-HA, -FLAG, and -His 
vectors (Invitrogen) for expression in mammalian cells. A20, TAX, and 
Ubiquitin expression vectors were gifts from G. Natoli, T. K. Jeang and G. 
Courtois, respectively. NEMO/IKKγ, IKKβ, CIKS and TRAF2 expression 
vectors were previously described (Leonardi et al. 2000a-b). All deletion 
mutants were prepared by conventional PCR and cloned into pcDNA3.1-HA or 
-FLAG vectors. Point mutants of A20 (C103S and D100A/C103S) were 
generated by the Quickchange Site-Directed Mutagenesis Kit (Stratagene), 
according to the manufacturer’s protocol. 
II – Immunohistochemical analysis 
Specimens from normal and pathological human thyroids were isolated, 
rinsed with PBS, fixed in 4% buffered neutral formalin and embedded in 
paraffin. 5-6 µm thick paraffin sections were deparaffinized, placed in a 
solution of absolute methanol and 0.3% hydrogen peroxide for 30 min, and 
washed in PBS before immunoperoxidase staining. Slides were incubated 
overnight at 4°C in a humidified chamber with antibody anti-p65 diluted 1:100 
in PBS and subsequently incubated, first with biotinylated goat anti-rabbit IgG 
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for 20 min and then with pre-mixed reagent ABC for 20 min (Vectostain ABC 
kits, Vector Laboratories). The immunostaining was performed by incubating 
slides in diaminobenzidine (DAB-DAKO) solution containing 0.06 mM DAB 
and 2 mM hydrogen peroxide in 0.05% PBS pH 7.6 for 5 min. After 
chromogen development, slides were washed, dehydrated with alcohol and 
xylene, and mounted on coverslips using a permanent mounting medium 
(Permount). 
III – Electro-Mobility Shift Assay (EMSA) 
To analyze NF-κB DNA binding activity, total cell extracts were 
prepared using a detergent lysis buffer [50 mM Tris pH 7.4, 250 mM NaCl, 50 
mM NaF, 1 mM Na3VO4, 0.5% Nonidet P-40, 0.5 mM dithiotheritol and 
Complete Protease Inhibitor Mixture (Roche)]. Cells were harvested by 
centrifugation, washed once in cold PBS and resuspended in detergent lysis 
buffer (30 µl/5x106 cells). The cell lysate was incubated on ice for 30 min, and 
then centrifuged for 5 min at 14,000 rpm 4°C. The protein content of the 
supernatant was determined, and equal amounts of protein (10 µg) were added 
to a reaction mixture containing 20 µg BSA, 2 µg poly(dI-dC), 10 µl binding 
buffer (20 mM HEPES pH 7.9, 10 mM MgCl2, 20% Glycerol, 100 mM KCl, 
0.2 mM EDTA, 0.5 mM DTT and 0.5 mM PMSF) and 100,000 cpm of a 32P-
labeled oligonucleotide containing specific binding sites for NF-κB, in a final 
volume of 20 µl. Samples were incubated at room temperature for 30 min and 
then run on a 4% acrylamide gel. 
To analyze AP-1 DNA binding activity, nuclear extracts were prepared 
as follows: cells were harvested by centrifugation, washed once in cold PBS 
and resuspended in buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2 and 0.1 mM EGTA). Then, cells were centrifuged for 5 min at 2,000 
rpm and resuspended in cold buffer C (20 mM HEPES pH 7.9, 400 mM NaCl, 
1.5 mM MgCl2, 0.1 mM EGTA and 25% Glycerol). The cell resuspension was 
subjected to strong shaking for 30 min at 4°C and then centrifuged for 15 min 
at 2,000 rpm. EMSA was performed as above, using 32P-labeled AP-1 
oligonucleotide. 
IV – In vitro and in vivo tumorigenicity assays 
To analyze the ability of various FRO clones to form colonies in soft 
agar, 1x104 cells were seeded in 60 mm dishes onto 0.3% Noble Agar (DIFCO) 
on top of a 0.6% bottom layer. Colonies larger than 50 cells were scored after 2 
weeks incubation at 37°C (Macpherson and Montagnier 1964). 
To analyze the ability of various FRO clones to induce tumor growth in 
nude mice, 2x107 cells were injected sub-coutaneously on a flank of each 6-
week-old nude mouse (Charles River). Thirty days later, mice were killed and 
tumors were excised. Weight of tumors was determined and their diameters 
were measured with calipers. Volumes were calculated by the formula: a2 x b x 
0.4, where a is the smallest diameter and b is the diameter perpendicular to a. 
None mouse showed signs of wasting or other visible indications of toxicity. 
Mice were maintained at the DBPCM animal facility, and experiments were 
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conducted in accordance with standards of animal care and Italian regulations 
for the welfare of animals used in studies of experimental neoplasia. Further, 
the study was approved by our institutional committee on animal care. 
V – Cytotoxic treatments and measurements of apoptosis 
1x103 cells/well were seeded in 96-well culture plates, and incubated 
for 48 h at 37°C with different concentrations of cisplatin or doxorubicin and 
w/wo the specific JNK inhibitor, SP600125. Cell survival was examined by 
using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) and an electron coupling 
reagent (phenazine methosulfate, PMS), according to manufacturer’s 
instructions (Promega). Cell death was assessed by staining of exposed 
phosphatidylserine on cell membranes with fluoresceinisothiocyanate (FITC)-
conjugated annexin V (BD PharMingen) or by propidium iodide staining 
according to Nicoletti et al. (1991). Samples were analyzed by flow cytometry 
using a FACScalibur (Beckman Coulter), equipped with ModFit Software. 
Results were mean ±SD of at least three independent experiments. 
VI – [3H]-thymidine DNA incorporation 
5x104cells/well were seeded in 12-well culture plates and incubated for 
4 h at 37°C with 0.5 µCi/well of [3H]-thymidine (Amersham). After three 
washings with cold PBS, cells were incubated for 10 min at 4°C with 0.5 ml of 
20% TCA. Then, cells were lysed with gentle shaking for 30 min at 37°C in the 
presence of 1 N NaOH (0.5 ml/well). An aliquot of lysate (0.1 ml) was used to 
evaluate the protein content by colorimetric assay (BioRad), while the 
remainder was analyzed at the β-counter (Beckman Coulter). 
VII – CFSE cell proliferation assay 
The analysis of cell proliferation was performed by labelling cells with 
CFSE (Molecular Probes) according to Lyons (1999). Flow citometry and data 
analysis were performed by using a two laser equipped FACScalibur apparatus 
and the CellQuest analysis software (Becton Dickinson). 
VIII – Gel filtration of cellular extracts 
Gel filtration procedures were performed as previously described 
(Mauro et al. 2003). Fractions were analyzed by Western blotting for ABIN-1, 
NEMO/IKKγ and IKKβ. 
IX – In vitro translation and GST pull-down assays 
 In vitro transcription and translation were carried out with 1 µg of 
ABIN-1 constructs according to the TNT Quick Coupled 
Transcription/Translation System protocol (Promega) in the presence of 35S 
methionine. GST-NEMO/IKKγ fusion protein was produced and purified as 
described by Chariot et al. (1999). GST pull-down assays were performed by 
incubating an aliquot of GST-NEMO/IKKγ bound to glutathion-sepharose 
beads (Amersham Biosciences) together with 10 µl of in vitro translated 
ABIN-1 proteins in PBS-1% Triton X-100 buffer (including Complete Protease 
Inhibitor mixture) for 2 h at 4oC. Beads were then washed five times with the 
 24
same buffer, resuspended in Laemmli buffer and run on a SDS-polyacrylamide 
gel before autoradiography. 
X – Transfection, immunoprecipitation and luciferase assay 
 Lipofect-AMINE-mediated transfections were performed according to 
the manufacturer’s instructions (Invitrogen). All transfections included extra 
empty vector to ensure that total amount of transfected DNA was kept constant 
in each culture dish. 
 For immunoprecipitation of transfected proteins, HEK293 cells (3x106) 
were transiently transfected and 24 h after transfection cells were lysed in 
Triton X-100 lysis buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 10% 
Glycerol, 1% Triton X-100, and Complete Protease Inhibitor mixture). After an 
additional 15 min on ice, cell extracts were centrifuged for 10 min at 14,000 
rpm 4oC, and supernatants were incubated for 4 h at 4oC with anti-FLAG 
antibodies bound to agarose beads (M2, Sigma). The immunoprecipitates were 
washed five times with Triton X-100 lysis buffer and subjected to SDS-PAGE. 
 For luciferase assay, HEK293 cells (4x105) were seeded in six-well-
plates. After 12 h cells were transfected with 0.5 µg of Ig-κB-luciferase 
reporter plasmid and various combinations of expression plasmids, as indicated 
in the experiments. 24 h after transfection, cells were stimulated with TNF-α 
for 3 h or left untreated. Cell extracts were prepared and reporter gene activity 
was determined via the luciferase assay system (Promega). Expression of the 
pRSV-βGal vector (0.2 µg) was used to normalize transfection efficiencies. 
XI – In vivo ubiquitination and de-ubiquitination assays 
HEK293 cells (3x106) were co-transfected with expression vectors 
containing epitope-tagged Ubiquitin (1 µg) and NEMO/IKKγ (200 ng), plus 
various constructs encoding A20 or ABIN-1 proteins. 24 h after transfection, 
cell lysates were prepared as above and analyzed for poly-ubiquitination of 
NEMO/IKKγ, either by Western blot anti-NEMO/IKKγ (-FLAG) on total 
extracts or by immunoprecipitating FLAG-NEMO/IKKγ with anti-FLAG 
beads followed by Western blot anti HA-Ubiquitin. 
XII – ABIN-1 and A20 siRNA expression vectors 
To knock-down ABIN-1 expression, we designed double-stranded 
oligo-nucleotides containing sequences derived from the human ABIN-1 ORF 
(nucleotides 1136-1156 and 1685-1705), in forward and reverse orientation, 
separated by a 7-base-pair spacer region (caagaga), to allow the formation of 
the hairpin structure in the expressed siRNAs. ABINi-370: sense strand, 5’-
aattcGAGGAGACCGACAAGGAGCAGcaagagaCTGCTCCTTGTCGGTCTC
CTCtttttc; anti-sense strand, 5’-
tcgagaaaaaGAGGAGACCGACAAGGAGCAGtctcttgCTGCTCCTTGTCGGT
CTCCTCg. ABINi-560: sense strand, 5’-
aattcCCACACCATGGCTTCGAGGACcaagagaGTCCTCGAAGCCATGGTG
TGGtttttc; anti-sense strand, 5’-
tcgagaaaaaCCACACCATGGCTTCGAGGACtctcttgGTCCTCGAAGCCATG
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GTGTGGg. The resulting double-stranded oligo-nucleotides were cloned into 
the pcRNAi vector that we derived from the pcDNA3.1 vector (Invitrogen) by 
replacing the viral promoter-cassette with the H1 gene promoter that is 
specifically recognized by RNA polymerase III. 
Plasmids used to knock-down A20 expression (pU6-A20i and the pU6) 
were kindly provided from S. Yamaoka (Saitoh et al. 2005). 
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Results and Discussion 
I – Basal NF-κB activity in human thyroid carcinomas 
To determine the activation state of NF-κB in primary thyroid cancer 
tissues, human specimens from normal thyroid and papillary, follicular, and 
anaplastic thyroid carcinomas were collected and stained with anti-p65 (RelA) 
antibodies. Results are summarized in Table 1. No nuclear staining for RelA 
was detected in normal thyroid follicular cells (Fig. 6A), while few nuclei from 
papillary carcinoma cells were positive for RelA. Follicular carcinoma cells 
showed ~50% of their nuclei stained for NF-κB, while anaplastic carcinoma 
cells showed almost 100% 
of their nuclei strongly 
positive for NF-κB (Fig. 6B, 
C, D and Tab. 1). 
Interestingly, the increased 
nuclear localization of NF-
κB correlates with the 
increased malignant 
phenotype of thyroid 
carcinomas, suggesting that 
sustained activation of NF-
κB confers an advantage for 
thyroid carcinoma 
progression. 
These results 
indicate that the nuclear 
localization of p65 is a 
feature of human anaplastic thyroid carcinomas, and suggest a role for NF-κB 
in human thyroid oncogenesis. 
3+ 4/4 Anaplasticcarcinoma 
2+ 5/5 Follicular carcinoma 
1+ 6/6 Papillary carcinoma 
0 0/4 Normal thyroid 
NF-κB staining 
score 
N° positive cases/N° total cases 
analyzed by 
immunohistochemistry 
Histological type of 
thyroid samples 
Table 1. NF-κB nuclear localization in normal and pathological human thyroid 
tissues. The percentage of cells with nuclear staining for NF-κB was scored from 
0 to 3: 0, no positive cells; 1+, <10% of positive cells; 2+, 11-50% of positive 
cells; 3+, 76-100% of positive cells.
A
D
B
C
Figure 6. Immunohistochemical analysis of NF-κB activity in 
normal human thyroid and anaplastic human thyroid 
carcinomas. Localization of RelA (p65) in situ was 
determined by immunohistochemistry in sections from 
normal thyroid tissue (A) and 3 different anaplastic thyroid 
carcinomas (B, C, D). 
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II – NF-κB transcriptional activity in human thyroid transformed cells 
The high levels of basal NF-κB activity in human thyroid carcinomas 
prompted us to investigate the role of NF-κB in thyroid neoplastic 
transformation. To this aim, we used three different cell lines which resembled 
the features of thyroid tumors: WRO, FRO and NPA (see Materials and 
Methods). In these cells we analyzed, by EMSA, the nuclear localization of 
NF-κB. FRO cells showed the highest NF-κB DNA binding activity, while it 
was barely detectable in NPA cells (Fig. 7A). Then, to demonstrate that nuclear 
NF-κB was transcriptionally active, we performed reporter gene assays. 
Consistent with EMSA assays, FRO cells showed the highest NF-κB 
transcriptional activity, while NPA cells showed an almost undetectable 
activity (Fig. 7B). 
Taken together, these data show that NF-κB is transcriptionally active 
in thyroid carcinoma cell lines, particularly in the human anaplastic thyroid cell 
line FRO. 
III – NF-κB activity is essential to confer resistance to drug-induced apoptosis 
in thyroid carcinoma cell lines 
In order to determine a correlation between NF-κB activity and cell 
sensitivity to drug-induced apoptosis, we tested the ability of cisplatin and 
doxorubicin to promote cell death in WRO, FRO and NPA cells. As shown in 
Fig. 8A-B, both drugs induced cell death in all three cell lines, at an extent 
which correlated with the levels of basal NF-κB activity. 
To causally link NF-κB activity to protection of neoplastic thyroid cells 
Figure 7. NF-κB activity in human thyroid carcinoma cell lines. A) EMSA 
on total cell extracts from human thyroid carcinoma cell lines WRO, FRO 
and NPA in the presence of a 32P-labeled NF-κB oligonucleotide alone 
(lanes -) or with a 50-fold molar excess of an analogous unlabeled 
oligonucleotide (lanes +), as competitor. B) Relative reporter activity was 
evaluated in the same human thyroid carcinoma cell lines transfected with 
Ig-κB-luciferase plasmid. Values shown in arbitrary units represent the 
means +/- SD of three experiments done in triplicate, normalized for β-
galactosidase expression of a co-transfected pRSV-βgal plasmid.
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from apoptosis induced by chemotherapeutic drugs, we stably transfected NPA 
cells with an expression vector encoding IKKβ, to induce constitutive NF-κB 
activity, and FRO cells with a super-repressor form of IκBα (IκBαM), to 
suppress basal NF-κB activity. Two NPA clones, +7 and +18, as well as two 
FRO clones, +14 and +16, were analysed, because they expressed different 
levels of IKKβ or IκBαM and were differentially able to activate NF-κB (data 
not shown). Stably transfected cells were treated with increasing amounts of 
cisplatin or doxorubicin for 48 h, and cell survival and death were measured. 
While NPA-Neo clones were sensitive to cell death induced by 
chemotherapeutic drugs, NPA-IKKβ clones became resistant to apoptosis 
induced by either cisplatin or doxorubicin (Fig. 9A-B). On the other hand, 
FRO-Neo clones were resistant to drug-induced cell death, while FRO-IκBαM 
clones underwent apoptosis after treatment, even at low dosage, of either 
cisplatin or doxorubicin (Fig. 9C-D). 
Since NF-κB controls cell proliferation, the inhibition of NF-κB activity 
in FRO cells could affect proliferation other than apoptosis. To test this 
hypothesis, we analyzed the proliferation rate of parental and transfected FRO 
cells by [3H]-thymidine DNA incorporation and CFSE assay (data not shown). 
No significative differences in the rate of [3H]-thymidine DNA incorporation 
Figure 8. Cytotoxic effects of chemotherapeutic drugs on human thyroid carcinoma cell lines. 1x103
cells/well were seeded in 96-well culture plates and incubated for 48 h with different concentrations of 
cisplatin (A) or doxorubicin (B). Cell survival was examined by MTS assay. Cell death was assessed by 
annexin V staining. Results were mean ±SD of at least three separate experiments.  
A
1 5 10
Cisplatin (µg/ml)
0
10
20
30
40
50
60
70
80
90
C
el
lv
ia
bi
lit
y
(%
)
WRO
FRO
NPA
0
10
20
30
40
50
60
0 0,1 1 10
C
el
ld
ea
th
(%
)
Cisplatin (µg/ml)B
0
10
20
30
40
50
60
70
80
90
1 5 10
Doxorubicin (µg/ml)
C
el
lv
ia
bi
lit
y
(%
)
WRO
FRO
NPA
0
10
20
30
40
50
60
0 0,1 1 10
C
el
ld
ea
th
(%
)
WRO
FRO
NPA
Doxorubicin (µg/ml)
WRO
FRO
NPA
C
el
lv
ia
bi
lit
y
(%
)
C
el
ld
ea
th
(%
)
C
el
lv
ia
bi
lit
y
(%
)
C
el
ld
ea
th
(%
)
C
el
lv
ia
bi
lit
y
(%
)
C
el
ld
ea
th
(%
)
C
el
lv
ia
bi
lit
y
(%
)
C
el
lv
ia
bi
lit
y
(%
)
C
el
ld
ea
th
(%
)
C
el
ld
ea
th
(%
)
 29
were appreciable between FRO-Neo and -IκBαM clones, and a very similar 
doubling time was detected after 12 and 24 h of CFSE treatment, indicating 
that NF-κB activation is not required to control proliferation of FRO cells. 
These results indicate that NF-κB activity confers resistance to drug-
induced apoptosis in neoplastic thyroid cells. 
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Figure 9. Cytotoxic effects of chemotherapeutic drugs on parental and transfected thyroid carcinoma cells. 
1x103 cells/well were seeded in 96-well culture plates and incubated for 48 h with different concentrations 
of cisplatin or doxorubicin. Cell survival was examined by MTS assay. Cell death was assessed by annexin 
V staining. A representative experiment out of three is shown. A-B) NPA-Neo and -IKKβ clones; C-D) 
FRO-Neo and -IκBαM clones. 
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IV – Inhibition of FRO transforming potential by NF-κB inactivation 
We next analyzed 
the in vitro and in vivo 
transforming potential of 
FRO-Neo and -IκBαM cells. 
The in vitro assay was 
performed by analyzing the 
ability of transformed cells 
to form colonies in soft agar. 
As shown in Fig. 10, while 
FRO-Neo gave rise to 
numerous and large colonies 
in soft agar (upper panels), -
IκBαM +14 and +16 clones 
lost this property (middle 
and lower panels). These 
results were also confirmed 
by in vivo assays. Table 2 
shows that injection in nude 
mice of FRO-Neo cells 
induced tumor formation in 
6 out of 6 nude mice. 
Injection of FRO-IκBαM 
+14 and +16 cells induced 
tumor formation in 0 out of 
6 and 2 out of 6 
mice, respectively. 
In addition, the two 
tumors developed 
from FRO-IκBαM 
+16 cells were 
about 5-fold 
smaller than those 
derived from 
injection of 
parental cells 
(Table 2).  
Thus, 
inhibition of NF-
κB activity led to a 
strong decrease of 
FRO transforming potential.  
V – The anti-apoptotic activity of NF-κB is mediated by down-regulation of 
JNK activity 
It has been shown that NF-κB inhibits TNF-α-induced apoptosis by 
FRO-Neo
FRO-
IκBαM +14
FRO-
IκBαM +16
A B
Figure 10. In vitro oncogenic potential of FRO-Neo and -
IκBαM clones. 1x104 cells were seeded in 60 mm dishes onto 
0.3% Noble Agar on top of a 0.6% bottom layer. Colonies 
larger than 50 cells were scored after 2 weeks. FRO-Neo >50 
colonies/plate; FRO-IκBαM +14 =0 colonies/plate; FRO 
IκBαM +16 <5 colonies/plate. A) 100 x magnification. B) 
200 x magnification.
0.029±0.002 0.27±0.06 2/6 FRO IκBαM+16 
--0/6 FRO IκBαM +14 
Transfected 
cells 
0.146±0.04 1.48±0.4 6/6 FRO Neo 
Parental cells
Tumor weight 
average (g) 
Tumor volume 
average (cm3) 
Tumor 
incidence Cell type 
Table 2. In vivo tumor growth induced by FRO-Neo and -IκBαM clones. 
2x107 cells were injected s.c. on a flank of each 6-week-old nude mouse 
Thirty days later, mice were killed and tumors were excised. Tumors 
weight was determined and their diameters were measured with calipers. 
Tumor volumes were calculated by the formula: a2 x b x 0.4, where a is 
the smallest diameter and b is the diameter perpendicular to a. 
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repressing the JNK 
pathway (De Smaele et al. 
2001, Pham et al. 2004, 
Tang et al. 2001). 
Therefore, we investigated 
if inhibition of NF-κB 
activity in FRO-IκBαM 
clones affects JNK 
activation. To this aim, we 
first analyzed 
transcriptional activity of 
AP-1, a target of JNK 
activity, by EMSA, on 
nuclear extracts from 
FRO-Neo and -IκBαM 
clones. As shown in Fig. 
11A, AP-1 DNA binding 
activity, almost 
undetectable in FRO-Neo 
cells, was partially 
restored in FRO-IκBαM 
clones. Next, we 
investigated JNK activity 
in FRO-Neo and -IκBαM clones, by analyzing its phosphorylation status 
following anisomycin stimulation (Fig. 11B, upper panel). Anisomycin 
induced JNK phosphorylation as early as 10 minutes of treatment in all cell 
lines. However, while p-JNK level in FRO-Neo cells decreased with time, it 
remained sustained in -IκBαM clones. Anisomycin treatment had no effect on 
total JNK levels, as assessed by Western blot analysis.  
These data suggest that sensitivity of FRO-IκBαM clones to apoptosis 
induced by chemotherapeutic agents could be due to restoration of JNK 
activity. To investigate this hypothesis, we analyzed the apoptosis rate in FRO-
Neo and -IκBαM +14 clones after treatment with cisplatin or doxorubicin in 
the presence of SP600125, a specific inhibitor of JNK activity (Bennett et al. 
2001). Cell death was assessed by propidium iodide staining and was 
represented by the fraction of cells in sub-G1 phase (Fig. 12). The inhibition of 
JNK activity by SP600125 rendered FRO-IκBαM resistant to apoptosis 
induced by cisplatin (Fig. 12B) and doxorubicin (data not shown). 
These results demonstrate that NF-κB inhibits chemotherapeutic drug-
induced apoptosis in FRO cells by, at least partially, negatively regulating JNK 
signaling. 
VI – ABIN-1 is an inhibitor of NF-κB and an interactor of NEMO/IKKγ 
Our data together with many reports already present in literature 
(Aggarwal 2004) strongly support the idea that sustained activation of NF-κB 
is deeply involved in oncogenesis. Thus, we focused our efforts on the 
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Figure 11. JNK activity in FRO-Neo and -IκBαM clones. A) EMSA 
on nuclear extracts from human thyroid carcinoma cell lines FRO-
Neo, -IκBαM +14 and -IκBαM +16 in the presence of 32P-labeled 
wild type (left panel) or mutant (right panel) AP-1 oligonucleotide. 
ns= nonspecific. B) 5x105 cells/well were seeded in six-well plates 
and incubated for different time with 10 µg/ml anisomycin. Cell 
lysates were analyzed by Western blot anti-p-JNK1/2 (upper panel) 
or total JNK1/2 (lower panel).
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identification of molecular mechanisms involved in switching off NF-κB 
activity. In the last few years, our group has largely used biochemical and 
genetic approaches to isolate critical interactors of the IKK-complex, the 
kinase complex controlling NF-κB activation (Leonardi et al. 2000a, Chariot et 
al. 2000, Mauro et al. 2003, Stilo et al. 2004). Thus, we have access to a 
collection of promising candidate genes in regulating NF-κB signal 
transduction. Following a careful analysis, we decided to study ABIN-1 to gain 
an understanding into the basis for its inhibition of NF-κB. In fact, ABIN-1 
FRO-IκBαM +14 
-SP600125
-Cisplatin
Apoptosis: 1.51%
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G1
G2
Channels (FL2-A)
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G2Sub-G1
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Channels (FL2-A)
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+Cisplatin
Apoptosis: 12.74%
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Figure 12. Inhibition of JNK activity restored cell death resistance in FRO-IκBαM 
clones. 1x105 cells/well were seeded in six-well culture plates and incubated for 48 h 
with 5 µg/ml cisplatin, in the presence of 10 µM JNK inhibitor SP600125. Cell death 
was assessed by propidium iodide staining. A representative experiment out of two done 
in triplicate is shown.
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(A20 binding inhibitor of NF-κB) was identified as an interactor of A20, able 
to mimic the NF-κB inhibiting effects of A20 (Heyninck et al. 1999). We 
identified ABIN-1 in a yeast two-hybrid screening of a human liver c-DNA 
library, as an interactor of NEMO/IKKγ, the regulatory subunit of the IKK-
complex. 
To define the region of NEMO/IKKγ required for its interaction with 
ABIN-1, we tested various deletion mutants of NEMO/IKKγ for binding to 
ABIN-1 fragment (AA 380-636) in yeast. Data shown in Fig. 13A indicate that 
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Figure 13. Mapping of the ABIN-1 interaction domain on NEMO/IKKγ. A) Mapping of the NEMO-
ABIN interaction by yeast-two hybrid experiments. B) In vivo mapping of the NEMO-ABIN interaction. 
HEK293 cells were transfected with the indicated combinations of expression constructs encoding HA-
ABIN and either FLAG-NEMO or FLAG-NEMO∆N91. Cell extracts were analyzed by immuno-blotting 
either directly or after immuno-precipitation with anti-FLAG antibodies. C) Chromatographic distribution 
of endogenous ABIN-1, NEMO and IKKβ. Cytoplasmic extracts were prepared from HEK293 treated 
with TNF for 120 min or left unstimulated, and subjected to chromatography on a Superdex S-200 
column. Fractions were analyzed by Western blot by using the indicated antibodies. Molecular weight 
markers are indicated at the top of the figure.
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the region between amino acids 50 and 100 of NEMO/IKKγ is required for 
interaction with ABIN-1. The binding was confirmed in mammalian cells (Fig. 
13B). HA-ABIN-1 was transiently co-expressed in HEK293 cells together with 
FLAG-NEMO/IKKγ or a NEMO/IKKγ mutant lacking the first 91 amino acids 
(FLAG-NEMO∆N91). Immunoprecipitates of FLAG-NEMO/IKKγ contained 
HA-ABIN-1 only if both proteins were co-expressed. In agreement with data 
obtained in yeast, ABIN-1 did not co-immunoprecipitate with NEMO∆N91. 
We were unable to detect the association between endogenous NEMO/IKKγ 
and ABIN-1, probably because of the transient nature of the association and/or 
the high stringent conditions we used to perform co-immunoprecipitation 
experiments. However, gel filtration experiments showed that endogenous 
ABIN-1 was eluted from the column in the same fractions containing 
endogenous NEMO/IKKγ and other components of IKK-complex (Fig 13C). 
VII – Mapping of the NEMO/IKKγ and the A20 binding domains on ABIN-1 
To define the domain of ABIN-1 required for its interaction with 
NEMO/IKKγ, we performed pull-down assays by using recombinant GST-
NEMO/IKKγ and in vitro translated [35S]ABIN-1 (Fig. 14A). ABIN-1 bound to 
GST-NEMO/IKKγ, indicating a direct interaction between the two proteins. 
Furthermore, amino acids 500-588 of ABIN-1 represent the minimal region 
that binds to NEMO/IKKγ (Fig. 14A, upper panel). To confirm that the region 
between amino acids 500 and 588 of ABIN-1 was responsible for the 
interaction with NEMO/IKKγ, we generated an internal deletion mutant of 
ABIN-1 (∆500-588) and evaluated its ability to interact with NEMO/IKKγ. As 
expected, the internal deletion of 89 amino acids from ABIN-1 abolished the 
interaction with NEMO/IKKγ (Fig. 14B). 
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Because ABIN-1 was identified as an A20-interacting protein 
(Heyninck et al. 2003), we also confirmed that the region between amino acids 
407-431 of ABIN-1 is responsible for interaction with A20 (data not shown). 
VIII – ABIN-1 and A20 inhibit NF-κB at level of the IKK-complex by 
associating with NEMO/IKKγ 
Both ABIN-1 and A20 are inhibitors of NF-κB. It has been proposed 
that they interfere with a RIP and TRAF2-mediated trans-activating signal 
(Heyninck et al. 1999). The identification of the interaction between ABIN-1 
and NEMO/IKKγ prompted us to investigate if ABIN-1 was involved in 
controlling NF-κB activation not only upstream but also at the level of the 
IKK-complex. To this aim, we performed reporter assays by transfecting 
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Figure 15. ABIN-1 and A20 are inhibitors of NF-κB. A, B) ABIN-1 and A20 inhibit NF-κB at 
level of the IKK-complex. Relative reporter activity was evaluated in HEK293 cells co-
transfected with Ig-κB-luciferase plasmid and the indicated expression vectors. 24 h after 
transfection cells were stimulated with TNF for 3 h or left untreated, as indicated. Values shown 
in arbitrary units represent the means +/- SD of three experiments done in triplicate, normalized 
for β-galactosidase expression of a co-transfected pRSV-βgal plasmid.
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HEK293 cells with Ig-κB-luciferase plasmid in the presence of ABIN-1 and 
various activators of NF-κB. ABIN-1 efficiently inhibited TNF-α- and 
TRAF2-dependent activation of NF-κB (Fig 15A). It also blocked NF-κB 
A
L
uc
ife
ra
se
ac
tiv
ity
(a
rb
itr
ar
y
un
its
)
0
20
40
60
80
100
120
hTNF-α
HA-CIKS
HA-TRAF2
HA-ABIN FL
HA-ABIN∆407-431/
500-588
-
-
-
-
-
-
-
-
-
+ -
-
-
-
+ -
-
-
+
-
-
-
-
+
+ -
-
-
+
+ -
-
-
+
+
-
-
-
+
- -
-
-
+
+ -
-
-
+
+
-
-
-
+
- -
-
-
+
+
WB αHA
B
HA-ABIN
∆500-588
FLAG-NEMO
HA-A20
-
-
-
+
-
-
-
+
-
+
+
-
+
+
+
WB αFLAG
WB αHA
IP αFLAG
WB αHA
A20
ABIN
∆500-588
A20
ABIN
∆500-588
C
His-ABIN
FLAG-NEMO
HA-A20
-
-
-
+
-
-
+
-
+
+
+
+
+
+
+
WB αFLAG
WB αHA
IP αFLAG
WB αHA
WB αABIN
Figure 16. ABIN-1 interacts with NEMO/IKKγ and A20 to inhibit NF-κB activity. A) The deletion 
mutant of ABIN-1 lacking both NEMO- and A20-binding domains (ABIN∆407-431/∆500-588) 
does not block NF-κB activation. HEK293 cells were co-transfected with Ig-κB-luciferase reporter 
plasmid and the indicated combinations of expression plasmids. 24 h after transfection cells were 
stimulated with TNF for 3 h or left untreated, as indicated. Analysis was done as in Fig. 15. Lower 
panel show the relative expression levels of transfected proteins. B) ABIN-1 forms a complex with 
NEMO and A20. HEK293 cells were transfected with constructs encoding NEMO, A20 and a 
deletion mutant of ABIN lacking the NEMO binding domain (ABIN∆500-588). Cell extracts were 
immunoprecipitated with anti-FLAG antibodies (NEMO) and Western blotted anti-HA to reveal the 
co-precipitation of A20 and ABIN. The presence of -HA and -FLAG proteins in total extracts is 
shown. C) ABIN-1 promotes association of A20 with NEMO. HEK293 cells were transiently 
transfected with constructs encoding FLAG-NEMO, HA-A20 and increasing amount of His-ABIN. 
Cell extracts were immunoprecipitated with anti-FLAG antibodies (NEMO) and Western blotted 
anti-HA to reveal the co-precipitation of A20. The presence of ABIN, NEMO and A20 in the whole 
cell lysate is shown.
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activation induced by proteins acting at level of the IKK-complex, such as 
CIKS and TAX (Chu et al. 1999, Harhaj and Sun 1999, Jin et al. 1999, 
Leonardi et al. 2000a). In contrast, ABIN-1 was not able to inhibit the IKKβ-
mediated activation of NF-κB (Fig. 15A). Similarly, A20 inhibits NF-κB 
activation mediated by TNF-α or ectopic expression of TRAF2, CIKS and 
TAX but not IKKβ (Fig. 15B). These results indicate that both ABIN-1 and 
A20 interfere with activation of NF-κB at level of the IKK-complex, 
suggesting that the association of ABIN-1 with NEMO/IKKγ plays an 
important role in the inhibition of NF-κB. 
Because ABIN-1 interacts with both NEMO/IKKγ and A20, we tested 
whether the NEMO/IKKγ- and A20-binding domains of ABIN-1 were required 
for inhibition of NF-κB. ABIN-1 deletion mutants lacking either the 
NEMO/IKKγ binding domain (ABIN∆500-588) or the A20 binding domain 
(ABIN∆407-431) were still able to inhibit the activity of a NF-κB-driven 
luciferase reporter following different stimuli (data not shown). In contrast, a 
mutant of ABIN-1 in which both the NEMO/IKKγ- and the A20-binding 
domains were deleted (ABIN∆407-431/∆500-588) lost the ability to block 
activation of NF-κB (Fig. 16A). These data were consistent with the hypothesis 
that ABIN-1 forms a complex with both NEMO/IKKγ and A20. To address 
this hypothesis, we immunoprecipitated FLAG-NEMO/IKKγ and monitored 
the co-precipitation of the ABIN-1 mutant lacking the NEMO/IKKγ binding 
domain (HA-ABIN∆500-588) either in the presence or absence of A20 (Fig. 
16B). ABIN∆500-588 co-immunoprecipitated with NEMO/IKKγ only in the 
presence of A20. To further support the idea that ABIN-1 promotes association 
of A20 with NEMO/IKKγ, we transfected A20 and NEMO/IKKγ in the 
presence of increasing amount of overexpressed ABIN-1. As expected, the 
amount of A20 co-immunoprecipitating with NEMO/IKKγ increased in the 
presence of ABIN-1 (Fig. 16C). Taken together, these data indicated that 
ABIN-1 interferes with activation of NF-κB at level of the IKK-complex, and 
support the idea that ABIN-1 promotes association of A20 with NEMO/IKKγ. 
IX – A20 inhibits NF-κB by de-ubiquitinating NEMO/IKKγ 
To explore the mechanism by which the interactions of both A20 and 
ABIN-1 with NEMO/IKKγ down-regulate the NF-κB signaling, we assessed 
the effect of either A20 or ABIN-1 on NEMO/IKKγ ubiquitination. 
Transfection of FLAG-NEMO/IKKγ in the presence of HA-Ubiquitin resulted 
in the poly-ubiquitination of NEMO/IKKγ (Fig. 17A, lane 3). Co-transfection 
of A20 and NEMO/IKKγ resulted in a dose-dependent disappearance of the 
ubiquitinated forms of NEMO/IKKγ (Fig. 17A, lanes 4 and 5). In contrast, co-
transfection of ABIN-1 did not affect NEMO/IKKγ ubiquitination (Fig. 17A, 
lanes 6 and 7). We did not observe reduction in the overall level of 
ubiquitinated cellular proteins in the presence of A20, indicating that A20 does 
not have a global de-ubiquitinating activity. Importantly, A20 also blocks IκBα 
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degradation and NEMO/IKKγ ubiquitination induced by TNF-α (Fig. 17B). To 
demonstrate that the de-ubiquitinating activity of A20 was required for the 
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Figure 17. A20 inhibits NF-κB by de-ubiquitinating NEMO/IKKγ. A) A20 but not ABIN-1 de-
ubiquitinates NEMO. HEK293 cells were transfected with FLAG-NEMO and HA-Ubiquitin, plus 
increasing amounts of either HA-A20 or HA-ABIN. Cell extracts were immunoprecipitated with anti-
FLAG antibodies (NEMO) followed by Western blot anti-HA. Western blot analyses against FLAG, 
HA, A20, ABIN, and Tubulin were performed on total extracts. B) A20 blocks the ubiquitination of 
NEMO and the degradation of IκBα induced by TNF. HEK293 cells were transfected with FLAG-
NEMO, HA-Ubiquitin and HA-A20. 24 h after transfection cells were stimulated with TNF for 5 min 
or left untreated, as indicated. Cell extracts were immunoprecipitated with anti-FLAG antibodies 
(NEMO) and Western blotted anti-HA. Western blots anti-NEMO, -IκBα, -A20, and -Tubulin are 
shown. C) A catalytically inactive form of A20 (D100A/C103S) does not de-ubiquitinate NEMO. 
Conditions were similar to those in A, except for the plasmids encoding HA-A20 C103S, or 
D100A/C103S. D) A20 D100A/C103S does not inhibit NF-κB activation dependent on TRAF2 in 
contrast to wild type A20. Reporter assay was performed as above.
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observed reduction in NEMO/IKKγ ubiquitination, we generated two mutants 
in the OTU domain of A20, which is the domain responsible for the de-
ubiquitinating activity of A20 (Evans et al. 2003). We replaced the cysteine 
residue of the DXXC motif with serine (C103S), or both the aspartic acid and 
the cysteine residues (D100A/C103S) with alanine and serine. The mutation 
C103S affected the ability of A20 to de-ubiquitinate NEMO/IKKγ compared to 
wild type A20, whereas the double mutant D100A/C103S resulted in the 
complete loss of the de-ubiquitinating activity of A20 on NEMO/IKKγ (Fig. 
17C). As expected, the D100A/C103S mutant was not able to block the NF-κB 
activity induced by different stimuli, such as TRAF2 (Fig. 17D and data not 
shown). 
These findings strongly suggest that NEMO/IKKγ is a target for the de-
ubiquitinating activity of A20 and confirmed that the ubiquitination of 
NEMO/IKKγ is a crucial step in the mechanisms of NF-κB activation. 
X – ABIN-1 mediates the de-ubiquitinating activity of A20 on NEMO/IKKγ 
Next, we explored whether ABIN-1 was involved in the A20-dependent 
de-ubiquitination of NEMO/IKKγ. To this purpose, we transfected HEK293 
cells with sub-optimal amount of A20 and increasing amount of ABIN-1 and 
checked for NEMO/IKKγ ubiquitination. We found that ABIN-1 increases the 
ability of A20 to de-ubiquitinate NEMO/IKKγ (Fig. 18A). To demonstrate a 
role for ABIN-1 in the A20-mediated de-ubiquitination of NEMO/IKKγ, we 
generated small interfering RNA constructs (siRNAs) targeting ABIN-1 
(ABIN-i-370 and i-560; data not shown). Then, we evaluated whether RNA-
interference of ABIN-1 impairs the de-ubiquitinating activity of A20 on 
NEMO/IKKγ. We co-transfected HEK293 cells with FLAG-NEMO/IKKγ and 
HA-Ubiquitin and we assessed the de-ubiquitinating activity of A20 alone or in 
the presence of either i-370 or i-560 constructs. The A20-dependent de-
ubiquitination of NEMO/IKKγ decreased only in the presence of i-370 
construct (Fig. 18B). The i-370 construct led to a two fold increase of both 
basal and induced (TRAF2 and CIKS) NF-κB activity compared to the empty 
vector or the i-560 construct, that we used as controls (Fig. 18C). Accordingly 
with the data showed in Fig. 15A, interference of ABIN-1 did not influence the 
activation of NF-κB dependent on transfected IKKβ. Also in this case, the NF-
κB activity correlated with the levels of NEMO/IKKγ ubiquitination. In fact, 
transfected i-370 increased the ubiquitination of NEMO/IKKγ respect to both 
empty vector and i-560 (data not shown). From these experiments, we 
concluded that reduced levels of ABIN-1 affect the ability of A20 to de-
ubiquitinate NEMO/IKKγ and, consequently the A20-mediated inhibition of 
NF-κB. To further support the functional interplay between ABIN-1 and A20, 
we knocked-down A20 (Saitoh et al. 2005) and evaluated the ability of ABIN-
1 to interfere with NF-κB activation. As shown in Fig. 18D, ABIN-1 requires 
A20 to efficiently block NF-κB activation induced by TNF and TRAF2. 
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Taken together, these results support a model whereby ABIN-1 and 
A20 co-operate in inhibiting NF-κB activation, by inducing de-ubiquitination 
of NEMO/IKKγ (Fig. 19). In conclusion, blocking the inflammatory processes 
dependent on NF-κB activation, A20 and ABIN-1 represent candidate targets 
for developing innovative anti-cancer therapies. 
B
- - + + +
- + + + +
-
-- - -
- - - -
+
FLAG-NEMO
HA-Ubiquitin
ABINi-370
ABINi-560
HA-A20 - - - + +
+
+
+
-
+
WB αFLAG
IP αFLAG
WB αHA
WB αTubulin
Ub
WB αA20
A
- - + + +
- + + + +
-- - -
FLAG-NEMO
HA-Ubiquitin
HA-ABIN
HA-A20 - - - + +
+
+
+
WB αFLAG
IP αFLAG
WB αHA
WB αTubulin
WB αABIN
Ub
WB αA20
0
20
40
60
80
100
120
140
TRAF2
CIKS
IKKβ
ABINi-370
ABINi-560
L
uc
ife
ra
se
ac
tiv
ity
(a
rb
itr
ar
y
un
its
)
C
hTNF-α
-
-
-
-
-
-
-
-
-
+ -
-
-
-
+ -
-
-
-
-
-
-
-
-
+ -
-
-
-
+ -
+
-
-
+
-
+
-
-
- -
+
-
-
+ -
-
-
+
+
-
-
+
-
- -
-
-
+
+
- - - + + + -- - -- -
+
-
+
-
- -
-
-
+
-
- -
-
-
+
-
+
-
0
10
20
30
40
50
60
L
uc
ife
ra
se
ac
tiv
ity
(a
rb
itr
ar
y
un
its
)
CTLi
A20i
TRAF2
ABIN
D
-
-
- -
+
-
+
-
-
+
+
-
-
+
-
-
+
+
+
+
-
+ +- - ++ -
-
-
-
+
-
-
+ -
+
+
+
-
Figure 18. ABIN-1 participates to the A20-dependent de-ubiquitination of NEMO/IKKγ. A) ABIN-1 
increases the effects of A20 on NEMO ubiquitination. HEK293 cells were transfected with FLAG-
NEMO, HA-Ubiquitin, sub-optimal amount of HA-A20 and increasing amount of HA-ABIN. Cell 
extracts were immunoprecipitated with anti-FLAG antibodies (NEMO) and Western blotted anti-HA. 
Western blots anti-FLAG, -A20, -ABIN and -Tubulin are shown. B) ABIN-1 siRNAs impairs the A20-
dependent de-ubiquitination of NEMO. HEK293 cells were co-transfected with FLAG-NEMO, HA-
Ubiquitin and -A20, plus either ABINi-370 or -560. Cell extracts were immunoprecipitated with anti-
FLAG antibodies and Western blotted anti-HA. Western blots anti-FLAG, -A20 and -Tubulin were 
performed on total extracts. C) ABIN-1 siRNAs increase NF-κB activation by TRAF2 and CIKS. 
HEK293 cells were co-transfected with TRAF2, CIKS, or IKKβ, plus Ig-κB-luciferase reporter and 
either ABINi-370 or -570. 24 hours after transfection cells were stimulated with TNF for 3 h or left 
untreated. Analysis of reporter activity was done as above. D) RNA-interference of A20 impairs the 
ABIN-1-mediated inhibition of NF-κB. Relative reporter activity was evaluated in HEK293 cells co-
transfected with Ig-κB-luciferase reporter, TRAF2 and either A20i or CTLi plasmids. 24 h after 
transfection cells were stimulated with TNF for 3 h or left untreated, as indicated. Analysis of reporter 
activity was done as above.
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Figure 19. The model of ABIN-1/A20-mediated inhibition of 
NF-κB.
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Conclusions 
NF-kB is a master regulator of cell survival and its anti-apoptotic 
activity plays a key role in oncogenesis. However, very little was known on the 
oncogenic potential of NF-κB in thyroid. 
In the present study, we have shown that the activity of NF-κB is 
constitutively elevated in primary human thyroid carcinomas and correlates 
with malignant phenotype. In particular, anaplastic thyroid carcinoma cells 
display almost 100% of their nuclei positively stained for NF-κB. Activated 
NF-κB is also detected in an in vitro model of human thyroid cancer which 
resembles the in vivo differentiated and undifferentiated thyroid tumors. In 
these cell lines we have demonstrated that persistent NF-κB activity is 
progressively increasing from papillary thyroid carcinoma cells (NPA) to 
follicular carcinoma cells (WRO) until to reach the highest levels in anaplastic 
carcinoma cells (FRO), suggesting that sustained activation of NF-κB confers 
an advantage for malignant thyroid oncogenesis. 
NF-κB inhibition in FRO cells strongly enhances their sensitivity to 
undergo drug-induced apoptosis, and causes a dramatic decrease of their 
transforming potential. These in vitro functions of NF-κB are consistent with 
its role in tumor growth in vivo. In fact, FRO-IκBαM cells fail to form tumor in 
nude mice. The increased susceptibility to apoptosis of FRO-IκBαM and the 
evidence that constitutive activation of the NF-κB pathway rends NPA cells 
resistant to drug-induced apoptosis extend the idea that protection from 
apoptosis represents the major mechanism through which NF-κB enhances 
neoplastic transformation. 
Our data also suggest that the anti-apoptotic function of NF-κB is 
mediated by the inhibition of JNK signaling. We have shown that JNK activity 
is restored in FRO-IκBαM cells, where its duration is sustained after treatment 
with anisomycin. In addition, incubation of FRO-IκBαM cells with the specific 
JNK inhibitor SP600125 restores their resistance to chemotherapeutic drug-
induced apoptosis.  
Taken together, these data clearly substantiate the fundamental role of 
sustained activation of NF-κB in thyroid oncogenesis and open new 
perspectives for diagnosis and therapy of anaplastic thyroid carcinoma. 
To come through our idea to identify molecular targets of NF-κB 
potentially druggable against cancer, we have focused our efforts on studying 
mechanisms to switch off NF-κB activation. We have identified a previously 
not reported association between ABIN-1 and NEMO/IKKγ, the regulatory 
sub-unit of the IKK-complex. Further, we have provided evidence that ABIN-1 
targets A20 on NEMO/IKKγ. This trimeric association interferes with 
NEMO/IKKγ ubiquitination, thus resulting in down-regulation of NF-κB 
activation. 
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Appendix: Original papers 
Endoplasmic Reticulum Stress Causes Thyroglobulin
Retention in this Organelle and Triggers Activation of
Nuclear Factor-B Via Tumor Necrosis Factor Receptor-
Associated Factor 2
ANTONIO LEONARDI, PASQUALE VITO, CLAUDIO MAURO, FRANCESCO PACIFICO,
LUCA ULIANICH, EDUARDO CONSIGLIO, SILVESTRO FORMISANO, AND BRUNO DI JESO
Dipartimento di Biologia e Patologia Cellulare e Molecolare (A.L., C.M., L.U., S.F.), BioGem Consortium (P.V.), Centro di
Endocrinologia e Oncologia Sperimentale (F.P., E.C.), Federico II, University of Naples, 80100 Naples, Italy; and
Laboratorio di Patologia Generale, Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, University of Lecce
(B.D.J.), 73100 Lecce, Italy
Perturbing the endoplasmic reticulum homeostasis of thyroid
cell lines with thapsigargin, a specific inhibitor of the sarco-
endoplasmic reticulum Ca2 adenosine triphosphatases, and
tunicamycin, an inhibitor of the N-linked glycosylation,
blocked Tg in the endoplasmic reticulum. This event was sig-
naled outside the endoplasmic reticulum and resulted in ac-
tivation of the c-Jun N-terminal kinase (JNK)/stress-activated
protein kinase and nuclear factor-B (NF-B) stress response
pathways. Activation of the JNK/stress-activated protein ki-
nase signaling pathway was assessed by measuring the
amount of phospho-JNK and the activity of JNK by kinase
assays. Activation of the NF-B signaling pathway was as-
sessed by measuring the level of inhibitory subunit IB, DNA
binding, and transcriptional activity of NF-B. Cycloheximide
treatment, at a dose able to profoundly inhibit protein syn-
thesis in FRTL-5 cells, obliterated the decrease in the level of
the inhibitory subunit IB produced by thapsigargin and
tunicamycin. Therefore, protein synthesis was required to
generate a signal from stressed endoplasmic reticulum. This
substantiates the hypothesis that endoplasmic reticulum re-
tention of newly synthesized Tg and other cargo (secretory
and membrane) proteins functions upstream of signal activa-
tion. Dominant negative TNF receptor-associated factor 2
(TRAF2) inhibited activation of NF-B, which was also inhib-
ited in embryonic fibroblasts derived from TRAF2/ mice,
respect to their normal counterpart. These data extend the
recent demonstration that TRAF2 mediated JNK activation in
response to endoplasmic reticulum stress and strongly
strengthened the idea that endogenous stress signals initiated
in the endoplasmic reticulum proceed by a pathway similar to
that initiated by plasma membrane receptors in response to
extracellular signals. (Endocrinology 143: 2169–2177, 2002)
MEMBRANE AND SECRETORY proteins are cotrans-lationally translocated in the lumen of the endoplas-
mic reticulum where addition of N-linked oligosaccharide
chains, folding, and assembly occur. Protein folding and
processing within the lumen of the endoplasmic reticulum
are dependent upon the maintenance of a oxidizing envi-
ronment, a high Ca2 concentration, and a battery of endo-
plasmic reticulum-resident enzymes and chaperones. Alter-
ations in the endoplasmic reticulum redox potential,
glycosylation machinery, or Ca2 levels of the endoplasmic
reticulum secondary to various pathophysiological condi-
tions or pharmacological manipulations, as well as many
diseases, such as cystic fibrosis, Alzheimer’s disease, and
primary congenital hypothyroidism, cause misfolded pro-
teins to accumulate in the endoplasmic reticulum lumen.
These retained proteins, which are eventually degraded, trig-
ger a complex chains of events termed the unfolded protein
response (UPR) (1). Activation of mammalian UPR is char-
acterized in part by increased transcription of several genes
encoding endoplasmic reticulum molecular chaperones, as
well as induction of CHOP/GADD153, a transcription factor
that regulates growth arrest and apoptosis (2). These changes
occur concomitantly with a marked decrease in the rate of
protein synthesis (3). Stress of the endoplasmic reticulum
induced by agents that cause accumulation of misfolded
proteins in that compartment also activates c-Jun N-terminal
kinases (JNKs)/stress-activated protein kinases (SAPKs) (4).
In mammals it has been shown that an overload of the en-
doplasmic reticulum by protein overexpression (major his-
tocompatibility complex class I, adenovirus E3/19K) acti-
vates nuclear factor-B (NF-B), and this phenomenon has
been termed the endoplasmic reticulum overload response
(EOR) (5). However, many stimuli, such as tunicamycin,
thapsigargin, and brefeldin A, trigger both the UPR and the
EOR (6).
The signal transmission pathways that mediate the dif-
ferent responses in the UPR and EOR have been extensively
studied over the past several years. Mammalian cells contain
at least three endoplasmic reticulum signaling proteins. Ino-
sitol requiring (IRE) 1 and IRE1, encoded by different
genes, are transmembrane proteins that act as folding sensors
with their luminal domain and initiate the signal transmis-
sion with their cytosolic domain containing both an essential
Abbreviations: EndoH, Endo--N-acetylglucosaminidase H; EOR,
endoplasmic reticulum overload response; IRE, inositol requiring; JNK,
c-Jun N-terminal kinase; MEF, mouse embryonic fibroblast; NF-B, nu-
clear factor-B; PERK, PKR-ER-related kinase; PNGase F, Peptide N-
glycohydrolase F; SAPK, stress-activated protein kinase; THAPS, thap-
sigargin; TRAF, TNF receptor-associated factor; Tun, tunicamycin; UPR,
unfolded protein response.
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serine/threonine kinase and a ribonuclease module (7, 8).
The induction of both endoplasmic reticulum chaperone
genes and CHOP/GADD153 involves IRE1 activation (7, 8).
The third identified endoplasmic reticulum signaling protein
is PERK (PKR-ER-related kinase), which shows a luminal
domain and a cytosolic domain homologous to the cytosolic
RNA-dependent protein kinase (9). PERK mediates the re-
pression of protein synthesis through phosphorylation of
eIF-2a (9). Finally, the pathway that leads to NF-B involves,
in sequence, Ca2 loss from the endoplasmic reticulum lu-
men, increased production of reactive oxygen intermediates,
and activation of NF-B (10). Very recently, the pathway that
leads to JNK activation has been elucidated. After an endo-
plasmic reticulum stress, IRE1 becomes oligomerized and
activated, and this causes the clustering of TRAF2 to the
cytoplasmic portion of IRE1 and JNK activation (11). It ap-
pears, therefore, that the activation of JNK by endoplasmic
reticulum stress proceeds by a pathway similar to that used
by cells to respond to extracellular signals such as TNF. In
fact, TNF-induced receptor trimerization results in recruit-
ment of adapter proteins to their cytosolic side, among which
are the TRAF proteins, in particular TRAF2 (12, 13). The
TRAFs activate proximal kinases to initiate a kinase cascade,
causing JNK activation (14, 15). Notably, TRAF recruitment
to TNF receptors activates not only JNK, but also NF-B (12,
16). Therefore, we reasoned that if TRAF2 recruitment by
TNF receptors causes both JNK and NF-B activation, per-
haps TRAF2 recruitment by IRE1 after an endoplasmic re-
ticulum stress activates not only JNK, but also NF-B.
We have been studying a cellular system of fully differ-
entiated thyroid cells in continuous culture, the FRTL-5 and
PC-Cl3 cell lines. These cell lines synthesize and secrete very
large amounts of Tg, a high molecular weight glycoprotein
that constitutes the molecular site of synthesis and storage of
thyroid hormones. We have shown that treatment of FRTL-5
cells with thapsigargin in a low Ca2 medium (0.1 mm)
dramatically inhibits the secretion of Tg that is trapped in the
endoplasmic reticulum and alters its folding and oligomer-
ization (17). Moreover, we directly tested the action of thap-
sigargin on the endoplasmic reticulum Ca2 stores of FRTL-5
cells (17). Therefore, we decided to use this cellular system
to test the hypothesis that an endoplasmic reticulum stress,
chiefly a Ca2 loss from the endoplasmic reticulum lumen
caused by thapsigargin, activates through TRAF2 not only
JNK, but also NF-B.
Materials and Methods
Cell culture and biological reagents
FRTL-5 cells (CRL 8305, American Type Culture Collection, Manas-
sas, VA) are a continuous cloned line of thyroid differentiated cells (18).
These cells were maintained as previously described (19). WT and
TRAF2/ mouse embryonic fibroblast (MEF) were provided by Drs.
T. W. Mak and W. C. Yeh (20). These cells were cultured in MEM-
Glutamax (Life Technologies, Inc., Gaithersburg, MD) supplemented
with 10% FCS and 0.1 mm sodium pyruvate. Polyclonal anti-Tg rabbit
antibodies were raised against rat Tg as previously described (21). All
other antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Thapsigargin was obtained from Calbiochem (La Jolla,
CA); tunicamycin was purchased from Roche (Indianapolis, IN). The
dominant negative form of TRAF6 N275 was generated by PCR. The
dominant negative form of TRAF2N105 was previously described (22).
Metabolic labeling and immunoprecipitation
FRTL-5 cells (2  106) were labeled for 5 min at 37 C in medium
without cysteine and methionine containing [35S]cysteine and [35S]me-
thionine (50 Ci l-35S in vitro cell labeling mix/ml; Amersham Phar-
macia Biotech, Piscataway, NJ). The labeled cells were washed with cold
PBS and lysed in 1 ml 1% Triton X-100 lysis buffer [25 mm HEPES (pH
7.4), 150 mm NaCl, 10% glycerol, 5 mm EDTA, 2 mm dithiothreitol, and
Complete protease inhibitor mixture (Roche)]. Nuclear and cellular de-
bris were removed by centrifugation at 10,000 g for 10 min at 4 C. The
lysate was incubated for 2 h at 4 C with 2l anti-Tg polyclonal antibodies
and was collected with 20 l protein G-Sepharose beads (Amersham
Pharmacia Biotech). Beads were washed extensively with lysis buffer
and boiled in SDS sample buffer, and the supernatant was subjected to
5% SDS-PAGE and autoradiography.
Kinase assay
Anti-JNK immunoprecipitates were used for the immune complex
kinase assay that was performed at 30 C for 10 min with 2 g substrate,
10 Ci [-32P]ATP, and 50 m ATP in a total of 20 l kinase buffer [20
mm HEPES (pH 7.4), 10 mm MgCl2, 25 mm -glycerophosphate, 50 m
Na3VO4, and 50 m dithiothreitol]. The substrate was GST-c-Jun (amino
acids 1–79). The reactions were terminated by boiling in SDS sample
buffer, and the products were resolved by 12% SDS-PAGE. Phosphor-
ylated proteins were detected by autoradiography.
Reporter assay
FRTL-5 cells (4  105 cells/well) were seeded in six-well (35-mm)
plates. After 12 h cells were transfected with 0.5 g Ig-B-luciferase
reporter gene plasmid and various amount of each expression plasmid.
Lipofectamine-mediated transfections were performed according to the
manufacturer’s instructions (Life Technologies, Inc.). Total amounts of
transfected DNA were kept constant by supplementing empty expres-
sion vector plasmids as needed. Twenty-four hours after transfection
cells were stimulated with thapsigargin or tunicamycin for 8 h, cell
extracts were prepared, and reporter gene activity was determined via
the luciferase assay system (Promega Corp.). Expression of the Rous
sarcoma virus promoter--galactosidase vector (0.2 g) was used to
normalize transfection efficiencies.
EMSA
Total cell extracts were prepared using a detergent lysis buffer [50 mm
Tris (pH 7.4), 250 mm NaCl, 50 mm NaF, 1 mm Na3VO4, 0.5% Nonidet
P-40, 0.5 mm dithiotheritol, and Complete protease inhibitor mixture
(Roche)]. Cells were harvested by centrifugation, washed once in cold
PBS, and resuspended in detergent lysis buffer (30 l/5 106 cells). The
cell lysate was incubated on ice for 30 min, then centrifuged for 5 min
at 10,000  g at 4 C. The protein content of the supernatant was deter-
mined, and equal amounts of protein (10 g) were added to a reaction
mixture containing 20 g BSA, 2 g poly(dI-dC), 10 l binding buffer
[20 mm HEPES (pH 7.9), 10 mm MgCl2, 20% glycerol, 100 mm KCl, 0.2
mm EDTA, 0.5 mm dithiothreitol, and 0.5 mm phenylmethylsulfo-
nylfluoride] and 100,000 cpm of a 32P-labeled oligonucleotide in a final
volume of 20l. Samples were incubated at room temperature for 30 min
and run on a 4% acrylamide gel.
Other procedures
Endo--N-acetylglucosaminidase H (EndoH) and peptide N-glyco-
hydrolase F (PNGase F) digestions were performed as previously re-
ported (19).
Results
Thapsigargin and tunicamycin caused retention of Tg in
the endoplasmic reticulum
The ability of TRAF2 to transduce signals from both the
plasma membrane and the endoplasmic reticulum prompted
us to investigate its role in mediating NF-B activation after
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an endoplasmic reticulum stress. To this end we used a
thyroid cell line system in which an endoplasmic reticulum
stress was evaluated by monitoring the intracellular fate of
newly synthesized Tg. Treatment of FRTL-5 cells with thap-
sigargin, a specific inhibitor of the sarco-endoplasmic retic-
ulum Ca2-adenosine triphosphatases, in medium contain-
ing 0.1 mm Ca2 led to depletion of Ca2 from endoplasmic
reticulum stores and dramatically inhibited the secretion of
Tg. Tg was trapped in the endoplasmic reticulum and
showed alteration in its folding and oligomerization (17). To
improve the endoplasmic reticulum-stressing effect of thap-
sigargin, we decided to perform the thapsigargin treatments
in a nominally Ca2-free medium instead of a 0.1 mm Ca2
medium. FRTL-5 cells were pulse-labeled with [35S]methi-
onine and chased in a nominally Ca2-free medium in the
absence or presence of thapsigargin. At the indicated time of
chase, the amounts of secreted and intracellular Tg were
evaluated by immunoprecipitation and SDS-PAGE. As
shown in Fig. 1A, treatment with thapsigargin dramatically
inhibited Tg secretion in the culture medium. This suggested
that depletion of Ca2 from the endoplasmic reticulum
caused intracellular retention of Tg. As there were no dif-
ferences between the total Tg (secreted plus retained) im-
munoprecipitated from cells incubated with or without thap-
sigargin in either media (not shown), the differences
observed were due to inhibition of secretion and not to in-
tracellular degradation. This effect was not specific for thap-
sigargin, as a 2-h treatment of cells with 10 g/ml tunica-
mycin, an inhibitor of protein glycosylation, caused Tg to be
retained in FRTL-5 cells, as well (data not shown).
To confirm that thapsigargin also blocked Tg in the en-
doplasmic reticulum in a nominally Ca2-free medium, we
decided to repeat in this condition the experiment exploring
the EndoH sensitivity of the retained Tg. Newly synthesized
Tg is N-linked glycosylated in the endoplasmic reticulum,
where high mannose chains are attached to the protein. The
carbohydrate chains are then processed, and they become
EndoH resistant upon transport of the protein to the medial
Golgi (23). FRTL-5 cells were pulse-labeled with [35S]methi-
onine and chased for different times in a nominally Ca2-free
FIG. 1. A, Inhibition of Tg secretion by thapsigargin
in FRTL-5 cells cultured in a nominally Ca2-free
medium. B, Thapsigargin blocks the processing of Tg
high mannose oligosaccharides into complex carbo-
hydrates. C, Tunicamycin profoundly inhibits the N-
linked glycosylation of Tg. A, FRTL-5 cells were la-
beled with [35S]cysteine and [35S]methionine as
outlined in Materials and Methods and chased in a
nominally Ca2-free medium in the absence (Co) or
presence (Thaps) of 5 M thapsigargin for the indi-
cated times. Secreted and intracellular Tg were im-
munoprecipitated, resolved by SDS-PAGE, and
quantified by scanning densitometry. The mean la-
beled secreted Tg in three independent experiments
(SD) is plotted against the time of chase. B, FRTL-5
cells were labeled with [35S]cysteine and [35S]methi-
onine as outlined in Materials and Methods and
chased in a nominally Ca2-free medium in the ab-
sence (Co) or presence (Thaps) of 5 M thapsigargin
for the indicated times. Cells were lysed, and intra-
cellular Tg was immunoprecipitated, divided in two
aliquots, digested with or without EndoH, and re-
solved by SDS-PAGE. C, FRTL-5 cells were mock-
treated or treated with 10 g/ml tunicamycin for 60
or 120 min in a nominally Ca2-free medium and
labeled with [35S]cysteine and [35S]methionine as
outlined in Materials and Methods. Intracellular Tg
was immunoprecipitated, digested or mock-digested
with PNGase F as outlined in Materials and Meth-
ods, and resolved by SDS-PAGE.
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medium in the absence or presence of thapsigargin. Cells
were lysed, and intracellular Tg was immunoprecipitated
and digested with EndoH. The appearance of a slowly mi-
grating, EndoH-resistant Tg species in untreated cells indi-
cated that Tg moved from the endoplasmic reticulum to the
medial Golgi (Fig. 1B). Tg immunoprecipitated from FRTL-5
cells treated with thapsigargin did not show any slowly
migrating, EndoH-resistant form, thus demonstrating that a
loss of Ca2 from the endoplasmic reticulum caused Tg to be
retained at a point before the medial Golgi (Fig. 1B). To show
that 10 g/ml tunicamycin inhibited N-linked glycosylation
of Tg we explored the sensitivity of Tg, after tunicamycin
treatments, to PNGase F, which cleaves all N-linked chains.
As shown in Fig. 1C, treatment of FRTL-5 cells with 10g/ml
tunicamycin for 1 h inhibited the N-linked glycosylation of
the newly synthesized Tg by 50%, and treatment for 2 h
almost completely inhibited the N-linked glycosylation of
newly synthesized Tg. These data demonstrated that thap-
sigargin had a similar, perhaps more pronounced, effect on
FRTL-5 cells in a nominally Ca2-free medium compared
with a 0.1 mm Ca2 medium and that tunicamycin, in our
experimental conditions, strongly inhibited the N-linked gly-
cosylation of newly synthesized Tg. We conclude, therefore,
that both agents caused a block of Tg in the endoplasmic
reticulum very likely because of a folding defect (17), prob-
ably causing an endoplasmic reticulum stress.
Endoplasmic reticulum stress causes activation of the JNK
signaling pathway
It is well known that accumulation of proteins in the lumen
of the endoplasmic reticulum initiates a stress response
known as UPR/EOR. One of the pathways activated after
endoplasmic reticulum stress is the SAPK/JNK pathway
(11). To investigate whether the endoplasmic reticulum
stress triggered by thapsigargin and tunicamycin was able to
activate the SAPK/JNK pathway in FRTL-5 cells, we mea-
sured the levels of phospho-JNK, which is the active form of
JNK, in cells treated with tunicamycin or thapsigargin.
FRTL-5 cells were treated with tunicamycin for 60 and 120
min or with thapsigargin for 30 and 60 min. Cells were lysed,
and the amount of phospho-JNK was measured by Western
blot using phospho-specific anti-JNK antibodies. Both tuni-
camycin and thapsigargin increased the amount of phos-
phorylated JNK (Fig. 2A). Treatment of FRTL-5 cells with
thapsigargin consistently caused activation of JNK within 60
min, whereas the effect of tunicamycin was clearly visible
only after 120 min of treatment. Although it is possible that
a higher dose of tunicamycin would shorten the signaling
time, it is important to note that the time required for tuni-
camycin to activate JNK correlated well with the time re-
quired for tunicamycin to inhibit the N-linked glycosylation
of newly synthesized Tg, which is complete after 120 min
(Fig. 1C). To further demonstrate that the activity of JNK was
increased after induction of endoplasmic reticulum stress,
we also measured the relative levels of JNK kinase activity
in cells treated with thapsigargin or tunicamycin by using an
immune complex kinase assay. FRTL-5 cells were treated
with tunicamycin for 120 min or with thapsigargin for 60
min. The cell lysates were immunoprecipitated with anti-
JNK antibodies, and the activity of endogenous JNK was
measured in an in vitro kinase assay using GST-c-Jun as
substrate. Lysate from endoplasmic reticulum-stressed
FRTL-5 cells all exhibited increased JNK kinase activity
(Fig. 2B).
Endoplasmic reticulum stress causes activation of NF-B
NF-B is a ubiquitously expressed family of transcription
factors controlling the expression of numerous genes in-
volved in inflammation, immune responses, and protection
from apoptosis (24, 25). In most cell types NF-B is present
in an inactive form bound to its inhibitory subunit, IB. Upon
stimulation of cells with a variety of agents, such as inflam-
matory cytokines, UV irradiation, as well as bacterial and
viral infection, IB is phosphorylated on specific serine res-
idues and degraded through a proteosome-dependent path-
way (26). The released NF-B dimer rapidly translocates to
the nucleus, where it activates transcription of target genes.
To investigate whether the endoplasmic reticulum stress
triggered by thapsigargin and tunicamycin was able to ac-
tivate NF-B in FRTL-5 cells, we treated cells with thapsi-
gargin and tunicamycin and monitored the level of the in-
hibitory subunit IB by Western blot. As shown in Fig. 3A,
FIG. 2. Thapsigargin and tunicamycin activate the JNK signaling
pathway. A, FRTL-5 cells were treated with thapsigargin (Thaps; 5
M) for 30 and 60 min and with tunicamycin (Tun; 10 g/ml) for 60
and 120 min in a nominally Ca2-free medium. Cells were lysed, and
the amount of phospho-JNK was measured by Western blot using
phospho-specific anti-JNK antibodies. The amounts of cell lysate
loaded were normalized using polyclonal antitubulin antibodies. B,
FRTL-5 cells were treated with tunicamycin (10 g/ml) for 120 min
or thapsigargin (5 M) for 60 min in a nominally Ca2-free medium.
Cell lysates were immunoprecipitated with anti-JNK antibodies, and
the activity of endogenous JNK was measured by using GST-c-Jun
(amino acids 1–79). To normalize the amounts of cell lysate used in
the kinase assay, one tenth of each cell lysate was separately analyzed
for tubulin content by Western blot.
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the level of IB in the whole cell lysate was decreased after
treatment with thapsigargin and tunicamycin. As for JNK
activation, in the NF-B activation there was a striking cor-
relation between the time required to inhibit glycosylation of
Tg and the time required to signal outside the endoplasmic
reticulum. To further demonstrate the activation of NF-B
after endoplasmic reticulum stress, we performed an EMSA
on nuclear extract from FRTL-5 cells treated in the same way.
Both drugs caused the nuclear translocation of NF-B and
induced its DNA-binding activity (Fig. 3B). The specificity of
the protein-DNA complex was confirmed by a competition
assay. Binding was competed by the addition of nonradio-
active B oligonucleotide (Fig. 3B).
We subsequently tested whether the NF-B activated by
treatment with thapsigargin and tunicamycin was transcrip-
tionally active. FRTL-5 cells were transfected with an Ig-B
luciferase reporter plasmid and 24 h after transfection were
treated with thapsigargin and tunicamycin for 8 h. Both
thapsigargin and tunicamycin activated the NF-B-driven
luciferase activity (Fig. 3C).
FIG. 3. Thapsigargin and tunicamycin activate NF-B. A, FRTL-5 cells were treated with thapsigargin (Thaps; 5 M) and tunicamycin (Tun;
10 g/ml) for the indicated period of time. Cell extracts were Western blotted with anti-IB antibodies. The lower panel shows a Western blot
antitubulin as control for protein loading. B, FRTL-5 cells were treated with thapsigargin (Thaps; 5 M) and tunicamycin (Tun; 10 g/ml) for
the indicated period of time. Total cell extracts were prepared and analyzed by EMSA using a 32P-labeled oligonucleotide probe containing an
NF-B-binding site. The right part of the autoradiograph shows the same cell extracts incubated with a 50-fold molar excess of unlabeled NF-B
oligonucleotide. C, Relative luciferase activity observed in FRTL-5 cells transfected in triplicate with 0.5 g Ig-B luciferase reporter plasmid.
Twenty-four hours after transfection cells were stimulated with thapsigargin (Thaps; 5 M) or tunicamycin (Tun; 10 g/ml) for 12 h or were
left untreated (Co) and then harvested. Measurements were normalized for -galactosidase of a cotransfected Rous sarcoma virus--galacto-
sidase plasmid. Values shown (in arbitrary units) represent the mean (SD) of at least three independent experiments.
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Thus, endoplasmic reticulum stress after a luminal Ca2
loss or a block of glycosylation activated a functional NF-B
complex.
Protein synthesis is required to activate NF-B from the
endoplasmic reticulum
Our data suggest that the stressing effect of thapsigargin
and tunicamycin is linked to the retention in the endoplasmic
reticulum of Tg and other cargo proteins. To further support
this contention we tested whether a block of protein syn-
thesis by decreasing the level of newly synthesized Tg and
other cargo (membrane and secretory) proteins was able to
inhibit generation of the signal from the endoplasmic retic-
ulum. We monitored the activation of NF-B by assaying the
level of IB by Western blot after cycloheximide treatment.
Preliminary experiments showed that in FRTL-5 cells, cy-
cloheximide (0.5 g/ml for 1 h) was the optimal treatment,
because in these conditions protein synthesis was inhibited
by 70–80%, and a higher concentration did not give any
significant additional inhibition (not shown). Cells were
treated with cycloheximide (0.5 g/ml for 1 h), then with
thapsigargin for 60 and 90 min and with tunicamycin for 60
and 120 min, in the presence of cycloheximide, and the levels
of IB were assayed by Western blot. As shown in Fig. 4,
A and B, under control conditions thapsigargin and tunica-
mycin decreased IB by about 50%; in presence of cyclo-
heximide there was no reduction in IB. In addition, the
TNF-induced inhibition of IB was cycloheximide insensi-
tive. In these experiments we observed a reduction in IB
in the controls in the presence of cycloheximide compared
with the control level in the absence of cycloheximide. This
was probably caused by the action of cycloheximide to de-
crease the steady state levels of IB.
We concluded, therefore, that protein synthesis is specif-
ically required to generate a signal from the endoplasmic
reticulum, thus suggesting that signaling is a downstream
event of endoplasmic reticulum retention of newly synthe-
sized Tg and other cargo proteins.
TRAF2 mediates the endoplasmic reticulum stress-induced
activation of NF-B
Recently, it has been demonstrated that endoplasmic re-
ticulum stress activates JNK via the IRE1/TRAF2 complex
(11). Given the central role of TRAF2 in mediating endo-
plasmic reticulum responses, we investigated whether
TRAF2 was able to also mediate the endoplasmic reticulum
stress-induced NF-B activation. We tested the effect of an
N-terminal deletion mutant of TRAF2, which acts as a dom-
inant negative form of TRAF2 (22), on thapsigargin-induced
B reporter expression using a transient transfection assay in
FRTL5 cells. FRTL5 cells were transiently transfected with a
NF-B-driven luciferase reporter plasmid in the presence of
increasing amount of TRAF2N105. This dominant negative
form of TRAF2 was able to block the activation of NF-B after
thapsigargin treatment in a dose-dependent manner (Fig. 5).
Overexpression of a dominant negative form of another
FIG. 4. Protein synthesis is required to ac-
tivate NF-B from the endoplasmic reticu-
lum. A, FRTL-5 cells were treated with or
without 0.5g/ml cycloheximide for 1 h then
with thapsigargin (Thaps; 5 M) and tuni-
camycin (Tun; 10 g/ml) for the indicated
period of time in the presence or absence of
0.5 g/ml cycloheximide. Cell extracts were
Western blotted with anti-IB antibodies.
The lower panel shows a Western blot an-
titubulin as a control for protein loading. B,
IB/tubulin ratios from two different ex-
periments were plotted as a percentage of
the control in the absence () and in the
presence (f) of cycloheximide.
2174 Endocrinology, June 2002, 143(6):2169–2177 Leonardi et al. • Endoplasmic Reticulum Stress Causes Tg Retention
member of the TRAF family, TRAF6N275, did not affect the
NF-B activation after thapsigargin treatment (Fig. 5). The
dominant negative effect of TRAF2 N105 on TRAF2-
mediated signal transmission and that of TRAF6 N275 on
TRAF6-mediated signal transmission were demonstrated by
the ability of TRAF2N105 and TRAF6N275 to block TNF-
and IL-1-induced NF-B activation, respectively (Fig. 5).
To further demonstrate that TRAF2 is involved in signal-
ing from endoplasmic reticulum, we used TRAF2/ MEF.
The TRAF2/ phenotype is characterized by sensitivity to
TNF-induced cell death, almost complete reduction of JNK
activation, and delayed kinetics of activation of NF-B upon
TNF treatment (20, 27). Treatment of TRAF2/ MEF with
tunicamycin and thapsigargin did not caused a decrease in
IB (Fig. 6). In contrast, treatment of control MEF with the
same drugs resulted in strong decrease in IB (Fig. 6). These
results indicate that NF-B is activated in endoplasmic re-
ticulum-initiated signal transduction and suggest that
TRAF2 is involved in this pathway.
Discussion
In this paper we show that an alteration in endoplasmic
reticulum homeostasis causes retention of Tg in this or-
ganelle and activation of SAPKs and NF-B signal transmis-
sion pathways. Most importantly, we show that NF-B ac-
tivation involves, at least partially, the adaptor protein
TRAF2.
Alterations in the endoplasmic reticulum homeostasis
cause misfolded proteins to accumulate in the endoplasmic
reticulum lumen. These retained proteins, which are even-
tually degraded, trigger a complex chains of events termed
the UPR (1). Although the final effects of the UPR are well
known, the involved signal transmission pathways are less
understood and actively studied over the past several years.
It has been recently shown in pancreatic acinar epithelial
AR42J cells and in 293T cells that an endoplasmic reticulum
stress causes activation of the SAPK pathway and that this
involves TRAF2 (11). TRAF2 is a member of the TRAF family
of adapter molecules that link members of the TNF receptor
superfamily, IL-1 receptors, and Toll receptors to NF-B and
SAPK/JNK (16). In particular, TRAF2 appears to be central
to signaling via TNF receptors I and II. On the other hand,
the pathway originating from the endoplasmic reticulum
that leads to NF-B involves, in sequence, a Ca2 loss from
the endoplasmic reticulum lumen, an increased production
of reactive oxygen intermediates, and activation of NF-B
(10). Our results suggest the existence of a common mech-
anism coupling endoplasmic reticulum stress to SAPKs and
NF-B activation, in that both activation pathways use
TRAF2. Notably, the time required to activate NF-B and
SAPK was essentially the same, 1–2 h, which is considerably
shorter than the time required to up-regulate immunoglob-
ulin heavy chain binding protein mRNA in FRTL-5 cells after
treatments with thapsigargin and tunicamycin (6 h; data not
shown). Moreover, our data strengthened the idea that en-
dogenous stress signals initiated in the endoplasmic reticu-
lum proceed by a pathway similar to that initiated by plasma
membrane receptors in response to extracellular signals. In
fact, it is well know that the signal transmission pathway
originating from TNF receptors I and II activates both SAPKs
and NF-B via TRAF2. However, our results are compatible
with the fact that in response to an endoplasmic reticulum
stress, NF-B could also be activated by other signal trans-
mission mechanisms, for instance that described by Pahl and
Bauerle (10). If this is indeed the case, the similarity of the
pathways originating from TNF receptors and IRE1 is further
corroborated. In fact, TRAF2 is critically important in TNF-
initiated activation of SAPK/JNK. This has been confirmed
by the failure of TNF to activate this signaling path in cells
of mice lacking TRAF2 or expressing a dominant negative
form of TRAF2 (20, 27) However, NF-B activation is only
partially affected in the same cells. It was suggested that
other TRAF proteins, such as TRAF5, might have compen-
sated for the lack of TRAF2 (20). The latter hypothesis is
FIG. 5. Dominant negative TRAF2 blocks thapsigargin-dependent
NF-B activation. FRTL-5 cells (4 105) were transfected in triplicate
with 0.5 mg Ig-B luciferase reporter plasmid together with increas-
ing amounts of dominant negative forms of TRAF2 (T2N) or TRAF6
(T6N). Twenty-four hours after transfection cells were either stim-
ulated with thapsigargin (THAPS; 5 M) for 8 h or were left untreated
(Co) and then harvested. Measurement were normalized for -galac-
tosidase activity, and data (SD) are shown as arbitrary units.
FIG. 6. In mouse embryonic fibroblasts TRAF2/ thapsigargin and
tunicamycin were unable to activate NF-B. MEF and MEF
TRAF2/ cells were treated with thapsigargin (Thaps; 5 M) and
tunicamycin (Tun; 10 g/ml) for the indicated periods of time. Cell
extracts were Western blotted with anti-IB antibodies. The lower
panel shows a Western blot antitubulin as a control for protein
loading.
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supported by the lack of NF-B activation after TNF stim-
ulation in MEF derived from mice lacking both TRAF2 and
TRAF5 (28). It also possible, however, that an independent
mechanism exists by which the TNF receptor may activate
NF-B.
Accumulation of cargo proteins in the endoplasmic retic-
ulum occurs not only in various pharmacological manipu-
lations, but also in a variety of diseases, such as viral infec-
tions, primary congenital hypothyroidism (29), cystic fibrosis
(30), juvenile pulmonary emphysema (31), osteogenesis im-
perfecta (32), autosomal dominant neurohypophyseal dia-
betes insipidus (33), and familial hypercholesterolemia (34).
In about 20% of primary congenital hypothyroidism a mu-
tation is present in one of the genes encoding proteins es-
sential in the biosynthesis of thyroid hormones (29). One of
these proteins is Tg. Mutations of the Tg gene have been
found in both animals (35–38) and humans (39–43). Among
these mutations, missense mutations of the mouse gene (36),
the rat gene (38), and the human gene (42, 43) cause impaired
intracellular transport of Tg. In these cases there are greatly
enlarged thyroids, with the exception of the rdw/rdw rat (38),
and enlarged thyreocyte endoplasmic reticulum membranes.
The enlargement of the endoplasmic reticulum is due to the
expression of compensatory levels of endoplasmic reticulum
chaperones (triggered by accumulation of Tg), whereas the
increase in thyroid volume is caused by increased levels of
TSH (42). Using this feedback mechanism, cells maintain a
chaperone reserve to further binding to unfolded/misfolded
proteins that enter the endoplasmic reticulum. However, less
clear is the physiological role of NF-B in the UPR. NF-B
could trigger chaperone and/or endoplasmic reticulum
membrane formation to relieve the congestion of the endo-
plasmic reticulum. These hypotheses remain to be investi-
gated. On the other hand, it is well known that NF-B triggers
an inflammatory response. This induction could play a role
during viral infections where large quantities of viral pro-
teins are produced, causing an endoplasmic reticulum over-
load. In fact, interferons and cytokines, induced by NF-B,
can act as antiviral agents. Moreover, inflammation is well
documented in a subset of cystic fibrosis patients with the
PiZ variant of the 1-antitrypsin that have extensive hepatic
damage and early cirrhosis of the liver (44). An analogous
case could be represented by the rdw/rdw rat, which dra-
matically contrasts with most human patients and animal
models of congenital hypothyroid goiter. In this case a Tg
mutation causing impaired intracellular transport does not
exist in goiter, but, rather, in a hypoplastic thyroid gland (38).
In these cases NF-B could play a role in controlling endo-
plasmic reticulum stress-induced apoptosis in a way analo-
gous to TNF receptor-triggered apoptosis. Our results show-
ing that NF-B activation from the endoplasmic reticulum
involves the adaptor protein TRAF2, as NF-B activation
from TNF receptors does, further suggest this hypothesis.
This possibility is currently under investigation. Indeed, the
recent finding that caspase-12, an endoplasmic reticulum-
resident caspase, physically and functionally interacts with
TRAF2 (45) also substantiates the central role of TRAF2 as a
key switch of the endoplasmic reticulum controlling the al-
ternative adaptation/apoptosis.
In conclusion, in this study we demonstrate that an en-
doplasmic reticulum stress caused by thapsigargin and tu-
nicamycin triggers activation of SAPK/JNK and NF-B
stress response pathways, very likely acting through a re-
tention of Tg and other cargo proteins in the endoplasmic
reticulum. Moreover, we provide further evidence for the
central role that the adapter molecule TRAF2 plays in the
transduction of signals from the endoplasmic reticulum to
the cytosol during endoplasmic reticulum stress.
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Nuclear factor jB (NF-jB) plays a pivotal role in numerous cellular processes, including stress response, inﬂammation, and
protection from apoptosis. Therefore, the activity of NF-jB needs to be tightly regulated. We have previously identiﬁed a novel
gene, named CIKS (connection to IjB-kinase and SAPK), able to bind the regulatory sub-unit NEMO/IKKc and to activate NF-
jB. Here, we demonstrate that CIKS forms homo-oligomers, interacts with NEMO/IKKc, and is recruited to the IKK-complex
upon cell stimulation. In addition, we identiﬁed the regions of CIKS responsible for these functions. We found that the ability of
CIKS to oligomerize, and to be recruited to the IKK-complex is not suﬃcient to activate the NF-jB. In fact, a deletion mutant of
CIKS able to oligomerize, to interact with NEMO/IKKc, and to be recruited to the IKK-complex does not activate NF-jB,
suggesting that CIKS needs a second level of regulation to eﬃciently activate NF-jB.
 2003 Elsevier Inc. All rights reserved.
Keywords: NF-jB; CIKS/Act1; NEMO/IKKc; Signal transductionThe NF-jB proteins are an evolutionary conserved
family of transcription factors that regulate the expres-
sion of a variety of cellular genes involved in control of
apoptosis, immune and inﬂammatory responses [1,2]. In
most cell types NF-jB is sequestered in the cytoplasm,
bound to inhibitors, collectively called IjBs [3]. Various
stimuli, including cytokines, pathogens, and pathogen-
related factors, lead to phosphorylation of IjB proteins
on speciﬁc serine residues (Ser 32 and 36 for IjBa). This
phosphorylation marks IjBs for ubiquitination by the
SCF E3 ligase and subsequent degradation through a
proteosome-dependent pathway [4]. The IjB inhibitors
are phosphorylated by kinases residing in a large mo-
lecular weight complex (700–900 kDa) called the IjB
kinase-complex (IKK-complex). IKK-complexes are
composed of two catalytic sub-units, IKKa and b [5–9],
and a regulatory sub-unit called NEMO/IKKc [10,11].
In addition to the IjB proteins, it has been recently* Corresponding author. Fax: +39-081-770-1016.
E-mail address: leonardi@unina.it (A. Leonardi).
0006-291X/$ - see front matter  2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0006-291X(03)01532-8demonstrated that IKKs phosphorylate and regulate the
processing of the precursors of p50 and p52 sub-units,
respectively, p105/NF-jB1 and p100/NF-jB2 [12–14].
Beside these functions, IKKs may also modulate the
transcriptional activity of NF-jB proteins, phosphory-
lating the transactivation domain of RelA [15].
NEMO/IKKc was originally identiﬁed in a genetic
complementation assay, as a factor able to restore NF-
jB activation in cells unresponsive to a variety of stimuli
that normally induce the NF-jB pathway [10]. NEMO/
IKKc was also identiﬁed in biochemical studies as a
component of the high molecular weight IKK-complex
[11]. NEMO/IKKc contains a leucine zipper and two
coiled–coil domains. These motifs are important for its
oligomerization, which is critical for activating the IKK
kinase activity [16] and for recruitment of upstream
signalling mediators. Diﬀerent proteins have been
demonstrated to interact with NEMO/IKKc. These in-
clude a kinase known as RIP [17], the cellular protein
A20 [17], the viral transactivator tax [18–20], the cellular
protein CIKS [21], and the adaptor protein TANK [22].
C. Mauro et al. / Biochemical and Biophysical Research Communications 309 (2003) 84–90 85Thus NEMO/IKKc can interact with a variety of dif-
ferent regulatory proteins that are important in regu-
lating the activation of the NF-jB pathway in response
to diﬀerent stimuli. Despite all these evidences the
functions and the mechanisms of NEMO/IKKc activa-
tion remain to be determined. Particularly, it is still
unclear how the IKKs are activated following diﬀerent
stimuli. It has been proposed that oligomerization of
NEMO/IKKc is suﬃcient to activate the kinase activity
of the complex. For example, in response to TNF
stimulation, RIP may trigger oligomerization of the
IKK-complex through oligomerization of NEMO/IKKc
[16]. However, other mechanisms may exist to activate
the kinase activity of the IKK-complex, such as direct
phosphorylation of the IKKa=b by other kinases.
Previously, we reported on the identiﬁcation of a
NEMO/IKKc-interacting protein identiﬁed in a yeast
two-hybrid screen using NEMO/IKKc as bait, which we
called CIKS [21] (a.k.a. Act-1) [23]. CIKS does not have
any known enzymatic activity and contains a helix–
loop–helix motif at the amino terminus and a coiled–coil
at the carboxyl terminus. Forced expression of CIKS
activates NF-jB and JNK/SAPK pathways, suggesting
that CIKS may act as an adaptor protein, linking up-
stream signalling pathways to the NF-jB and JNK/
SAPK pathways. Recently, Qian et al. [24] reported that
CIKS may be involved in CD40 signalling, at least in
epithelial cells. Kanamori et al. [25] reported a potential
involvement of CIKS in the IL-1/Toll pathway, by
virtue of its ability to interact with TRAF6.
In this study, we used CIKS as a model to investigate
the molecular mechanism by which the IKK-complex is
activated. Particularly, we demonstrated that CIKS
forms oligomers, interacts with NEMO/IKKc, and is
recruited to the IKK-complex after cell stimulation. In
addition we identiﬁed the regions of CIKS responsible
for these functions. However, a deletion mutant of
CIKS able to oligomerize, to interact with NEMO/
IKKc, and to be recruited to the IKK-complex does not
activate NF-jB, suggesting that CIKS needs a second
level of regulation to eﬃciently activate NF-jB.Materials and methods
Cell culture and biological reagents. HeLa, HEK293 were main-
tained in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
fetal calf serum, 1% (w/v) penicillin/streptomycin, and 1% glutamine.
We used two anti-CIKS polyclonal antibodies: one was generated
in rabbits and was directed against a recombinant peptide encom-
passing amino acids 190–382 of human CIKS; the other was from
Santa Cruz Biotechnologies. The mouse monoclonal IgM to human
CD40 (clone 14G7) was from Caltag. Anti-FLAG and anti-FLAG
agarose gel were from Sigma. All other antibodies were from Santa
Cruz Biotechnologies.
Full-length NEMO/IKKc and full-length CIKS have been previ-
ously described [21]. The HA-CIKS DC300 (aa 1–274), HA-CIKS
DN300 (aa 300–574), and HA-CIKS DN87 (aa 87–574) were generatedby PCR. For yeast experiments CIKS full-length and diﬀerent CIKS
deletion mutants were cloned in-frame with the Gal4 DNA binding
domain of the vector pGBKT7 (Clontech) or with the Gal4 activation
domain of the vector pGADT7 (Clontech).
Transfection, immunoprecipitation, and luciferase assays. Lipofect-
AMINE-mediated transfections were performed according to the
manufacturer’s instructions (Life Technologies). For immunoprecipi-
tation of transfected proteins, HeLa cells (2 106) or HEK293
(3 106) were transiently transfected and 24 h after transfection cells
were lysed in Triton X-100 lysis buﬀer [20mM Hepes, pH 7.4, 150mM
NaCl, 10% glycerol, 1% Triton X-100, 1mM Na3VO4, 10mM b-
glycerophosphate, 5mM NaF, and “Complete Protease Inhibitor”
mixture (Roche Molecular Biochemicals)]. After an additional 15min
on ice, cell extracts were centrifuged for 20min at 14,000 rpm at 4 C
and supernatants were immunoprecipitated by using anti-HA or anti-
FLAG antibodies bound to agarose beads. The immunoprecipitates
were washed ﬁve times with Triton X-100 lysis buﬀer and subjected to
SDS–PAGE.
For immunoprecipitation of column fractions, fractions were in-
cubated overnight with 10 ll of anti-FLAG antibodies bound to aga-
rose beads. The immunoprecipitates were washed ﬁve times with
Triton X-100 lysis buﬀer and subjected to SDS–PAGE.
For luciferase assay, HeLa (2 105) or HEK293 (4 105) were
seeded in 6-well (35mm) plates. After 12 h cells were transfected with
0.5 lg of Ig-jB-luciferase reporter plasmid and various amounts of
each expression plasmid. Total amount of transfected DNA was kept
constant by supplementing empty expression plasmid as needed. Cell
extracts were prepared 24 h after transfection and reporter gene ac-
tivity was determined via the luciferase assay system (Promega). Ex-
pression of the pRSV-bGal vector (0.2lg) was used to normalize
transfection eﬃciencies.
Gel ﬁltration of cellular extract. HeLa cells were lysed in Triton X-
100 lysis buﬀer. Lysates were incubated for 15min on ice and clariﬁed
by centrifugation at 14,000 rpm for 15min, 4 C. Supernatants were
collected and recentrifuged for 1 h at 100,000g at 4 C. One milligram
of the S-100 extracts (0.5ml) was loaded onto a Superdex S200 HR
(Amersham–Pharmacia Biotech). Proteins were eluted from the col-
umn at the ﬂow rate of 0.3ml/min. Fractions (0.4ml) were precipitated
with 10% trichloroacetic acid, resuspended in Laemmli’s buﬀer, and
analyzed by SDS–PAGE followed by Western blotting for IKKa,
IKKb, NEMO/IKKc, and CIKS using appropriate antibodies.
Kinase assay. For IKK kinase assay, endogenous IKKb was
immunoprecipitated from the fractions eluted from the column by
using anti-IKKb antibodies and the kinase activity was assayed by
using GST-IjB (aa 1–54) as substrate.Results
CIKS forms oligomers
We have previously identiﬁed a novel protein we
called CIKS by using NEMO/IKKc as bait in a yeast
two-hybrid screening [21] (a.k.a. Act1) [23]. The activi-
ties of CIKS loosely resemble those of TRAF proteins.
In fact, similar to TRAF2, 5 or 6, overexpression of
CIKS activates SAPK/JNK and IKK kinases [21,26–
30]. The capacity of TRAFs to activate downstream
pathways appears to be linked to the ability of these
proteins to oligomerize [30]. In order to investigate if a
similar molecular mechanism was involved in the ability
of CIKS to activate NF-jB, we examined, in yeast, if
CIKS was able to form oligomers. Yeast strain AH109
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fused to the GAL4DNA-BD in the presence of full-
length CIKS fused to the GAL4AD (Fig. 1A). The
ability of the two fusion proteins to interact was judged
by growth of the yeast strain AH109 on selective media.
It was possible to detect an interaction between CIKS-
DNABD and CIKS-AD, suggesting that CIKS was ableFig. 1. Mapping the oligomerization domain of CIKS. (A) Yeast-two
hybrid experiment. The CIKS constructs cloned in-frame with the
GAL4 DNA binding domain of the vector pGBKT7 are schematically
illustrated. Plus and minus signs indicate growth or absence of growth
of the transformed yeast on medium lacking tryptophan, leucine,
histidine, and adenine in the presence of 15mM of 3-aminotriazole. (B)
Co-immunoprecipitation experiment. HeLa cells were transfected with
the indicated expression vector. Total extracts were immunoprecipi-
tated with anti-FLAG antibodies followed by Western blot analyses
with anti-HA antibodies (top panel). The presence of the diﬀerent
constructs in the whole cell lysate is demonstrated by Western blot in
the middle and bottom panels.to oligomerize, at least in yeast. While any deletion at
the amino terminus of CIKS did not aﬀect its ability to
oligomerize, deletion of the carboxyl-terminus coiled–
coil domain disrupted the interaction.
We conﬁrmed the results obtained in yeast, in tran-
sient transfection experiments. HeLa cells were trans-
fected with FLAG-tagged CIKS together with
HA-tagged CIKS or HA-tagged deletion mutants of
CIKS, lacking the amino- or the carboxyl-terminus
(CIKS DN300 and CIKS DC300). Cell extracts were
immunoprecipitated by using anti-FLAG antibodies
and the co-immunoprecipitated proteins were visualized
by Western blot with anti-HA-antibodies (Fig. 1B, up-
per panel). Full- length HA-CIKS and HA-CIKS
DN300 were co-immunoprecipitated with FLAG-
CIKS (Fig. 1B upper panel, lanes 5 and 6) while HA-
CIKS DC300 was not (Fig. 1B upper panel, lane 7),
despite the higher level of expression in HeLa cells. We
obtained similar results also in HEK293 cells (data not
shown). These data strongly suggest that CIKS is able
to form homo-oligomers and that this ability resides in
the C-terminal region.
CIKS is recruited to the IKK-complex
We previously demonstrated that CIKS interacts
with NEMO/IKKc and when overexpressed activates
the transcription factor NF-jB via IKKs [21]. Given the
ability of CIKS to interact with NEMO/IKKc and to
activate NF-jB, we investigated if CIKS was recruited
to the IKK-complex. We reasoned that if forced ex-
pression of CIKS mimics the active form of the protein
then, when overexpressed, CIKS might be recruited to
the IKK-complex. To this purpose, HeLa cells were
transiently transfected with an expression vector en-
coding FLAG-tagged CIKS and cellular extract was
loaded onto a Superdex S200 HR Fast Protein Liquid
Chromatography column. Fractions eluted from the
column were analyzed for the presence of speciﬁc com-
ponents of the IKK-complex and CIKS, using Western
blot analysis (Fig. 2). The majority of endogenous
IKKa, IKKb, and NEMO/IKKc were eluted in a peak
centered around a volume of 9ml (relative molecular
mass higher than 660,000Da), conﬁrming that the IKK-
complex is preconstituted in unstimulated cells. Analysis
of chromatographic distribution of transfected CIKS
showed that this protein was eluted in the same fractions
containing the components of the IKK-complex. In
addition, immunoprecipitating transfected CIKS from
these high molecular weight fractions, it was possible to
detect endogenous NEMO/IKKc co-immunoprecipi-
tating with transfected CIKS. To further demonstrate
that the interaction of CIKS with the IKK-complex
correlates with the functional activation of the complex,
we immunoprecipitated endogenous IKKb from the
high molecular weight fractions and assayed its ability
Fig. 2. Chromatographic distribution of CIKS in transfected cells.
HeLa cells were transfected with an expression vector encoding
FLAG-tagged CIKS. Cell extracts (S-100) were loaded onto a Super-
dex S200 FPLC column. (A) Elution proﬁle of the column. Position of
the molecular weight standards used to calibrate the column is indi-
cated by arrows. Tg: thyroglobulin, MW 660,000Da; BSA: bovine
serum albumin, MW 67,000Da; and Lys: lysozyme, MW 14,000. (B)
Fractions isolated from the Superdex S-200 column were subjected to
either Western blot or immunoprecipitation or kinase assay. For im-
munoprecipitation, fractions were incubated with anti-FLAG mono-
clonal antibodies (clone M2 from Sigma) bound to agarose beads. For
kinase assay, fractions were incubated with anti-IKKb antibodies
(Santa Cruz #7607). Molecular weight markers are indicated at the top
of the ﬁgure.
Fig. 3. Chromatographic distribution of endogenous CIKS. HeLa cells
were either treated with a stimulating anti-CD40 monoclonal antibody
(clone 14G7 from Caltag) for 30min or left unstimulated. Cytoplasmic
extracts (S100) were prepared and subjected to chromatography on a
Superdex S-200 column. Fractions derived from the column were
subjected to Western blot by using anti-NEMO/IKKc (Santa Cruz
#8330) or anti-CIKS (Santa Cruz #11444 or rabbit polyclonal raised
against a recombinant CIKS fragment) antibodies.
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speciﬁc IjB kinase activity in high molecular weight
fractions from CIKS transfected cells. These data dem-
onstrated that transfected CIKS was recruited to the
IKK-complex, via its ability to interact with NEMO/
IKKc and triggered activation of the kinase activity of
the complex.
We then analyzed the chromatographic distribution
of endogenous CIKS in untransfected cells (Fig. 3).
Most of the protein was eluted in a peak centered
around a volume of 15ml, corresponding to a molecular
mass of about 70,000Da, very similar to its predicted
molecular weight of 64,000Da. Recently, it has been
reported that CIKS may function as an adaptor mole-
cule in CD40-mediated pathways in epithelial cells [24].
In order to investigate if also the functionally active
form of endogenous CIKS was recruited to the IKK-
complex, we analyzed the chromatographic distribution
of endogenous CIKS in HeLa cells after CD40 trig-
gering. To this purpose HeLa cells were treated with a
stimulating anti-CD40 antibody for thirty minutes.
After stimulation, cells were washed and the lysate wasloaded onto a Superdex S200 HR Fast Protein Liquid
Chromatography column. Part of endogenous CIKS
was still eluted in a peak corresponding to a molecular
mass of 70,000Da. However, a fraction of CIKS moved
to the high molecular weight fractions and was coeluted
with components of the IKK-complex (Fig. 3), sug-
gesting that following triggering of CD40, at least part
of endogenous CIKS was recruited to the IKK-com-
plex. These results suggested that endogenous CIKS
was retained in the cytoplasm in a monomeric form in
unstimulated cells, while after stimulation it was
recruited to the IKK-complex.
Both the N-terminal and the C-terminal regions of CIKS
are required for interaction with NEMO/IKKc
We next investigated which region of CIKS was
necessary for the interaction with NEMO/IKKc. HeLa
cells were transfected with an expression vector encod-
ing FLAG-tagged NEMO/IKKc in the presence of dif-
ferent HA-tagged CIKS deletion mutants. Cell extracts
were immunoprecipitated by using anti-FLAG anti-
bodies and the co-immunoprecipitated proteins were
visualized by Western blot with anti-HA antibodies
(Fig. 4). Full-length CIKS and the deletion mutant
CIKS DN87 were co-immunoprecipitated with FLAG-
CIKS (Fig. 4 upper panel, lanes 7 and 10). Neither the
DN300 nor the DC300 mutants interacted with NEMO/
IKKc, thus suggesting that the central region of CIKS
was involved in the interaction with NEMO/IKKc.
CIKS oligomerization, recruitment to the IKK-complex,
and interaction with NEMO/IKKc are not suﬃcient to
activate the IKK-complex
One of the proposed mechanisms for activation of the
IKK-complex is that forced oligomerization of NEMO/
IKKc, IKKa, and IKKb can induce IKK and NF-jB
activation [16]. Given the ability of CIKS to form olig-
omers, to be recruited to the IKK-complex and to
Fig. 4. Mapping the NEMO/IKKc interaction site on CIKS. HeLa
cells were transfected with the indicated expression vectors. Total ex-
tracts were immunoprecipitated with anti-FLAG antibodies followed
by Western blot analyses with anti-HA antibodies (top panel). The
presence of the diﬀerent constructs in the whole cell lysate is demon-
strated by Western blot in the middle and bottom panels.
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these properties was necessary to activate NF-jB. HeLa
cells were transfected with an Ig-jB luciferase reporter
plasmid in presence of CIKS full-length or diﬀerent
deletion mutants of CIKS (Fig. 5A). Full-length CIKSFig. 5. (A) NF-jB activity of diﬀerent CIKS constructs. Relative lu-
ciferase activity observed in HeLa cells transfected in triplicate with
0.5 lg of Ig-jB luciferase reporter plasmid, with CIKS and diﬀerent
CIKS deletion mutants. Values shown (in arbitrary units) represent
means (SD) of three independent experiments, normalized for b-
galactosidase activity of a cotransfected RSV-b-galactosidase plasmid.
(B) Chromatographic distribution of CIKS deletion mutants in
transfected cells. HeLa cells were transfected with expression vectors
encoding diﬀerent FLAG-tagged CIKS deletion mutants. Fractions
isolated from a Superdex S-200 column were subjected to Western blot
analysis by using anti-FLAG antibodies.was able to strongly activate a jB-driven luciferase re-
porter plasmid, while the N-terminal deletion mutants
DN87 and DN300 and the C-terminal deletion mutants
DC300 did not. The incapacity of the DN300 and DC300
mutants to activate NF-jB might be explained by the
inability of these mutants to form oligomers and to in-
teract with NEMO/IKKc. Interestingly, the DN87 de-
letion mutant that forms oligomers and interacts with
NEMO/IKKc does not activate NF-jB. The amount of
each transfected plasmid was normalized given the dif-
ferent expression levels of these constructs (see Fig. 1B
and data not shown).
Next we investigated the chromatographic distribu-
tion of these CIKS mutants. HeLa cells were transfected
with the DN87, DN300, and DC300 deletion mutants.
Cell extracts (S100) were loaded onto a Superdex S200
HR Fast Protein Liquid Chromatography column and
fractions eluted from the column were analyzed by
Western blot by using anti-FLAG antibodies (Fig. 5B).
The C-terminal deletion mutant DC300 was eluted in a
peak corresponding to a molecular mass of about
30,000Da. The N-terminus deletion mutants DN87 and
DN300 were eluted in peaks corresponding to molecular
masses higher than 660,000Da and of about 120,000Da,
respectively. The chromatographic distribution of these
mutants reﬂected their ability to form oligomers and to
interact with NEMO/IKKc. In fact, the DC300 mutant
that was not able to oligomerize and to interact with
NEMO/IKKc was eluted at a volume corresponding to
a molecular mass similar to its predicted molecular
weight. In contrast, the DN87 mutant, still able to in-
teract with NEMO/IKKc and to oligomerize, was co-
eluted with components of the IKK-complex. The
DN300 mutant that retained the ability to oligomerize
but not to interact with NEMO/IKKc was eluted at a
volume intermediate between the other two mutants.
Taken together these results suggest that the ability of
CIKS to form oligomers and to be recruited to the IKK-
complex resides in diﬀerent regions of the protein and
that both activities are necessary but not suﬃcient to
correctly activate NF-jB.Discussion
In the present paper, we reported a functional
characterization of the adaptor protein CIKS. We
demonstrated that CIKS was able to form oligomers
and once overexpressed was recruited to the IKK-
complex through interaction with NEMO/IKKc. In
addition, we demonstrated that both transfected CIKS
and endogenous CIKS after CD40 triggering were re-
cruited to the IKK-complex. The ability of CIKS to
form oligomers resided in the C-terminal region, while
the ability to interact with NEMO/IKKc was mediated
by the central region of the protein. Both the capacities
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necessary to activate NF-jB. In fact, deletions aﬀecting
one of these functions abolished the ability of CIKS to
activate NF-jB. However, these functions were not
suﬃcient for a correct activation of NF-jB. In fact a
small N-terminus deletion mutant (DN87) still able to
interact with NEMO/IKKc and to form oligomers did
not activate NF-jB. Our data suggest that in addition
to oligomerization and interaction with NEMO/IKKc,
CIKS needs a second level of regulation to eﬃciently
activate NF-jB.
CIKS has been proposed to interact with TRAF3 and
by virtue of this interaction has been proposed to be
involved in the CD40 signalling. Quian et al. [24] pro-
posed a role for CIKS in the CD40 pathway. Based on
this model CIKS is recruited to CD40 after receptor
triggering. Our data extend this model, demonstrating
that after CD40 triggering, CIKS connects the receptor
and the IKK-complex, through its interaction with
NEMO/IKKc, mediating the activation of NF-jB. It
remains to be determined whether the IKK-complex is
recruited to the cytoplasmic domain of the receptor or,
after interaction with CD40, CIKS dissociates from the
receptor to interact with NEMO/IKKc.
The functions of CIKS resemble those of TRAF
proteins. These are adaptor molecules that mediate NF-
jB activation by diﬀerent receptors, such as members of
the TNF and IL-1/Toll receptor family. Activation of
NF-jB following TNF-receptor engagement is known
to be initiated recruiting diﬀerent adaptor molecules like
TRADD, RIP, and TRAF on the trimerized cytoplas-
mic domain of the TNF receptor [31]. RIP and TRAF,
in turn, transiently recruit and activate the IKK com-
plex, via NEMO/IKKc [17,32]. However, it is not yet
clear how the IKK-complex is activated. Recently, it has
been demonstrated that the enforced oligomerization of
NEMO/IKKc or any component of the IKK-complex is
suﬃcient to activate the kinase activity of the complex.
By virtue of its ability to form oligomers and to interact
with NEMO/IKKc after CD40 triggering, CIKS may
function in a similar way to activate the IKK-complex.
However, while the ability of CIKS to oligomerize and
to be recruited to the complex is both necessary to ac-
tivate NF-jB, these are not suﬃcient. In fact, a small
deletion of the N-terminal domain of CIKS (CIKS
DN87), that leaves unaltered the ability of CIKS to in-
teract with NEMO/IKKc, to be recruited to the IKK-
complex and to form oligomers, abolished its ability to
activate NF-jB. It is possible that the DN87 mutant is
incapable of inducing conformational changes impor-
tant for the activation of the kinase activity of the IKK-
complex. However, it is tempting to speculate that the
N-terminus of CIKS is interacting with some other
adaptor molecule(s) or some kinase(s) that are, in turn,
responsible for the activation of the IKK-complex. This
hypothesis is currently under investigation. It has beenreported previously that CIKS interacts with the protein
kinase TAK1 [24] but the exact role of this kinase in
CD40-mediated NF-jB activation needs to be further
addressed. In addition, the importance of other MAP3
kinase kinase kinase such as NIK, MEKK1, and
MEKK3 in the activation of the IKKs is still contro-
versial.
In summary, our data provide evidences about the
role of the adaptor protein CIKS in the activation of the
IKK-complex. After CD40 triggering CIKS is recruited
to the IKK-complex, through its ability to interact with
NEMO/IKKc and to form oligomers. However, these
abilities are not suﬃcient to activate NF-jB, suggesting
that CIKS needs a second level of regulation to eﬃ-
ciently activate NF-jB.Acknowledgments
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INTRODUCTION
Studies on the degradation of dental resin composites have confirmed therelease of substances like 2-hydroxyethyl methacrylate (HEMA) and
triethyleneglycol dimethacrylate (TEGDMA) from resin composites and
bonding agents. This release is highly dependent on the degree of
polymerization of the system, which is never complete (Geurtsen, 2000).
HEMA is frequently used in dental bonding resins as a wetting agent. It
competes with water for penetration and infiltration into dentin, and it
copolymerizes with other monomers of resin composites (Peutzfeldt, 1997).
HEMA has been shown to diffuse rapidly across dentin toward the pulp, and
this may cause pulp irritation (Bouillaguet et al., 1996).
Biological parameters such as cellular proliferation, vitality and cell
death, mitochondrial activity, and protein or nucleic acid synthesis have
been used as indicators of cellular responses to resin components (Hanks et
al., 1991; Kostoryz et al., 2001; Schweikl et al., 2001; Noda et al., 2002).
So far, few studies have assessed the type of cell death caused by dental
monomers (Janke et al., 2003; Engelmann et al. 2004; Spagnuolo et al.,
2004). Two modes of cell death have been described: apoptosis and
necrosis. Apoptosis is an active and physiological mode of cell death, which
permits the organism to eliminate unwanted or sub-lethally damaged cells
without triggering inflammatory reactions. In contrast, necrosis generally
sets off a tissue inflammation associated with clinical symptoms (Majno and
Joris, 1995).
The execution of apoptosis is mediated by caspases, a family of cysteine
proteases that plays a central role in the disassembly of the cell (Villa et al.,
1997). Caspase-9 is the initiator caspase of the mitochondrial pathway of
apoptosis, while caspase-8 is an initiator caspase of death-receptor-induced
apoptosis (Thornberry and Lazebnik, 1998). Reactive oxygen species
(ROS)—including hydrogen peroxide, superoxide anion, and the hydroxyl
radical—are involved in apoptosis. ROS may induce apoptosis directly or
act as intracellular messengers induced by various kinds of stimuli (Mates
and Sanchez-Jimenez, 2000).
Numerous studies suggest that ROS serve as common intracellular
mediators of IB degradation and subsequent NF-B activation (Baeuerle
and Henkel, 1994). The NF-B family of proteins is an inducible
transcription factor that regulates the expression of genes involved in
disparate processes such as immunity and inflammation, growth,
development, cell-death regulation, and protection from apoptosis (Karin
and Ben-Neriah, 2000). NF-B is known to be one of the major pro-survival
factors in many cells (Beg and Baltimore, 1996). In mammalian cells, there
are 5 NF-B proteins: p50, p52, p65 (RelA), RelB, and c-Rel. NF-B is
composed of homodimers and heterodimers of these proteins, typically
p65:p50, which are held in the cytoplasm by the inhibitory IB proteins.
Several IB proteins have been identified, including IB, IB, IB, and
IB proteins, of which IB and IB have been the best-studied (Karin
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and Ben-Neriah, 2000). Activation of NF-B is most often
mediated by IB degradation, which permits NF-B to enter
the nucleus (Karin, 1999).
Recent studies were focused on the type of cell death
caused by dental materials and monomers (Cimpan et al., 2000;
Janke et al., 2003; Spagnuolo et al., 2004) and on a possible
link between an increase in ROS levels and the toxicity of
monomers (Stanislawski et al., 2003). So far, there are no
similar data available on HEMA toxicity. We hypothesized that
HEMA causes an increase in the production of ROS, leading to
apoptosis. We found that HEMA induced apoptosis and
increased ROS levels in human primary skin fibroblasts.
Unexpectedly, HEMA-induced apoptosis was not reduced but
was enhanced by an anti-oxidant. Since several anti-oxidants
are NF-B inhibitors (Brennan and O'Neill, 1995), and
considering that NF-B is a pro-survival factor involved in
protection from apoptosis, we further investigated the
hypothesis that HEMA induces NF-B activation by increasing
ROS, speculating that HEMA-induced apoptosis is
counteracted by NF-B activation.
MATERIALS & METHODS
Cell Culture and Treatments
Human skin fibroblasts were obtained from punch biopsies taken
from the forearms of healthy normal volunteers. The informed
consent and protocol were reviewed and approved by the
Institutional Review Board (University of Napoli "Federico II").
Primary explant cultures were established in 25-cm2 culture
flasks in Dulbecco's Modified Essential Medium (DMEM)
containing 1000 mg/L glucose, 10% FBS, 2 mM glutamine,
penicillin (100 U/mL), and streptomycin (100 g/mL).
Monolayer cultures were maintained at 37°C in 5% CO2. All
reagents were purchased from Invitrogen (Carlsbad, CA, USA.
Fibroblasts between the 4th and the 10th subpassages were used
in all experiments. Mouse embryonic fibroblasts (MEF) derived
from wild-type mice and p65 knock-out mice (p65-/-) (gift from
Dr. G. Franzoso) were cultured in the same way as human
primary fibroblasts (De Smaele et al., 2001).
For each experiment, HEMA (Sigma, St. Louis, MO, USA)
was dissolved in dimethylsulfoxide (DMSO) (1 M stock solution)
and then diluted in culture medium. Cells cultured in the presence
of 0.3% DMSO alone served as the control in all experiments. A
10-M quantity of pyrrolidine dithiocarbamate (PDTC; Sigma), a
low-molecular-weight thiol compound, was used as an anti-oxidant
(Schreck et al., 1992).
Detection of Apoptosis
Cells were exposed to different concentrations of HEMA (0-10
mM) for 24 hrs at 37°C, harvested by centrifugation, and washed
once with phosphate-buffered saline (PBS). Then, 1x 105-106 cells
were suspended in 500 L of binding buffer. Untreated and
treated cells were stained with annexin V-FITC and propidium
iodide (PI) (MBL Medical & Biological Laboratories Co., Ltd.,
Nagoya, Japan), and incubated at room temperature for 15 min
before being analyzed by flow cytometry (FACScan, Becton-
Dickinson, San Jose, CA, USA). Apoptotic cells (annexin V+) and
necrotic cells (both PI+/annexin V+ or PI+ alone) were detected
and quantified as a percentage of the entire population (Vermes et
al., 1995). Analysis of the data was performed by means of the
WinMDI 2.8 program.
Measurement of Intracellular ROS
Generation of reactive oxygen species was measured with the use of
an oxidation-sensitive fluorescent probe, 27-dichlorofluorescin
diacetate (DCFH-DA; Molecular Probe, Inc., Eugene, OR, USA),
whose oxidized form (27-dichlorofluorescein, DCF) is highly
fluorescent (Myhre et al., 2003). Cells from routine cell cultures
were harvested by centrifugation, washed twice with PBS, and
suspended in 1 mL PBS. The cells were then loaded with 10 M
DCFH-DA and incubated at 37°C for 15 min. After the addition of
HEMA (from 0 to 10 mM), cells were incubated at 37°C for various
times (from 0 to 60 min). We used a FACScan flow cytometer to
measure ROS generation by the fluorescence intensity (FL-1, 530
nm) of 10,000 cells. Mean fluorescence intensity was obtained by
histogram statistics with use of the WinMDI 2.8 program.
SDS-PAGE and Western Blotting
Human skin fibroblasts were grown until 70-80% confluent and
exposed to 0-10 mM HEMA for different time periods. Cytosolic
extracts were then prepared with the use of a lysis buffer (20 mM
HEPES, 1% Triton X-100, 150 mM NaCl, 10% glycerol),
supplemented with protease inhibitors (Boeringher Mannheim,
Mannheim, Germany) and phosphatase inhibitors (1 mM NaF, 1
mM Na3VO4). Equivalent amounts of proteins (40 g) were
resolved on a 10% SDS-PAGE. Proteins were transferred to an
Immobilion-P membrane (Millipore, Bedford, MA, USA). The
membranes were blocked with 10% non-fat dry milk in
TBS/Tween-20 and probed with rabbit polyclonal anti-caspases
antibodies (-8, -9, and -3) and anti-IB (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). The secondary
antibody was a horseradish-peroxidase-linked anti-rabbit IgG
(Amersham Biosciences, Little Chalfont, Buckinghamshire,
England). Signals were detected by the ECL system (Amersham
Biosciences, Little Chalfont, Buckinghamshire, England).
EMSA (Electromobility shift assay)
Cell were treated with 10 mM HEMA for various time periods, and
total cell extracts were prepared by the use of a detergent lysis
buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 0.5% Nonited P-40, 50
mM NaF, 1 mM Na3VO4 and complete protease inhibitor mixture
[Roche]). Cells were harvested by centrifugation, washed once in
cold PBS, and then re-suspended in lysis buffer (30 L 5 x 106
cells). The cell lysate was incubated on ice for 30 min and then
centrifuged for 10 min at 10,000 x g at 4°C. The protein content of
the supernatant was determined, and equal amounts of proteins (5
g) were added to a reaction mixture containing 20 g BSA, 2 g
poly (dI-dC), 10 L binding buffer (20 mM HEPES, pH 7.5, 10
mM MgCl2, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM
dithiothreitol), and 100,000 cpm of a 32P-labeled -B
oligonucleotide in a final volume of 20 L. For competition assay,
a 100-ng quantity of non-radioactive -B oligonucleotide was
added to the reaction mixture. Samples were incubated at room
temperature for 30 min and then run on a 4% acrylamide gel.
Statistical Analysis
The statistical analyses of the data were performed by t tests or one-
way ANOVA, followed by the Bonferroni procedure for multiple
comparisons. The level of significance was set at p < 0.05.
RESULTS
Induction of Apoptosis and Caspases Activation by HEMA
In the concentration range of 4-10 mM HEMA, the fraction of
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apoptotic cells increased linearly,
reaching a level of 30.5% of cells
at a concentration of 10 mM
HEMA. In contrast, the fraction of
necrotic cells did not significantly
increase (Fig. 1A) (n = 4).
Various caspases were
activated during HEMA-induced
apoptosis. Caspase-3 was activated
in a concentration-dependent
manner after 24 hrs of treatment
with HEMA (Fig. 1B). Caspase-3
activation started 6 hrs after
treatment with 10 mM HEMA
cells (Fig. 1C). Moreover, the
processing of procaspases-9 and -8
appeared to be complete, as shown
by the disappearance of the
precursor forms (Fig. 1D).
HEMA Induces ROS and NF-B
Activation
HEMA increased ROS levels in a
dose-dependent manner; treatment
of cell culture with 10 mM HEMA
produced a two-fold increase in
fluorescence units compared with
untreated controls (Fig. 2A) (n =
5). The time-course of ROS
showed that ROS were produced
immediately after HEMA
treatment at all concentrations
used. The increase of ROS in
untreated cell cultures indicated
high metabolic activity (Fig. 2B)
(n = 5).
We treated the cells with 10
mM HEMA for 30, 60, and 180
min, and monitored the level of the
NF-B inhibitory subunit IB.
The levels of IB in cell lysates were decreased 180 min after
exposure to 10 mM HEMA (Fig. 3A). In addition, IB
degradation was dose-dependent (Fig. 3B). To assess the DNA
binding of NF-B, we performed an EMSA on total cell
extracts. A 10-mM quantity of HEMA caused DNA binding
after 180 min (Fig. 3C). The specificity of the protein-DNA
complex was confirmed by a competition assay performed by a
non-radioactive -B oligonucleotide (Fig. 3C).
NF-B Counteracts HEMA-induced Apoptosis
Since HEMA induced elevated ROS levels, we determined
whether ROS mediates HEMA toxicity. To this end, we
investigated the anti-oxidant effects of PDTC on HEMA-
induced apoptosis. PDTC is a small thiol compound, which
displays potent anti-oxidant activity (Schreck et al., 1991).
PDTC significantly blocked basal and HEMA-induced ROS
(Fig. 4A). Paradoxically, PDTC alone did not affect basal
apoptosis but significantly increased HEMA-induced
apoptosis, notwithstanding the reduction of ROS (Fig. 4B).
To identify the signals influenced by HEMA and PDTC, we
treated cells with HEMA in the absence and in the presence of
PDTC for 180 min and then determined IB degradation and
Figure 1. HEMA-induced apoptosis and caspases activation. (A) Dose-dependent induction of apoptosis.
Cells were treated with various concentrations of HEMA for 24 hrs, and apoptotic and necrotic cells were
stained with annexin V-FITC or PI, respectively. Cells were then detected and quantified by flow
cytometry as a percentage of the entire population (see MATERIALS & METHODS). Results represent the
means ± SEM of 4 independent experiments in duplicate (n = 4). * Significantly different from the
untreated control group (one-way ANOVA followed by Bonferroni post hoc test, p < 0.05). (B) Dose-
dependent caspase-3 activation. Cytosolic extracts from cells treated with 0-10 mM HEMA for 24 hrs
were analyzed by Western blotting with anti-caspase-3 antibodies. (C) Time-dependence of caspase-3
activation. The cells were treated with 10 mM HEMA for the indicated periods of time, and cytosolic
extracts were analyzed by Western blotting with anti-caspase-3 antibodies. (D) Caspase-8 and -9
activation. Cytosolic extracts from cells treated with 10 mM HEMA for 24 hrs were analyzed by Western
blotting with anti-caspase-8 and -9 antibodies. The amounts of cell lysate were normalized with the use
of polyclonal anti-actin or tubulin antibodies. Each Western blot is representative of at least 2
independent experiments.
Figure 2. Generation of ROS by HEMA in human fibroblasts.
Suspended cells were incubated with 10 M DCFH-DA for 15 min at
37°C. (A) The indicated concentrations of HEMA were added to the
cells and incubated for 30 min at 37°C. (B) From 0 to 10 mM HEMA
was added to the cells and incubated for 15, 30, and 60 min at 37°C.
DCF fluorescence was measured by means of a flow cytometer with an
FL-1 filter. Results represent the means ± SEM (n = 5). *Values are
significantly different from untreated controls (one-way ANOVA
followed by the Bonferroni post hoc test, p < 0.05).
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DNA binding of NF-B. PDTC completely blocked the
binding and IB degradation induced by 10 mM HEMA
(Figs. 3C, 4C). Reduction of active NF-B resulted in an
amplification of apoptosis (Fig. 4B) (n = 3). To investigate
this hypothesis, we used MEF from p65-/- mice. MEF wild-
type and p65-/- cells were treated with a sub-lethal
concentration of 8 mM HEMA. Interestingly, p65-/-
fibroblasts showed a significant increase (n = 3) of apoptosis
(three-fold) and necrosis (two-fold) compared with that in
wild-type cells (Fig. 4D).
DISCUSSION
In the present study, it was shown that HEMA elicited
activation of apoptotic pathways in primary human
fibroblasts. To elucidate the cell responses associated with
HEMA-induced apoptosis, we investigated the roles of
several components of apoptotic cell death mechanisms. We
found evidence that HEMA caused cell death predominantly
due to apoptosis rather than necrosis. This finding was
confirmed quantitatively by flow cytometry and supported by
caspases activation. HEMA induced processing of the
initiator procaspases-8 and -9, and the common downstream
effector procaspase-3. Apoptosis was dose- and time-
dependent.
ROS are involved in apoptosis as well as in cell survival
(Mates and Sanchez-Jimenez, 2000). Here, elevated levels of
ROS were observed immediately after HEMA treatment. The
amounts of ROS due to treatment with HEMA may be
underestimated related to in vivo situations, since the solvent
DMSO has previously been reported
to have ROS scavenger activity
(Zegura et al., 2004). ROS gen-
eration was completely reduced by a
free radical scavenger such as
PDTC. However, reduction of ROS
generation by PDTC did not prevent
HEMA-induced apoptosis. This
strongly suggested that ROS do not
directly mediate HEMA-induced
toxicity.
Many studies have suggested
that ROS serve as intracellular
mediators of IB degradation and
subsequent NF-B activation
(Baeuerle and Henkel, 1994). NF-
B has been implicated as a key
regulatory molecule that may
function to mediate a cellular
survival response (Beg and
Baltimore, 1996). In our
experimental system, IB was
degraded after 3 hrs of HEMA
treatment. This delayed timing of
IB degradation and DNA binding
of NF-B suggests that HEMA did
not directly induce NF-B. It is
likely that HEMA caused cell
damage which, in turn, could be
responsible for NF-B activation.
The fact that PDTC can
independently inhibit NF-B activation has been used in
support of a general model in which NF-B activation is
governed by oxidative stress (Schreck et al., 1991, 1992;
Moellering et al., 1999). Evidence is emerging, however, that
the major mode of the inhibitory action of PDTC may not be
restricted to its anti-oxidant activity (Brennan and O'Neill,
1995). We have shown that inhibition of IB degradation and
DNA binding of NF-B by PDTC significantly increased
HEMA-induced apoptosis in human fibroblasts. This suggests
that NF-B may be important for protection from HEMA-
induced apoptosis. The role played by NF-B was further
confirmed by the evidence that MEF from p65-/- mice are
more susceptible to HEMA-induced apoptosis.
It has been shown that HEMA diffuses through dentin,
and the risk of cytotoxic effects in pulp cells might be
increased (Bouillaguet et al., 1996). Noda et al. (2002)
estimated that HEMA leaching from dentin adhesives might
reach concentrations up to 1.5-8 mM in the pulp. This
concentration is within the range of our study. If used in a
direct pulp-capping procedure, then this concentration is
clearly higher than those used here. The balance of the
apoptotic-necrosis response induced by HEMA may have
time-concentration dependence. Therefore, if the HEMA
concentration is high, then apoptosis would never occur. If
low, then apoptosis could be more prominent. This might be
a critical feature in pulp-capping (direct or indirect), where
high-acute or low-chronic amounts of HEMA are exposed to
pulpal cells.
In summary, we demonstrated that HEMA induces cell
death through an apoptotic pathway in primary human
Figure 3. HEMA induces IB degradation and DNA binding of NF-B. (A) The cells were treated
with 10 mM HEMA for the indicated periods of time and (B) with 0-10 mM HEMA for 180 min.
Cytosolic extracts were analyzed by Western blotting with anti-IB antibodies. The lower panel
shows a Western blot anti-tubulin as control for protein loading. Experiments were performed 3
times, and a representative result is shown. (C) EMSA from cells treated with 10 mM HEMA for the
indicated period of time with or without PDTC. Total cell extracts were prepared and analyzed by
EMSA with a 32P-labeled oligonucleotide probe containing a NF-B-binding site. The middle portion
of the autoradiograph shows the same cell extracts incubated with a 50-fold molar excess of
unlabeled (cold) NF-B oligonucleotide.
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fibroblasts, involving activation of
caspase-8, -9, and -3. The HEMA-
induced apoptosis is not directly
dependent on the generation of ROS,
because reduction of ROS by anti-
oxidants had no effect on apoptosis.
Moreover, we provided experimental
evidence that NF-B plays a major
role in protecting cells from
apoptosis induced by HEMA.
ACKNOWLEDGMENT
This project was supported by the
Medical School of the University of
Naples "Federico II", by MIUR
(Italian Ministry of University and
Research) and by AIRC (Associazione
Italiana Ricerca sul Cancro).
REFERENCES
Baeuerle PA, Henkel T (1994). Function
and activation of NF-B in the
immune system. Annu Rev Immunol
12:141-179.
Beg AA, Baltimore D (1996). An
essential role for NF-B in
preventing TNF-alpha-induced cell
death. Science 274:782-784.
Bouillaguet S, Wataha JC, Hanks CT,
Ciucchi B, Holz J (1996). In vitro
cytotoxicity and dentin permeability
of HEMA. J Endod 22:244-248.
Brennan P, O'Neill LA (1995). Effects of
oxidants and antioxidants on nuclear
factor kappa B activation in three
different cell lines: evidence against
a universal hypothesis involving
oxygen radicals. Biochim Biophys
Acta 1260:167-175.
Cimpan MR, Cressey LL, Skaug N, Halstensen A, Lie SA, Gjertsen
BT, et al. (2000). Patterns of cell death induced by eluates from
denture base acrylic resins in U-937 human monoblastoid cells.
Eur J Oral Sci 108:59-69.
De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, et al.
(2001). Induction of gadd45beta by NF-kappaB downregulates
pro-apoptotic JNK signalling. Nature 414:308-313.
Engelmann J, Janke V, Volk J, Leyhausen G, von Neuhoff N,
Schlegelberger B, et al. (2004). Effects of BisGMA on glutathione
metabolism and apoptosis in human gingival fibroblasts in vitro.
Biomaterials 25:4573-4580.
Geurtsen W (2000). Biocompatibility of resin-modified filling
materials. Crit Rev Oral Biol Med 11:333-355.
Hanks CT, Strawn SE, Wataha JC, Craig RG (1991). Cytotoxic effects
of resin components on cultured mammalian fibroblasts. J Dent
Res 70:1450-1455.
Janke V, von Neuhoff N, Schlegelberger B, Leyhausen G, Geurtsen W
(2003). TEGDMA causes apoptosis in primary human gingival
fibroblasts. J Dent Res 82:814-818.
Karin M (1999). How NF-B is activated: the role of the IB kinase
(IKK) complex. Oncogene 18:6867-6874.
Karin M, Ben-Neriah Y (2000). Phosphorylation meets ubiquitination:
the control of NF-kappaB activity. Annu Rev Immunol 18:621-
663.
Kostoryz EL, Tong PY, Strautman AF, Glaros AG, Eick JD, Yourtee
DM (2001). Effects of dental resin on TNF--induced ICAM-1
expression in endothelial cells. J Dent Res 80:1789-1792.
Majno G, Joris I (1995). Apoptosis, oncosis, and necrosis. An
overview of cell death. Am J Pathol 146:3-15.
Mates JM, Sanchez-Jimenez FM (2000). Role of reactive oxygen
species in apoptosis: implications for cancer therapy. Int J
Biochem Cell Biol 32:157-170.
Moellering D, McAndrew J, Jo H, Darley-Usmar VM (1999).
Effects of pyrrolidine dithiocarbamate on endothelial cells:
protection against oxidative stress. Free Radic Biol Med
26:1138-1145.
Myhre O, Andersen JM, Aarnes H, Fonnum F (2003). Evaluation of
the probes 2,7-dichlorofluorescin diacetate, luminol, and
lucigenin as indicators of reactive species formation. Biochem
Pharmacol 65:1575-1582.
Noda M, Wataha JC, Kaga M, Lockwood PE, Volkmann KR, Sano H
(2002). Components of dentinal adhesives modulate heat shock
Figure 4. Effects of PDTC on ROS production, apoptosis, and IB degradation induced by HEMA.
Cells were pre-treated with 10 M PDTC for 30 min. (A) The cells were loaded with DCFH-DA and
further treated with 10 mM HEMA and PDTC for 30 min. DCF fluorescence was analyzed by flow
cytometry. Results represent the means ± SEM (n = 4). (B) Apoptotic and necrotic cells were detected
after 10 mM HEMA and PDTC treatments for 24 hrs. Results represent means ± SEM (n = 3). *Values
are significantly different from untreated controls (one-way ANOVA, followed by the Bonferroni post
hoc test, p < 0.05). (C) IB degradation was evaluated after 10 mM HEMA and PDTC treatment for
180 min. Western blot is representative of 2 independent experiments. (D) HEMA-induced apoptosis
in MEF wild-type vs. p65-/- cells. MEF and p65-/- cells were treated with 8 mM HEMA for 24 hrs.
Apoptotic (lower right quadrant) and necrotic (left and right upper quadrants) cells were then
detected by flow cytometry. The dot plot is representative of 3 independent experiments.
842 Spagnuolo et al. J Dent Res 83(11) 2004
protein 72 expression in heat-stressed THP-1 human monocytes at
sublethal concentrations. J Dent Res 81:265-269.
Peutzfeldt A (1997). Resin composites in dentistry: the monomer
systems. Eur J Oral Sci 105:97-116.
Schreck R, Rieber P, Baeuerle PA (1991). Reactive oxygen
intermediates as apparently widely used messengers in the
activation of the NF-B transcription factor and HIV-1. EMBO J
10:2247-2258.
Schreck R, Meier B, Männel DN, Dröge W, Baeuerle PA (1992).
Dithiocarbamates as potent inhibitors of nuclear factor-B
activation in intact cells. J Exp Med 175:1181-1194.
Schweikl H, Schmalz G, Spruss T (2001). The induction of
micronuclei in vitro by unpolymerized resin monomers. J Dent
Res 80:1615-1620.
Spagnuolo G, Galler K, Schmalz G, Cosentino C, Rengo S, Schweikl
H (2004). Inhibition of phosphatidylinositol 3-kinase amplifies
TEGDMA-induced apoptosis in primary human pulp cells. J Dent
Res 83:703-707.
Stanislawski L, Lefeuvre M, Bourd K, Soheili-Majd E, Goldberg M,
Perianin A (2003). TEGDMA-induced toxicity in human
fibroblasts is associated with early and drastic glutathione
depletion with subsequent production of oxygen reactive species. J
Biomed Mater Res 66(A):476-482.
Thornberry NA, Lazebnik Y (1998). Caspases: enemies within.
Science 281:1312-1316.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995).
A novel assay for apoptosis. Flow cytometric detection of
phosphatidylserine expression on early apoptotic cells using
fluorescein labelled annexin V. J Immunol Methods 184:39-51.
Villa P, Kaufmann SH, Earnshaw WC (1997). Caspases and caspase
inhibitors. Trends Biochem Sci 22:388-392.
Zegura B, Lah TT, Filipic M (2004). The role of reactive oxygen
species in microcystin-LR-induced DNA damage. Toxicology
200(1):59-68.
Oncogenic and Anti-apoptotic Activity of NF-B in Human
Thyroid Carcinomas*
Received for publication, March 30, 2004, and in revised form, September 23, 2004
Published, JBC Papers in Press, October 8, 2004, DOI 10.1074/jbc.M403492200
Francesco Pacifico‡§, Claudio Mauro§¶, Ciro Barone¶, Elvira Crescenzi¶, Stefano Mellone‡,
Mario Monaco, Gennaro Chiappetta, Giuseppe Terrazzano¶, Domenico Liguoro‡,
Pasquale Vito**, Eduardo Consiglio‡¶, Silvestro Formisano¶, and Antonio Leonardi¶‡‡
From the ‡Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, the ¶Dipartimento di Biologia e Patologia
Cellulare e Molecolare, “Federico II,” University of Naples, via S. Pansini, 5, Istituto Nazionale Tumori “Fondazione G.
Pascale,” via M. Semmola, 80131 Naples, and the **Dipartimento di Scienze Biologiche ed Ambientali, Facolta` di Scienze
MM. FF. NN., Universita` degli Studi del Sannio, via Port’Arsa, 11, 82100 Benevento, Italy
Thyroid cancer includes three types of carcinomas
classified as differentiated thyroid carcinomas (DTC),
medullary thyroid carcinomas, and undifferentiated
carcinomas (UTC). DTC and medullary thyroid carcino-
mas generally have a good prognosis, but UTC are usu-
ally fatal. Consequently, there is a need for new effective
therapeutic modalities to improve the survival of UTC
patients. Here we show that NF-B is activated in hu-
man thyroid neoplasms, particularly in undifferentiated
carcinomas. Thyroid cell lines, reproducing in vitro the
different thyroid neoplasias, also show basal NF-B ac-
tivity and resistance to drug-induced apoptosis, which
correlates with the level of NF-B activation. Activation
of NF-B in the DTC cell line NPA renders these cells
resistant to drug-induced apoptosis. Stable expression
of a super-repressor form of IB (IBM) in the UTC
cell line FRO results in enhanced sensitivity to drug-
induced apoptosis, to the loss of the ability of these cells
to form colonies in soft agar, and to induce tumor
growth in nude mice. In addition, we show that FRO
cells display a very low JNK activity that is restored in
FRO-IBM clones. Moreover, inhibition of JNK activity
renders FRO-IBM clones resistant to apoptosis in-
duced by chemotherapeutic agents. Our results indicate
that NF-B plays a pivotal role in thyroid carcinogene-
sis, being required for tumor growth and for resistance
to drug-induced apoptosis, the latter function very
likely through the inhibition of JNK activity. Further-
more, the strong constitutive NF-B activity in human
anaplastic thyroid carcinomas, besides representing a
novel diagnostic tool, makes NF-B a target for the de-
velopment of novel therapeutic strategies.
Thyroid carcinomas are one of the most common neoplasias
of the endocrine system (1). Four types of thyroid cancer com-
prise more than 98% of all thyroid tumors: papillary thyroid
carcinoma, follicular thyroid carcinoma, both of which may be
summarized as differentiated thyroid carcinoma, medullary
thyroid carcinoma (MTC),1 and undifferentiated anaplastic
thyroid carcinoma (ATC) (2). Papillary thyroid carcinoma, fol-
licular thyroid carcinoma, and ATC are derived from the thy-
roid follicular epithelial cells, whereas MTC is derived from the
parafollicular C cells (3). Papillary thyroid carcinoma is the
most common malignant thyroid neoplasm in countries with
sufficient iodine diets and comprises up to 80% of all thyroid
malignancies. Follicular thyroid carcinoma is more common in
regions with insufficient iodine diets and represents 10–20%
of all thyroid malignancies. The overall 5–10 year survival rate
of patients with papillary thyroid carcinoma is about 80–95%,
whereas that of patients with follicular thyroid carcinoma is
about 70–95% (3). The incidence of MTC is not well known
because epidemiologic studies are rare. Generally, it is believed
that MTC comprises about 5–10% of all thyroid malignancies
(2–4). ATC is one of the most aggressive human malignancies,
with a very poor prognosis. Although rare, accounting for up to
10% of clinically recognized thyroid cancers, the overall median
survival is limited to months (2, 3, 5). Surgery, radiotherapy,
and chemotherapy, based primarily on doxorubicin and cispla-
tin treatment, do not meaningfully improve survival of ATC
patients (5, 6). Consequently, there is a need for new therapeu-
tic tools for the treatment of these tumors.
The NF-B family of transcription factors regulates the ex-
pression of a wide spectrum of genes involved in inflammation,
immune response, cellular stress, cancer, and apoptosis (7–9).
In most cell types, NF-B is present in a latent form in the
cytoplasm and bound to NF-B inhibitory proteins collectively
termed IBs (10). A wide variety of extracellular signals, such
as pro-inflammatory cytokines, bacterial and viral infections,
oxidative stress, etc., initiate signaling cascade that culminates
in the phosphorylation and subsequent degradation of IBs,
through a proteasome-dependent pathway (11, 12). Degradation
of IB frees NF-B to enter the nucleus and to activate transcrip-
tion of target genes (11). IB phosphorylation is mediated by a
large complex referred to as the IB kinase complex (IKK com-
plex), composed of two catalytic subunits, IKK and IKK (13) as
well as a regulatory protein, named NEMO/IKK (14, 15).
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Numerous studies have indicated that NF-B activation can
block cell-death pathways (16). NF-B-inducible anti-apoptotic
factors include those that inhibit caspase function, such as
cellular inhibitor of apoptosis (17), X-linked inhibitor of apo-
ptosis (XIAP) (18), and Fas-associated death domain-like inter-
leukin 1-converting enzyme (19), those that inhibit NF-B
signaling after TNF receptor stimulation, such as TNF recep-
tor-associated factors (20), those that preserve function of mi-
tochondria, such as Bcl-XL (21), and those that block JNK
function, such as XIAP and growth arrest and DNA damage
(GADD)45 (22). Because it has been proposed that suppres-
sion of apoptosis is associated with oncogenic potential, and
given the ability of NF-B inhibitors to increase susceptibility
to apoptosis in transformed cells (23), one role for NF-B acti-
vation could be to suppress transformation-associated apopto-
sis. The NF-B signal transduction pathway is misregulated in
a variety of human cancers, especially ones of lymphoid origin,
due either to genetic changes (such as chromosomal rearrange-
ments, amplifications, and mutations) or to chronic activation
of the pathway by epigenetic mechanisms (24). Basal activation
of the NF-B pathway can contribute to the oncogenic state in
several ways: by driving proliferation (25), by enhancing cell
survival (26), by promoting angiogenesis, or by metastasis (27).
Because the development of a highly malignant tumor requires
several changes in cellular metabolism, including ones affect-
ing apoptosis, it is not surprising that the NF-B signal trans-
duction pathway, which influences various aspects of cellular
physiology, has emerged as playing a major role in many hu-
man cancers.
c-Jun NH2-terminal protein kinase (JNK), also known as
stress-activated protein kinase (28), is a member of the mito-
gen-activated protein kinase superfamily (29), having three
isoforms, JNK1, JNK2, and JNK3, with splicing variants (30).
Several lines of evidence suggest that JNK signaling is in-
volved in stress-induced apoptosis via the mitochondrial path-
way (30, 31), even though some studies have indicated that
JNK may also contribute to cell survival (30). From different
experimental evidence, it seems clear that the duration of JNK
activation affects its role in apoptosis: i.e. prolonged but not
transient JNK activation promotes TNF--induced apoptosis
(32, 33). However, it has also been demonstrated that pro-
longed JNK activation alone may not be sufficient to induce
apoptosis (33). Thus, the dual role of JNK in both apoptotic and
antiapoptotic signaling pathways suggests that the function of
JNK is complex and that the physiological response most likely
reflects a balance between the ability of JNK to signal both
apoptosis and cell survival. It has long been speculated that the
role of the JNK pathway in apoptosis is affected by other
signaling pathways. This has been recently demonstrated by
two different groups (32, 33) in two independent ways. Both of
them showed that NF-B is able to inhibit TNF--induced
apoptosis by negatively regulating activation of the JNK path-
way. They also demonstrated that the negative regulation of
JNK activity exerted by NF-B is mediated by two genes,
GADD45 (32) and XIAP (33), both of them under the tran-
scriptional control of NF-B.
Very little is known about the role that NF-B plays in
thyroid physiology. There is little evidence that NF-B may be
important in RET-mediated carcinogenesis and that may be
involved in maintaining the transformed phenotype of thyroid
cell lines (34, 35). However, the role that NF-B plays “in vivo”
in human thyroid neoplasia has not been fully investigated.
Here we show that NF-B is aberrantly expressed in primary
human thyroid carcinomas, and we provide evidence that
NF-B is required for maintaining the transformed phenotype
of UTC cells.
EXPERIMENTAL PROCEDURES
Cell Lines—NPA is a cell line derived from human papillary thyroid
carcinoma (36); FRO is a cell line derived from human anaplastic
thyroid carcinoma (37); and WRO is a cell line derived from human
follicular thyroid carcinoma (38). They were grown in Dulbecco’s mod-
ified Eagle’s medium (Sigma) supplemented with 10% fetal bovine
serum (Sigma). FRO cells were transfected with the empty expression
vector pcDNA3.1-FLAG (Invitrogen) (FRO Neo cells) or with the ex-
pression vector pcDNA3.1-FLAG vector encoding a mutant form (S32A/
S36A) of IB (FRO IBM cells) (a kindly gift of Dr. G. Franzoso) (32).
NPA cells were transfected with the empty expression vector
pcDNA3.1-FLAG (Invitrogen) (NPA Neo cells) or with the expression
vector pcDNA3.1-FLAG vector encoding human IKK (39) (NPA IKK
cells). The stable transfected clones were selected and maintained
TABLE I
NF-B nuclear localization in normal and pathological
human thyroid tissues
The percentage of cells with nuclear staining for NF-B was scored
from 0 to 3: 0, no positive cells; 1, 10% of positive cells; 2, 11–50%
of positive cells; 3, 76–100% of positive cells.
Histological type of
thyroid samples
No. positive cases/no. total
cases analyzed by
immunohistochemistry
NF-B staining
score
Normal thyroid 0/4 0
Papillary carcinoma 6/6 1
Follicular carcinoma 5/5 2
Anaplastic carcinoma 4/4 3
FIG. 1. Immunohistochemical anal-
ysis of NF-B activity in normal hu-
man thyroid and anaplastic human
thyroid carcinomas. Localization of
RelA (p65) in situ was determined by im-
munohistochemistry in sections from nor-
mal thyroid tissue (A) and three different
anaplastic thyroid carcinomas (B–D).
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in the presence of geneticin (200 g/ml).
Immunohistochemical Analysis—Specimens from normal and path-
ological human thyroid were isolated, rinsed with PBS, fixed in 4%
buffered neutral formalin, and embedded in paraffin. 5–6-m-thick
paraffin sections were then deparaffinized and placed in a solution of
absolute methanol and 0.3% hydrogen peroxide for 30 min and then
washed in PBS before immunoperoxidase staining. Slides were then
incubated overnight at 4 °C in a humidified chamber with antibody
anti-p65 diluted 1:100 in PBS and subsequently incubated, first with
biotinylated goat anti-rabbit IgG for 20 min (Vectostain ABC kits,
Vector Laboratories) and then with pre-mixed reagent ABC (Vector
Laboratories) for 20 min. The antibody anti-p65 used was a rabbit
polyclonal antibody from Santa Cruz Biotechnology (SC 7151). The
same results were obtained by using a mouse monoclonal anti-nuclear
localization signal from Roche Applied Science. The immunostaining
was performed by incubating slides in diaminobenzidine (Dako) solu-
tion containing 0.06 mM diaminobenzidine and 2 mM hydrogen peroxide
in 0.05% PBS (pH 7.6) for 5 min, and after chromogen development,
slides were washed, dehydrated with alcohol and xylene, and mounted
with coverslips using a permanent mounting medium (Permount).
Electromobility Shift Assays—To analyze NF-B DNA binding activ-
ity, total cell extracts were prepared using a detergent lysis buffer (50
mM Tris (pH 7.4), 250 mM NaCl, 50 mM NaF, 1 mM Na3VO4, 0.5%
Nonidet P-40, 0.5 mM dithiothreitol, and Complete protease inhibitor
mixture (Roche Applied Science)). Cells were harvested by centrifuga-
tion, washed once in cold PBS, and resuspended in detergent lysis
FIG. 2. NF-B activity in human
thyroid carcinoma cell lines. A, EMSA
on total cell extracts from human thyroid
carcinoma cell lines WRO, FRO, and NPA
in the presence of a 32P-labeled NF-B
oligonucleotide alone (lanes ) or with a
50-fold molar excess of an analogous un-
labeled oligonucleotide (lanes ) as com-
petitor. B, reporter gene assay on human
thyroid carcinoma cell lines WRO, FRO,
and NPA cell lines. A plasmid, containing
NF-B-binding sites of immunoglobulin
promoter region (Ig-B) upstream to a
promoterless luciferase reporter gene (Ig-
B-Luc), was transfected in thyroid carci-
noma cell lines, and luciferase activity
was measured 24 h later. Values shown
(in arbitrary units) represent the means
(S.D.) of three independent experi-
ments, normalized for -galactosidase ac-
tivity of a cotransfected Rous sarcoma vi-
rus--galactosidase plasmid.
FIG. 3. Cytotoxic effects of chemotherapeutic drugs on human thyroid carcinoma cell lines. 1  103 cells/well were seeded in 96-well
culture plates and incubated for 48 h at 37 °C with different concentrations of cisplatin (A) or doxorubicin (B). Cell survival was examined by using
MTS and an electron coupling reagent (phenazine methosulfate), according to the manufacturer’s instructions (Promega, Madison, WI). Cell death
was assessed by staining of exposed phosphatidylserine on cell membranes with fluorescein isothiocyanate-conjugated annexin V (Pharmingen).
Samples were analyzed by flow cytometry using a FACSCalibur (Beckman Instruments, Fullerton, CA), equipped with ModFit Software. Results
were mean  S.D. of at least three separate experiments.
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buffer (30 l/5  106 cells). The cell lysate was incubated on ice for 30
min and then centrifuged for 5 min at 10,000  g at 4 °C. The protein
content of the supernatant was determined, and equal amounts of
protein (10 g) were added to a reaction mixture containing 20 g of
bovine serum albumin, 2 g of poly(dI-dC), 10 l of binding buffer (20
mM HEPES (pH 7.9), 10 mM MgCl2, 20% glycerol, 100 mM KCl, 0.2 mM
EDTA, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluo-
ride), and 100,000 cpm of a 32P-labeled oligonucleotide, containing
specific binding sites for NF-B, in a final volume of 20 l. Samples
were incubated at room temperature for 30 min and run on a 4%
acrylamide gel.
To analyze AP-1 DNA binding activity, nuclear extracts were pre-
pared as follows: cells were harvested by centrifugation, washed once in
cold PBS, and resuspended in buffer A (10 mM HEPES (pH 7.9), 10 mM
KCl, 1.5 mM MgCl2, and 0.1 mM EGTA). The cells were then centrifuged
for 5 min at 1,000  g and resuspended in cold buffer C (20 mM HEPES
(pH 7.9), 400 mMNaCl, 1.5 mMMgCl2, 0.1 mM EGTA, and 25% glycerol).
The cell resuspension was subjected to strong shaking for 30 min at 4 °C
and then centrifuged for 15 min at 1,000  g. The protein content of the
supernatant was determined, and equal amounts of protein (10 g)
were added to a reaction mixture containing 20 g of bovine serum
albumin, 2 g of poly(dI-dC), 10 l of binding buffer (20 mM HEPES (pH
7.9), 10 mM MgCl2, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM
dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride), and 100,000
cpm of wild-type or mutant 32P-labeled AP-1 oligonucleotides, in a final
volume of 20 l. Samples were incubated at room temperature for 30
min and run on a 4% acrylamide gel.
Luciferase Assays—4  105 cells/well were seeded in a 6-well plate.
After 12 h, cells were transfected with 0.5 g of the Ig-B-luciferase
reporter gene plasmid. Cell extracts were prepared 24 h after transfec-
tion, and reporter gene activity was determined by the luciferase sys-
tem (Promega). A pRSV--galactosidase vector (0.2 g) was used to
normalize for transfection efficiencies. Cells were stimulated with phor-
bol 12-myristate-13-acetate (400 ng/ml) plus ionomycin (2 M) for 3 h
before lysis.
In Vitro and in Vivo Tumorigenicity Assays—To analyze the ability of
the various FRO clones to form colonies in soft agar, 1  104 cells were
seeded in 60-mm dishes onto 0.3% Noble Agar (Difco) on top of a 0.6%
bottom layer. Colonies larger than 50 cells were scored after 2 weeks
incubation at 37 °C (40).
To analyze the ability of the various FRO clones to induce tumor
growth in nude mice, 2  107 cells were injected subcutaneously on a
flank of each 6-week-old nude mouse (Charles River Breeding Labora-
tories, Lecco, Italy). Thirty days later, mice were killed, and tumors
were excised. Tumors weight was determined, and their diameters were
measured with calipers. Tumors volumes were calculated by the for-
mula: a2  b  0.4, where a is the smallest diameter, and b is the
diameter perpendicular to a. No mouse showed signs of wasting or other
visible indications of toxicity. The mice were maintained at the Dipar-
timento di Biologia e Patologia Cellulare e Molecolare animal facility
and housed in barrier facilities on a 12-h light-dark cycle with food and
water available ad libitum. The animal experiments described here
were conducted in accordance with accepted standards of animal care
and in accordance with the Italian regulations for the welfare of ani-
FIG. 4. Characterization of NPA IKK and FRO IBM clones. NPA cells were transfected with the empty vector pcDNA3.1-FLAG
(Invitrogen) (NPA Neo cells) or with the pcDNA3.1-FLAG vector containing the full-length cDNA encoding human IKK (NPA IKK cells). FRO
cells were transfected with the empty vector pcDNA3.1FLAG (Invitrogen) (FRO Neo cells) or with the pcDNA3.1FLAG vector containing the
mutant form (S32A/S36A) of IB super-repressor (FRO IBM cells). The stable transfectants, selected and maintained in the presence of
geneticin (200 g/ml), were characterized for their ability to express FLAG-tagged IKK (A) or IBM (B) proteins by Western blot analysis with
the Ab-FLAG (F 7425) polyclonal antibody (Sigma), and to respond to phorbol 12-myristate-13-acetate (PMA) plus ionomycin treatment (C and D)
by luciferase assay.
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mals used in studies of experimental neoplasia, and the study was
approved by our institutional committee on animal care.
Cytotoxic Treatments and Measurements of Apoptosis—1  103 cells/
well were seeded in 96-well culture plates and incubated for 48 h at
37 °C with different concentrations of cisplatin or doxorubicin and,
where indicated, with/without 10 M JNK inhibitor SP600125 (BioMol
Research Laboratories Inc., Plymouth Meeting, PA). Cell survival was
examined by using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), and an
electron coupling reagent (phenazine methosulfate), according to the
manufacturer’s instructions (Promega, Madison, WI). Cell death was
assessed by staining of exposed phosphatidylserine on cell membranes
with fluorescein isothiocyanate-conjugated annexin V (Pharmingen) or
by propidium iodide staining according to Nicoletti et al. (41). Samples
were analyzed by flow cytometry using a FACSCalibur (Beckman In-
struments, Fullerton, CA), equipped with ModFit Software. Results
were mean  S.D. of at least three separate experiments.
Western Blot Analysis—Subconfluent monolayers of parental and
transfected FRO cells were washed three times with PBS and then
lysed in a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 10%
glycerol, 1% Triton X-100, and a mixture of protease inhibitors (Sigma).
An aliquot of the cell lysates was used to evaluate the protein content by
colorimetric assay (Bio-Rad). Total proteins from cell lysates (50 g)
were analyzed by 10% SDS-PAGE. After electroblotting of gels onto
polyvinylidene difluoride sheets (Millipore, Bedford, MA), filters were
blocked for 1 h at room temperature with 10% non-fat dry milk in TBST
buffer (10 mM Tris-HCl (pH 8.0), 0.1% Tween 20, 150 mM NaCl). The
filters were then incubated in the same buffer for 14–16 h at 4 °C with
1:2000 dilution of the Ab-FLAG (F 7425) polyclonal antibody (Sigma).
After TBST washing, blots were incubated for 1 h at room temperature
with anti-rabbit horseradish peroxidase-conjugated antibodies (Amer-
sham Biosciences) diluted 1:5000 in TBST buffer and then revealed by
ECL (Amersham Biosciences).
A similar procedure was achieved to analyze phospho-JNK and total
JNK levels on lysates from parental and transfected FRO cells after
treatment with 10 g/ml anisomycin (Sigma) at different time intervals.
In this case, the monoclonal Ab-pJNK1/2 (9255) (Cell Signaling Technol-
ogy Inc., Beverly, MA) recognizing phosphorylated JNK or the polyclonal
Ab-JNK1/2 (9252) (Cell Signaling Technology Inc.) recognizing total JNK
were used at 1:1000 dilution. After TBST washing, blots were incubated
for 1 h at room temperature with secondary antibodies horseradish per-
oxidase-conjugated (Amersham Biosciences), diluted 1:5000 in TBST
buffer, and then revealed by ECL (Amersham Biosciences).
[3H]Thymidine DNA Incorporation—5  104 cells/well were seeded
in 12-well culture plates and incubated for 4 h at 37 °C with 0.5
Ci/well of [3H]thymidine (Amersham Biosciences). After three wash-
ings with cold PBS, cells were incubated for 10 min at 4 °C with 0.5 ml
of 20% trichloroacetic acid. The trichloroacetic acid was removed, and
cells were lysed with gentle shaking for 30 min at 37 °C in the presence
of 1 N NaOH (0.5 ml/well). An aliquot of lysates (0.1 ml) was used to
FIG. 5. Cytotoxic effects of chemo-
therapeutic drugs on parental and
transfected thyroid carcinoma cells.
1  103 cells/well were seeded in 96-well
culture plates and incubated for 48 h at
37 °C with different concentrations of cis-
platin or doxorubicin. Cell survival was ex-
amined by using MTS and an electron cou-
pling reagent (phenazine methosulfate),
according to manufacturer’s instructions
(Promega, Madison, WI). Cell death was
assessed by staining of exposed phosphati-
dylserine on cell membranes with fluores-
cein isothiocyanate-conjugated annexin V
(Pharmingen). Samples were analyzed by
flow cytometry using a FACSCalibur
(Beckman Instruments, Fullerton, CA),
equipped with ModFit Software. A repre-
sentative experiment out of three is shown.
A and B, NPA Neo cells and NPA IKK
clones; C and D, FRO Neo cells and FRO
IBM clones.
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evaluate the protein content by colorimetric assay (Bio-Rad), whereas
the remnant was analyzed at the -counter (Beckman Instruments)
after adding an equal volume (0.4 ml) of 1 N HCl to neutralize the
samples. Results were the means  S.D. of two separate experiments.
CFSE Cell Proliferation Assay—The analysis of cell proliferation was
performed by labeling cells with CFSE (Molecular Probes, Eugene, OR)
as originally described (42). Flow cytometry and data analysis were
performed by using a two laser equipped FACSCalibur apparatus and
the Cellquest analysis software (BD Biosciences), as described (43).
RESULTS
Basal NF-B Activity in Human Thyroid Carcinomas—To
determine the activation state of NF-B in primary thyroid
cancer tissues, human specimens from normal thyroid, papil-
lary, follicular and anaplastic thyroid carcinomas were col-
lected and stained with anti-p65 (RelA) antibodies. The results
of these experiments are summarized in Table I. No nuclear
staining for RelA was detected in normal thyroid follicular cells
(Fig. 1A), whereas few nuclei from papillary carcinoma cells
were positive for RelA. Follicular carcinoma cells showed50%
of their nuclei stained for NF-B, whereas anaplastic carci-
noma cells showed almost 100% of their nuclei strongly positive
for NF-B (Fig. 1, B–D, and Table I). Most interestingly, the
increased nuclear localization of NF-B correlates with the
increased malignant phenotype of thyroid carcinomas, suggest-
ing that sustained activation of NF-B confers an advantage
for clonal selectivity. These results indicate that the nuclear
localization of p65 is a characteristic of human anaplastic thy-
roid carcinomas and suggest a role of NF-B in human
thyroid carcinomas.
NF-B Transcriptional Activity in Human Thyroid Trans-
formed Cells—The high levels of basal NF-B activity in hu-
man thyroid carcinomas prompted us to investigate the role of
NF-B in thyroid neoplastic transformation. To this aim, we
used three different cell lines that resembled the features of
thyroid tumors. These cell lines are as follows: WRO (38),
derived from a human follicular thyroid carcinoma, FRO (37),
derived from a human anaplastic thyroid carcinoma, and NPA
(36), derived from a human papillary thyroid carcinoma.
In these cells we analyzed by EMSA the nuclear localization
of NF-B and, by reporter assay, its transcriptional activity. As
shown in Fig. 2A, FRO cells showed the highest NF-B DNA
binding activity, whereas it was barely detectable in NPA cells
(Fig. 2A). The specificity of the protein-DNA complex was con-
firmed by a competition assay with nonradioactive B oligonu-
cleotide. To demonstrate that the nuclear NF-Bwas transcrip-
tionally active, we performed reporter gene assays in all three
cell lines. Consistent with EMSA experiments, FRO cells
showed the highest NF-B transcriptional activity, whereas
NPA cells showed an almost undetectable activity (Fig. 2B).
Taken together, these data indicate that NF-B was transcrip-
tionally activated in thyroid carcinoma cell lines, particularly
in the human anaplastic thyroid cell line FRO.
NF-B Activity Is Essential to Confer Resistance to Drug-
induced Apoptosis in Thyroid Carcinoma Cell Lines—In order
to determine a correlation between NF-B activity and cell
sensitivity to drug-induced apoptosis, we tested the ability of
cisplatin and doxorubicin in promoting cell death in WRO,
FRO, and NPA cells. As shown in Fig. 3, A and B, both drugs
induced cell death in all three cell lines, at an extent that
correlated with the levels of basal NF-B activity. To test
whether NF-B activation protects neoplastic thyroid cells
from apoptosis induced by chemotherapeutic drugs, we stably
transfected NPA cells with an expression vector encoding
IKK, to induce constitutive NF-B activity, and FRO cells
with a super-repressor form of IB (IBM), to suppress basal
NF-B activity. Two NPA clones, NPA IKK 7 and NPA
IKK 18, as well as two FRO clones, FRO IBM 14 and
FRO IBM 16, were used in our study. They expressed
different levels of IKK (Fig. 4A) or IBM (Fig. 4B) and were
differentially able to activate NF-B (Fig. 4, C and D). In fact,
although the constitutive IKK expression strongly increased
basal NF-B activity in NPA clones (Fig. 4C), the presence of
IBM in FRO clones led to a decrease of both basal and
phorbol 12-myristate-13-acetate/ionomycin-induced NF-B ac-
tivity (Fig. 4D).
Stably transfected and mock-transfected cells were then
treated with increasing amounts of cisplatin (Fig. 5, A and C) or
doxorubicin (Fig. 5, B and D) for 48 h, and the cell survival and
cell death were measured. Although NPA Neo cells were sen-
sitive to cell death induced by chemotherapeutic drugs, NPA
IKK clones became resistant to apoptosis induced by either
cisplatin (Fig. 5A) or doxorubicin (Fig. 5B). On the other hand,
FRO Neo cells were still resistant to drug-induced cell death,
whereas FRO IBM clones underwent apoptosis after treat-
ment even at low dosage of either cisplatin (Fig. 5C) or doxo-
rubicin (Fig. 5D). These results indicate that NF-B activity is
required and sufficient to confer resistance to drug-induced
apoptosis of neoplastic thyroid cells.
Inhibition of FRO Cells Transforming Potential by NF-B
Inactivation—We next investigated if in addition to its role in
protecting cells from apoptosis, NF-B was also involved in
other oncogenic properties of thyroid carcinoma cells. There-
TABLE II
In vivo tumor growth induced by FRO Neo cells and
FRO IkBaM clones
2  107 cells were injected subcutaneously on a flank of each 6-week-
old nude mouse (Charles River Breeding Laboratories, Lecco, Italy).
Thirty days later, mice were killed, and tumors were excised. Tumor
weight was determined, and their diameters were measured with cali-
pers. Tumor volumes were calculated by the formula: a2  b  0.4,
where a is the smallest diameter, and b is the diameter perpendicular
to a.
Cell type Tumorincidence
Tumor volume
average
Tumor weight
average
cm3 g
Parental cells
FRO Neo 6/6 1.48  0.4 0.146  0.04
Transfected cells
FRO IBM 14 0/6
FRO IBM 16 2/6 0.27  0.06 0.029  0.002
FIG. 6. In vitro oncogenic potential of FRO Neo cells and FRO
IBM clones. 1  104 cells were seeded in 60-mm dishes onto 0.3%
Noble Agar (Difco) on top of a 0.6% bottom layer. Colonies larger than
50 cells were scored after 2 weeks of incubation at 37 °C. FRO Neo
cells  50 colonies/plate; FRO IBM 14 cells  0 colonies/plate;
FRO IBM 16  5 colonies/plate. A, 100 magnification. B, 200
magnification.
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FIG. 7. Analysis of cell proliferation rate in FRO Neo cells and FRO IBM clones. A, 5  104 cells/well were seeded in 12-well culture
plates and incubated for 4 h at 37 °C with 0.5 Ci/well of [3H]thymidine (Amersham Biosciences). After three washings with cold PBS, cells were
incubated for 10 min at 4 °C with 0.5 ml of 20% trichloroacetic acid. Trichloroacetic acid was then removed, and cells were lysed with gentle shaking
for 30 min at 37 °C in the presence of 1 N NaOH (0.5 ml/well). An aliquot of lysates (0.1 ml) was used to evaluate the protein content by colorimetric
assay (Bio-Rad), whereas the remnant was analyzed at the -counter (Beckman Coulter) after adding an equal volume (0.4 ml) of 1 N HCl to
neutralize the samples. Results were the mean  S.D. of three separate experiments. B, FRO Neo cells and FRO IBM clones were collected and
analyzed after 0, 12, and 24 h after CFSE labeling, as indicated. x axes indicate the CFSE fluorescence log intensity, whereas y axes refer to cell
number count. Data are representative of one of two independent experiments.
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fore, we analyzed in vitro and in vivo the transforming poten-
tial of FRO Neo and FRO IBM cells. The in vitro assay was
performed by analyzing the ability of transformed cells to form
colonies on soft agar. As shown in Fig. 6, whereas parental FRO
cells (FRO Neo) gave rise to numerous and large colonies in soft
agar (upper panels), FRO IBM 14 and FRO IBM 16
clones lost this property (middle and lower panels). These
results were also confirmed by in vivo assays. Table II shows
that injection in nude mice of FRO Neo cells induced tumor
formation in 6 out of 6 nude mice. Injection of FRO IBM
14 and FRO IBM 16 cells induced tumor formation in 0
out of 6 and 2 out of 6 mice, respectively. In addition, the two
tumors developed from FRO IBM 16 cells were about
5-fold smaller than that formed after injection of parental
cells (Table II). Thus, inhibition of NF-B activity in FRO
cells led to a strong decrease of their transforming potential,
suggesting a role for this transcription factor in thyroid
carcinogenesis.
The Inhibition of NF-B Activity in FRO Cells Did Not Affect
Their Proliferative State—The imbalance between proliferation
and apoptosis is one of the critical cellular events that lead to
oncogenesis. Because NF-B controls transcription of genes
involved in the regulation of apoptosis and cell proliferation,
the inhibition of NF-B activity in FRO cells could affect both
proliferation and apoptosis. To test for this, we analyzed the
proliferation rate of parental and transfected FRO cells by
[3H]thymidine DNA incorporation and by CFSE assay (Fig. 7).
No significant differences in the rate of [3H]thymidine DNA
incorporation were appreciable between FRO Neo cells and
FRO IBM clones (Fig. 7A), and a very similar doubling time
was detected after 12 and 24 h of CFSE treatment (Fig. 7B),
indicating that NF-B activation is not required to control
proliferation of FRO cells.
The Anti-apoptotic Activity of NF-BWas Mediated by Down-
regulation of JNK Activity—NF-B is crucial to oncogenesis
and to chemoresistance in cancer, controlling activation of pro-
survival genes and down-regulation of pro-apoptotic genes (16).
For example, it has been shown recently that NF-B inhibits
TNF--induced apoptosis by repressing the JNK pathway (32,
33). Therefore, we investigated if inhibition of NF-B activity
in FRO IBM clones affects JNK activation. To this aim, we
first analyzed transcriptional activity of AP-1, a target of JNK
activity, by EMSA on nuclear extracts from FRO Neo cells and
FRO IBM clones (Fig. 8A). As shown in the Fig. 8, AP-1 DNA
binding activity, almost undetectable in FRO Neo cells, was
partially restored in FRO IBM clones (Fig. 8A, left panel).
Next, we investigated JNK activity in FRO Neo cells and FRO
IBM clones by analyzing its phosphorylation status follow-
ing anisomycin stimulation (Fig. 8B, upper panel). As shown in
Fig. 8, anisomycin induced JNK phosphorylation as early as 10
min of treatment in all cell lines, but, while the pJNK level in
FRO Neo cells decreased with time, it remained sustained in
FRO IBM clones. Anisomycin treatment had no effect on
JNK expression, as assessed by Western blot analysis.
These data suggest that the basal NF-B activation re-
pressed JNK activity in FRO cells, and suggested that the
FIG. 8. JNK activity in FRO Neo
cells and FRO IBM clones. A, EMSA
on nuclear extracts from human thyroid
carcinoma cell lines FRO Neo, FRO
IBM 14, and 16 in the presence of a
32P-labeled wild-type AP-1 oligonucleo-
tide (left panel) or in the presence of a
32P-labeled mutant AP-1 oligonucleotide
(right panel). n. s.  nonspecific. B, 5 
105 cells/well were seeded in 6-well cul-
ture plates and incubated for different
time intervals at 37 °C with 10 g/ml ani-
somycin (Sigma). Cell lysates were ana-
lyzed by Western blot assays with the
monoclonal Ab-pJNK1/2 (9255) (Cell Sig-
naling Technology Inc.) raised against
phosphorylated JNK (upper panel) or
with the polyclonal Ab-JNK1/2 (9252)
(Cell Signaling Technology, Inc.) raised
against total JNK (lower panel).
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sensitivity of FRO IBM clones to apoptosis induced by che-
motherapeutic agents could be due to restoration of JNK activ-
ity. To investigate this hypothesis, we analyzed the apoptosis
rate in FRO Neo and FRO IBM 14 cells after treatment
with 5 g/ml cisplatin or doxorubicin in the presence of 10 M
SP600125, a specific inhibitor of JNK activity (44). Cell death
was assessed by propidium iodide staining and was repre-
sented by the fraction of cells in sub-G1 phase (Fig. 9). The
inhibition of JNK activity by SP600125 rendered FRO IBM
resistant to apoptosis induced by cisplatin (Fig. 9B) or doxoru-
bicin (Fig. 9D). These results suggest that NF-B inhibits che-
motherapeutic drug-induced apoptosis of FRO cells by, at least
partially, negatively regulating JNK signaling.
DISCUSSION
In the present paper, we show that the transcription factor
NF-B plays an important role in thyroid cancer. Its activity was
constitutively elevated in primary human thyroid carcinomas
and was correlated with malignant phenotype. In particular,
anaplastic thyroid carcinoma cells displayed almost 100% of their
nuclei positively stained for NF-B. Activated NF-B was also
detected in an in vitro model of human thyroid cancer that
resembles the in vivo differentiated and undifferentiated thyroid
tumors. In these cell lines we demonstrate that persistent NF-B
activity was progressively detected in papillary thyroid carci-
noma cells (NPA) to follicular carcinoma cells (WRO) until reach-
ing the highest levels in anaplastic carcinoma cells (FRO), sug-
gesting that sustained activation of NF-B confers an advantage
for clonal selectivity. An interesting question is how thyroid can-
cer cells acquired a basal NF-B activity. By using Western blot
analysis, we detected low levels of IB protein in FRO cells
(data not shown). Given that transcription of the IB gene is
strongly up-regulated by NF-B, the low level of IB protein
suggests a high turnover of the protein. One may speculate that
thyroid cells may have acquired defects in components that reg-
ulate IB phosphorylation, ubiquitination, and degradation,
thus resulting in basal NF-B activity. Another possibility is that
thyroid cells produce an autocrine factor that chronically acti-
vates the NF-B pathway. The latter hypothesis is supported by
the recent evidence that at least some differentiated thyroid
carcinomas secrete growth factors and chemotactic factors poten-
tially responsible for NF-B up-regulation (45). In addition, it has
been demonstrated recently that CXC chemokine receptor 4 is
highly expressed in a human thyroid cell line (46) and that the
ability of breast cancer cells to migrate and form metastasis
depends on the NF-B-mediated CXC chemokine receptor 4 ex-
pression (47).
NF-B inhibition in FRO cells strongly enhanced the sensi-
tivity of these cells to undergo apoptosis induced by cisplatin or
doxorubicin treatment, and caused a dramatic decrease of their
transforming potential. These in vitro functions of NF-B were
consistent with its role in tumor growth in vivo; FRO IBM
FIG. 9. Inhibition of JNK activity restored cell death resistance in FRO IBM clones. 1  105 cells/well were seeded in 6-well culture
plates and incubated for 48 h at 37 °C with 5 g/ml cisplatin (A and B) or doxorubicin (C and D) in the presence of 10 M JNK inhibitor SP600125.
Cell death was assessed by propidium iodide staining according to Nicoletti et al. (41). Samples were analyzed by flow cytometry using a
FACSCalibur (Beckman Coulter, Fullerton, CA), equipped with ModFit Software. A representative experiment out of two is shown.
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cells failed to form tumors in nude mice. The increased suscep-
tibility to apoptosis of FRO IBM and the evidence that con-
stitutive activation of the NF-B pathway rendered NPA cells
resistant to drug-induced apoptosis confirms and extends the
idea that one of the roles played by NF-B in neoplastic trans-
formation is protection from apoptosis.
Even though escape from apoptosis may play an important
role in the development of cancer, deregulation of this process,
alone, may not fully explain the inability of FRO IBM to
grow in soft agar and to form tumors in nude mice. Given that
NF-B controls expression of genes involved in different cell
functions such as proliferation (cyclin D1 and myc), apoptosis,
and drug resistance (MDR1), it is very possible that a combi-
nation of different factors are responsible for the loss of the
transforming potential of these cells. However, stable trans-
fected FRO IBM14 and16 did not show gross differences
in proliferation rate compared with the mock-transfected coun-
terpart, indicating that NF-B is not playing a central role in
controlling proliferation of neoplastic cells, at least in our ex-
perimental system.
Our data also suggest that the anti-apoptotic function of
NF-B was mediated by the inhibition of JNK signaling. In
fact, JNK activity was restored in FRO IBM cells, where its
duration was prolonged after treatment with anisomycin. In
addition, incubation of FRO IBM cells with the specific JNK
inhibitor SP600125 restored their resistance to chemothera-
peutic drug-induced apoptosis. The role of JNK in programmed
cell death is debated. Recently, it has been shown that NF-B
is able to inhibit TNF--induced apoptosis by negatively regu-
lating activation of the JNK pathway (32, 33). This effect is
mediated by two genes, GADD45 and XIAP, both of them
under the transcriptional control of NF-B. In our experimen-
tal system GADD45 expression paralleled the levels of NF-B
activity in thyroid carcinoma cells and decreased in FRO
IBM clones (data not shown), suggesting that this gene
might mediate the anti-apoptotic role of NF-B in thyroid can-
cer. Taken together, the data presented in this paper clearly
substantiate the fundamental role of NF-B in thyroid onco-
genesis and could open new perspectives for diagnosis and
therapy of human ATC.
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Central Role of the Scaffold Protein Tumor Necrosis Factor
Receptor-associated Factor 2 in Regulating Endoplasmic
Reticulum Stress-induced Apoptosis*□S
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The endoplasmic reticulum represents the quality control site of
the cell for folding and assembly of cargo proteins. A variety of con-
ditions can alter the ability of the endoplasmic reticulum (ER) to
properly fold proteins, thus resulting in ER stress. Cells respond to
ER stress by activating different signal transduction pathways lead-
ing to increased transcription of chaperone genes, decreased pro-
tein synthesis, and eventually to apoptosis. In the present paper we
analyzed the role that the adaptor protein tumor necrosis factor-
receptor associated factor 2 (TRAF2) plays in regulating cellular
responses to apoptotic stimuli from the endoplasmic reticulum.
Mouse embryonic fibroblasts derived from TRAF2/ mice were
more susceptible to apoptosis induced by ER stress than the wild
type counterpart. This increased susceptibility to ER stress-induced
apoptosiswas because of an increased accumulation of reactive oxy-
gen species following ER stress, and was abolished by the use of
antioxidant. In addition, we demonstrated that the NF-B pathway
protects cells from ER stress-induced apoptosis, controlling ROS
accumulation.Our results underscore the involvement of TRAF2 in
regulating ER stress responses and the role of NF-B in protecting
cells from ER stress-induced apoptosis.
In eukaryotic cells, proteins must be correctly folded and assembled
before to transit to intracellular organelles and the cell surface (1, 2). A
number of cellular stress conditions can interfere with protein folding,
leading to accumulation of unfolded or misfolded proteins in the endo-
plasmic reticulum (ER)3 lumen. The ER has evolved specific signaling
pathway to deal with the potential danger represented by the misfolded
proteins. This adaptive response is named unfolded protein response
(3). Activation of unfolded protein response results in attenuation of
protein synthesis, and up-regulation of genes encoding chaperones that
facilitate the protein folding process in the ER. Thus, unfolded protein
response reduces accumulation and aggregation of malfolded proteins,
giving the cell the possibility of correcting the environment inside the
ER (3, 4). However, if the damage is too strong and homeostasis cannot
be restored, themammalian unfolded protein response initiates apopto-
sis. In mammalian cells, three transmembrane proteins Ire1 (5), Ire1
(6), and PERK (7) act as ER stress sensor proteins and play important
roles in transducing the stress signals initiated by the accumulation of
malfolded proteins from the ER to the cytoplasm and nucleus. Ire1s and
PERK are kept in an inactive state through association of their N-termi-
nal lumen domain with the chaperone BiP. Following accumulation of
malfolded proteins in the lumen of the ER, BiP dissociates to bind the
malfolded proteins and Ire1s and PERK undergo oligomerization and
transphosphorylation within their cytoplasmic kinase domains (8, 9).
Other stress response pathways are activated following ER stress,
such as the JNK/SAPK andNF-Bpathways (10, 11). Activation of these
pathways following ER stress is mediated by the physical and functional
interaction of Ire1 and TRAF2 (10). The central role played by TRAF2
in mediating cellular response to ER stress has been proposed based
upon the observation that ectopic expression of a dominant negative
mutant of TRAF2 lacking theN terminus Ring finger domain, blocks ER
stress-induced NF-B and JNK/SAPK activation, and that mouse
embryonic fibroblast derived from TRAF2 knock-out mice failed to
activate NF-B following ER stress (10, 11). TRAF2 was initially identi-
fied as a TNF receptor 2 interacting protein (13). Interestingly, TRAF2-
deficientMEFs are very sensitive to cell death induced byTNF andother
members of the TNF receptor family (14, 15). At least part of the anti-
apoptotic effect of TRAF2 can be explained by its function as amediator
of NF-B activation, thus leading to NF-B-dependent expression of
anti-apoptotic genes. The anti-apoptotic activity of NF-B also involves
inhibition of the JNK cascade via at least two distinct mechanisms:
through GADD45--mediated blockade of MKK7 and interference
with ROS production (16, 17). It is well known that ROS or oxidative
stress plays an important role in various physiological and pathological
processes such as aging, inflammation, and neurodegenerative diseases
(18–20). Recently, it has been demonstrated that accumulation of mis-
folded protein within the lumen of the ER causes accumulation of ROS
and cell death (21). However, it is currently unknown whether some of
the key molecules involved in ER stress response, such as TRAF2, are
involved inmodulation of ROS and induction of apoptosis. Here we use
MEFs derived from TRAF2 knock-out mice to study the role of TRAF2
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in the regulation of pro-survival or pro-apoptotic pathways following
ER stress.
EXPERIMENTAL PROCEDURES
Cell Culture and Biological Reagents—Wild type (WT) and
TRAF2/murine embryonic fibroblasts (MEFs) were provided byDrs.
T. W. Mak and W. C. Yeh (14). WT and JNK1/2/ and WT and
p65/ MEFs were provided by Dr. R. Davis and Dr. G. Franzoso,
respectively (22, 23). Cells were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum, 100
units/ml penicillin, and 100 g/ml streptomycin. Thapsigargin was
from Calbiochem and used at 5–50 nM; tunicamycin was purchased
from Roche and used at 50–150 ng/ml. Dichlorodihydrofluorescein
diacetate (H2DCFDA) (Calbiochem) was dissolved in Me2SO and used
at 5 M; L-NAC was dissolved in sterile water and used at 5 mM. Anti-
TRAF2, anti-IB, and anti-JNK antibodies were purchased from Santa
Cruz Biotechnology. The TRAF2 full-length expression vector was pre-
viously described (24).
Western Blot Analysis—Subconfluent monolayer of murine embry-
onic fibroblasts were washed with phosphate-buffered saline and then
lysed in a lysis buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl,
10% glycerol, 1% Triton X-100, supplemented with a mixture of prote-
ase inhibitors (Roche). Equal amounts of total proteins (50 g) were
resolved by SDS-polyacrylamide gels. Separated proteins were trans-
ferred to polyvinylidene difluoride membranes (Millipore, Bedford,
MA) at 4 °C for Western blot analysis. Filters were blocked for 1 h at
room temperature with 10% nonfat dry milk in TBS-T buffer (10 mM
Tris-HCl, pH 8, 150 mM NaCl, 0.1% Tween 20). Then, filters were
probed with specific antibodies in the same buffer for 14–16 h at 4 °C.
After TBS-T washing to remove excess primary antibodies, the blots
were incubated in horseradish peroxidase-coupled secondary antibody
for 1 h followed by enhanced chemiluminescence detection of the pro-
teins with Hyper-film ECL detection (Amersham Biosciences).
Luciferase Assay—For luciferase assay, WT, TRAF2/, and
TRAF2FL MEFs (4 105 cells per well) were seeded in 6-well (35 mm)
plates. After 12 h cells were transfected with 0.5 g of Ig-B-LUC
reporter gene plasmid using Lipofectamine. Cells were stimulated with
thapsigargin or tunicamycin for 8 h, and reporter gene activity was deter-
mined by the luciferase assay system (Promega). A pRSV--galactosidase
vector (0.2g) was used to normalize for transfection efficiencies.
Retroviral Infection—Full-length hemagglutinin-tagged TRAF2 was
subcloned into the retroviral expression vector pBMN by standard
cloning techniques. pBMN vector was then transfected in a packaging
cell line using Lipofectamine. 48 h after transfection, the viral superna-
tants were supplemented with Polybrene (9 mg/ml) and filtered through a
0.45-mm filter. TRAF2/ fibroblasts (1 106) were incubated with viral
supernatants for 48 h. The expression of exogenous proteinwas assayed by
Western blot analysis on total cell extracts using anti-TRAF2 antibodies.
ER Stress Induction and Measurements of Apoptosis—5  103 cells/
well were seeded in 96-well culture plates and incubated for 24 or 48 h at
37 °Cwith different concentrations of thapsigargin or tunicamycin. Cell
survival was examined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS) and an electron coupling reagent (phenazine methosulfate),
according to the manufacturer’s instructions (Promega). Cell death was
assessed by staining the exposed phosphatidylserine on cell membranes
with fluorescein isothiocyanate-conjugated annexin V (BD Pharmin-
gen), or propidium iodide staining according to Nicoletti et al. (25).
Samples were analyzed by flow cytometry using a FACScalibur (Beck-
man Coulter, Fullerton, CA), equipped with ModFit Software. Results
were mean S.D. of at least three separate experiments.
Measurement of ROS Production—Reactive oxygen species were
detected with H2DCFDA (Calbiochem). H2DCFDA diffuses into the
cells where it is converted into a non-fluorescent derivative (H2DCF) by
endogenous esterases. H2DCF is oxidized to green fluorescent DCF in
the presence of intracellular ROS. Cells were routinely treated with
either tunicamycin or thapsigargin for 24 or 48 h, washed, and incu-
bated at 37 °C for 30 min in the presence of H2DCFDA in serum-free
medium. Me2SO-treated cells were used as controls. After incubation,
cells were washed twice with phosphate-buffered saline, resuspended in
phosphate-buffered saline, and analyzed by flow cytometry using a
FACScan Cell Scanner (BD Biosciences).
Kinase Assay—JNK immunoprecipitates were used for the immune
complex kinase assay that was performed at 30 °C for 10 min with 2 g
of substrate, 10Ci of [-32P]ATP in a total of 20l of kinase buffer (20
mM HEPES, pH 7.4, 10 mM MgCl2, 25 mM -glycerophosphate, 50 M
Na3VO4, and 50 M dithiothreitol). The substrate was glutathione
S-transferase-c-Jun (amino acids 1–79). The reaction was termi-
nated by boiling in SDS sample buffer, and the products were
resolved by 12% SDS-PAGE. Phosphorylated proteins were detected
by autoradiography.
RESULTS
Increased Susceptibility of TRAF2/ MEFs to ER Stress-induced
Apoptosis—TRAF2 is a scaffold protein that transduces signals from
membrane receptors and the ERmembrane (10–12). To assess the role
of TRAF2 in apoptosis induced by ER stress, we treated MEFs derived
fromTRAF2/mice andWTMEFs with increasing concentrations of
thapsigargin and tunicamycin. Both drugs induce ER stress by inhibiting
ER-resident Ca2-ATPase, and N-glycosylation, respectively. After a
48-h treatment, some morphological changes were observed. In partic-
ular, WT MEFs showed an extended shape, typical of cellular stress
response, whereas TRAF2/MEFs appeared detached and shrunken
(Fig. 1A). Because these morphological changes were reminiscent of
apoptosis, we performed annexin V staining on WT and TRAF2/
MEFs. As shown in Fig. 1B, treatment with thapsigargin or tunicamycin
caused a dramatic increase in apoptosis in TRAF2/MEFs but not in
WT MEFs. The higher sensitivity to apoptosis observed in TRAF2/
MEFs was not because of an intrinsic defect of these cells, given that
reintroduction of TRAF2 (TRAF2FL) completely rescued cell viability
(Fig. 1, C–E). TRAF2/MEFs showed the same susceptibility as WT
MEFs to serum starvation- and doxorubicin-induced cell death (Fig.
1F). These results suggest a specific role for TRAF2 in modulating sur-
vival signals from the ER.
ROSMediate Increased Apoptosis in TRAF2/MEFs—ER stress has
recently been shown to promote oxidative stress and apoptosis (21).
Hence, to have some insight on the molecular mechanism determining
the increased susceptibility to ER stress-induced apoptosis, we com-
pared ROS production inWT andTRAF2/MEFs. As shown in Fig. 2,
treatment with thapsigargin or tunicamycin caused an increase in ROS
production in TRAF2/MEFs but not inWT. Reconstitution of these
cells with TRAF2 (TRAF2FL) blocked ROS accumulation following
treatmentwith thapsigargin and tunicamycin (Fig. 2,A andB). To inves-
tigate whether the increased production of ROS was responsible for the
susceptibility of TRAF2/ MEFs to ER stress-induced apoptosis,
TRAF2/MEFs were treated with thapsigargin or tunicamycin in the
presence of different antioxidants and 48 h later cell viability was meas-
ured by MTS assay and the ROS level by flow cytometry. As shown in
Fig. 3, NAC abolished ROS accumulation and protected these cells from
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FIGURE 1. ER stress causes apoptosis in TRAF2/MEFs. A, WT and TRAF2/ MEFs were treated with 100 ng/ml tunicamycin or vehicle for 48 h. Cell death was examined by
morphological changes under a phase-contrast microscope. B, WT and TRAF2/MEFs were treated with 5 nM thapsigargin or 50 ng/ml tunicamycin for 48 h. Apoptosis was
assessed by flow cytometry after staining with fluorescein isothiocyanate-conjugated annexin V. Percentage of the apoptotic cell is indicated. C, restoration of TRAF2 protein
expression. TRAF2/ MEFs were infected with an expression vector encoding full-length TRAF2. Expression of the TRAF2 protein was assessed by Western blot in WT,
TRAF2/, and TRAF2-reconstituted cells (TRAF2FL). D, restoration of TRAF2 protein expression rescues TRAF2/ cells from ER stress-induced apoptosis. WT, TRAF2/, and
TRAF2FL MEFs were treated with Me2SO (Co), tunicamycin (Tun), or thapsigargin (Thaps) for 48 h. Cell viability was assessed by MTS assay. Data are mean  S.D. from five
independent experiments. Statistical analysis was by unpaired Student’s t test: **, p 0.002; ***, p 0.0001. E, restoration of TRAF2 protein expression rescues TRAF2/ cells
from endoplasmic reticulum stress-induced apoptosis. TRAF2/, WT, and TRAF2FLMEFswere treatedwithMe2SO (Co), 20 nM thapsigargin, or 150 ng/ml tunicamycin for 48 h
and analyzed by flow cytometry. Percentage of sub-Go cells is indicated. F, TRAF2
/ andWTMEFs were serum starved for 24 and 48 h, or treated with 0.2 M doxorubicin for
24 and 48 h, and cell viability was assessed by MTS assay. Data are mean S.D. from three independent experiments. Statistical analysis was by the unpaired Student’s t test:
**, p  0.002; ***, p  0.0001. KO, knock-out.
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apoptosis. Similar results were obtained by using dithiothreitol as anti-
oxidant (data not shown). Interestingly, also the small percentage ofWT
MEFs and reconstituted TRAF2/ MEFs undergoing apoptosis fol-
lowing treatment with tunicamycin and thapsigargin were almost com-
pletely protected by both antioxidants (Fig. 3 and data not shown).
These results demonstrated that susceptibility of TRAF2/ MEFs to
ER stress-induced apoptosis was because of increased accumulation of
ROS. It is worth noting that in TRAF2/ cells, higher levels of ROS and
apoptosis were detected, even in the absence of ER stressing agents (Fig.
1, B and E, and data not shown).
TRAF2-mediated NF-B Activation Protects Cells from ER Stress-
induced Apoptosis—Given the central role played by TRAF2 to cor-
rectly signal activation of NF-B and JNK from ER, we investigated
which of these pathways control ROS accumulation and protect cells
from ER stress-induced apoptosis. MEFs derived from p65 knock-out
and JNK1/2 double knock-out mice were treated with thapsigargin or
tunicamycin in the presence or absence of NAC. As shown in Fig. 4A,
p65/MEFs showed very high levels of ROS following treatment with
thapsigargin and tunicamycin. As expected, treatment with NAC
decreased ROS accumulation by about 40%. In contrast, JNK1/2/
MEFs showed an accumulation of ROS similar to WT MEFs (Fig. 4A).
Statistical analysis is reported in Fig. 4B. We next investigated the sus-
ceptibility of p65/ and JNK1/2/ MEFs to apoptosis induced by
thapsigargin or tunicamycin in the presence or absence of NAC. As
shown in Fig. 4C, p65/ MEFs were highly susceptible to apoptosis
compared with WT MEF and treatment with NAC significantly
increased cell viability. JNK1/2/MEFs did not show susceptibility to
ER stress-induced cell death, as compared with WT MEFs. These
results suggest that NF-B protects cells from ER stress-induced apo-
ptosis by controlling ROS accumulation.
FIGURE 2. Susceptibility of TRAF2/ MEFs to
endoplasmic reticulum-dependent oxidative
stress. A, WT, TRAF2/, and TRAF2FL MEFs were
treated with Me2SO (Co), 20 nM thapsigargin
(Thaps), or 150 ng/ml tunicamycin (Tun) for 24 or
48 h. Cells were labeled with 5 M H2DCFDA and
analyzed by flow cytometry. B, Kolmogorov-Smir-
nov statistical analysis of flow cytometric data
were used according to Cell Quest Software (BD
Biosciences Immunocytometry Systems).D values
by Kolmogorov-Smirnov analysis (p  0.001) are
shown.
TRAF2 Regulates ER Stress-induced Apoptosis
2634 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 5•FEBRUARY 3, 2006
FIGURE 3. ROS production correlates with endoplasmic reticulum stress-induced apoptosis. WT, TRAF2/, and TRAF2FL MEFs were treated with Me2SO (Co), 150 ng/ml
tunicamycin (Tun), or 20 nM thapsigargin (Thaps) for 48 h, in the presence or absence of antioxidants (NAC or dithiothreitol). ROS production was assessed by flow cytometry after
labelingwithH2DCFDA. Cell viabilitywas evaluatedbyMTS assay. Data aremean S.D. from three independent experiments. Statistical analysiswas by the unpaired Student’s t test:
*, p 0.02; **, p 0.002; ***, p 0.0001.
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FIGURE 4.Differential susceptibility of p65/ and JNK1/2/MEFs to endoplasmic reticulum-dependent oxidative stress.A, JNK1/2/ and p65/MEFswere treatedwith
Me2SO (Co), 20 nM thapsigargin (Thaps), or 150 ng/ml tunicamycin (Tun) for 24 h, in the presence or absence of 5 mM NAC. ROS production was assessed by flow cytometry after
labeling with H2DCFDA. B, Kolmogorov-Smirnov statistical analysis of flow cytometric data were used according to Cell Quest Software (BD Biosciences). D values by Kolmogorov-
Smirnov analysis (p 0.001) are shown.C, p65/ and JNK1/2/MEFswere treatedwithMe2SO (Co), thapsigargin (Thaps), or tunicamycin (Tun) for 24 h, in the presence or absence
of 5mM dithiothreitol. Cell viability was evaluated byMTS assay. Data aremean S.D. from three independent experiments. Statistical analysis was by the unpaired Student’s t test:
*, p 0.02; **, p 0.002. KO, knock-out.
TRAF2 Regulates ER Stress-induced Apoptosis
2636 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 5•FEBRUARY 3, 2006
To have further insight on the cross-talk between the NF-B and the
JNK pathways after ER stress, we evaluated activation of both pathways
inWT, TRAF2/, and reconstituted TRAF2FLMEFs. Treatment with
tunicamycin caused activation of NF-B inWT andTRAF2FLMEFs, as
demonstrated by the disappearance of the inhibitory subunit IB (Fig.
5A) and by the increased activity of a B-driven luciferase reporter gene
(Fig. 5B). In the absence of TRAF2 it was not possible to detect activa-
tion of NF-B. The observed activation of NF-B was functional as
demonstrated by the reappearance of the inhibitory subunit IB, a
known early target gene of NF-B (Fig. 5A).
Activation of JNK in WT and TRAF2FL MEFs stimulated with
tunicamycin was detected 90 min after stimulation and decreased
thereafter. Treatment with antioxidant did not affect JNK activation
(Fig. 6). In contrast, in TRAF2/ MEFs, activation of JNK was
detectable only 6 h after stimulation and remained sustained for up
to 12 h. This sustained activation of JNK was almost completely
suppressed by NAC (Fig. 6). This result confirms that TRAF2 was
necessary to activate JNK after ER stress, and suggests that the
increased level of ROS detected in the absence of TRAF2 may mediate
the sustained activation of JNK. This is in agreement with previous
reports showing that after TNF stimulation the early activation of JNK
depends on TRAF2 and that the sustained activation of JNK depends on
ROS (26). Altogether these results suggested that following ER stress,
the TRAF2-mediated activation of NF-B was responsible for protec-
tion from apoptosis by decreasing ROS levels and controlling sustained
JNK activation.
DISCUSSION
The endoplasmic reticulum is the principal site for protein synthesis
and folding, and also serves as a cellular storage site for calcium. Agents
that interfere with protein folding or export lead to ER stress and even-
tually cell death. Although initiation of apoptosis induced by death
receptors andmitochondria is well studied, themechanismbywhich ER
stress triggers apoptosis is still not clear. In the present paper, we pres-
ent evidence supporting a central role played by TRAF2 in regulation of
pro-apoptotic and anti-apoptotic pathways initiated at the ER.Wedem-
onstrate that TRAF2/ MEFs have increased susceptibility to ER
stress-induced apoptosis. This increased susceptibility to ER stress-in-
duced apoptosis was because of accumulation of ROS following ER
stress, and was abolished by the use of antioxidants, such as NAC. In
addition, we demonstrated that NF-B was protecting cells from ER
stress-induced apoptosis by controlling ROS accumulation.
TRAF2 has been demonstrated to be involved in signaling from endo-
plasmic reticulum being able to interact with Ire1 (10), one of the ER
transmembrane proteins involved in initiating signals from the ER.
TRAF2mediates activation of both the JNK/SAPK and theNF-B path-
ways following ER stress (10, 11). This scenario is reminiscent of TNF
signaling, in which TRAF2 mediates simultaneous activation of the
NF-B survival pathway and pro-apoptotic JNKpathway, and the fate of
the cell would be determined by interplay between these opposing sig-
nals. NF-B exerts its anti-apoptotic activity by inhibiting caspase func-
tion (28–30), preserving function of mitochondria (31), and down-reg-
ulating JNK activity (23, 32). The latter function is mediated by at least
two different mechanisms: by blocking activation of MKK7 via
GADD45 (16) and decreasing ROS accumulation via the ferritin heavy
chain (17). The importance of ROS in regulating sustained activation of
JNK followingTNF receptor triggering has been recently investigated in
a NF-B null cell model (26). Based on this study, TRAF-mediated
NF-B activation suppresses the TNF-induced ROS accumulation that,
in turn, induces prolonged JNK activation and cell death. Our result
supports this model and suggests that a similar mechanism may also
operate for the ER. In fact, induction of ER stress causes activation of
both NF-B and JNK. In the absence of TRAF2 or p65, the NF-B
FIGURE 5.Defective activation of theNF-Bpathway in TRAF2/MEFs after endo-
plasmic reticulum stress. A, WT, TRAF2/, and reconstituted TRAF2FL MEFs were
treated with tunicamycin (Tun) (150 ng/ml), and expression of the IB protein was
analyzed by Western blot. Filters were stripped and reprobed with anti--tubulin
antibodies, as loading control. B, relative luciferase activity observed in WT,
TRAF2/, and TRAF2FL MEFs transfected in triplicate with 0.5 g of the Ig-B-
luciferase reporter plasmid, stimulated with thapsigargin or tunicamycin, as indi-
cated. Values shown (in arbitrary units) represent themean (S.D.) of two independ-
ent experiments, normalized for -galactosidase activity of a cotransfected Rous
sarcoma virus--galactosidase plasmid.
FIGURE 6. Sustained activation of the JNK pathway in TRAF2/MEFs after endo-
plasmic reticulum stress.WT, TRAF2/, and TRAF2FL MEFs were treated with tunica-
mycin (150 ng/ml) for the indicated periods of time in the presence or absence of the
antioxidant NAC, and activity of endogenous JNK was assessed by kinase assay using
glutathione S-transferase-c-Jun as substrate. Lower panel shows a Western blot for total
JNK.WB, Western blot.
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pathway is not activated, and the late, ROS-dependent JNK activity is
not counteracted, leading to cell death.
How does ROS affect JNK activation? ROSmay affect JNK activation
by at least two different mechanisms: by oxidizing and inhibiting mito-
gen-activated protein kinase phosphatase (33) and activating the pro-
tein ASK1 (34). This kinase may be activated via ROS and TRAF2 and
has been demonstrated to be essential for inducing cell death after ER
stress, at least in neuronal cells (34, 35). It may be possible that after ER
stress and in the absence of a functional NF-B activation, ASK1 is
activated by the increased level of ROS and mediates sustained JNK
activation and cell death.
Whereas it is clear from our results that the presence of a functional
NF-B is necessary for survival, counteracting increased induction of
ROS following ER stress, the mechanism by which NF-B exerts this
function is not fully understood. It has been recently demonstrated that
NF-B up-regulates expression of ferritin heavy chain, an enzyme
involved in ironmetabolism and suppression of ROS accumulation (17).
However, it is possible that in addition to up-regulation of genes
involved in disposal of the ROS,NF-Bmay also control transcription of
genes that suppress production of ROS.
Our results confirm the central role played by TRAF2 in regulating
activation of NF-B following ER stress, and also sheds light on the
functional significance of this activation. Recently, it has been demon-
strated that in addition to the TRAF2-mediated NF-B activation,
another mechanism leading to activation of NF-B following ER stress
might exist. Based on this model, following ER stress, phosphorylation
of eukaryotic initiation factor 2 represses synthesis of the inhibitory
subunit IB, leading to activation of NF-B (36). The two models of
activation of NF-B following ER stress, the TRAF2-mediated and the
eukaryotic initiation factor 2-mediated, are not mutually exclusive. It is
possible that both mechanisms contribute to activate NF-B upon ER
stress. However, whereas the biological significance of the link between
eukaryotic initiation factor 2 phosphorylation and NF-B activation is
not fully understood, the functional significance of TRAF2-mediated
NF-B activation seems to be clear, at least in our experimental system.
In fact, cells lacking TRAF2 or functional NF-B undergo massive cell
death after ER stress.
In conclusion, in the present study we provide evidence, for the first
time, that the adaptor protein TRAF2 plays a central role in regulating
signaling from the ER and that the activation of NF-B, mediated by
TRAF2, protects cells from ER stress-induced apoptosis. Therefore
TRAF2 and NF-B may be potential targets to control ER stress-in-
duced apoptosis.
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ABIN-1 Binds to NEMO/IKK and Co-operates with
A20 in Inhibiting NF-B*□S
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Nuclear factor B (NF-B) plays a pivotal role in inflammation,
immunity, stress responses, and protection from apoptosis. Canon-
ical activation of NF-B is dependent on the phosphorylation of the
inhibitory subunit IB that is mediated by a multimeric, high
molecular weight complex, called IB kinase (IKK) complex. This is
composed of two catalytic subunits, IKK and IKK, and a regula-
tory subunit, NEMO/IKK. The latter protein is essential for the
activation of IKKs and NF-B, but its mechanism of action is not
well understood. Here we identified ABIN-1 (A20 binding inhibitor
of NF-B) as a NEMO/IKK-interacting protein. ABIN-1 has been
previously identified as anA20-binding protein and it has been pro-
posed to mediate the NF-B inhibiting effects of A20. We find that
bothABIN-1 andA20 inhibit NF-B at the level of the IKK complex
and that A20 inhibits activation of NF-B by de-ubiquitination of
NEMO/IKK. Importantly, small interfering RNA targeting
ABIN-1 abrogates A20-dependent de-ubiquitination of NEMO/
IKK and RNA interference of A20 impairs the ability of ABIN-1 to
inhibit NF-B activation. Altogether our data indicate that ABIN-1
physically links A20 to NEMO/IKK and facilitates A20-mediated
de-ubiquitination of NEMO/IKK, thus resulting in inhibition of
NF-B.
NF-B is a ubiquitously expressed family of transcription factors that
controls the expression of numerous genes involved in immune and
inflammatory responses (1). NF-B also plays an important role during
cellular stress responses, due to its anti-apoptotic and proliferation-
promoting functions (2). Aberrant activation of NF-B is a major hall-
mark of several inflammatory diseases such as arthritis (3, 4), and a
variety of human cancers (5, 6). In resting cells, NF-B is sequestered in
the cytoplasm in an inactive formbymembers of the inhibitory family of
IB proteins (1). Various stimuli including pathogens, pathogen-related
factors, and cytokines lead to phosphorylation of the inhibitory subunit
IB on specific serine residues (Ser32 and Ser36) (7) catalyzed by two
IB kinases (IKKs),3 namely IKK and IKK (8–12). This step marks
the IB protein for ubiquitination and subsequent degradation through
a proteasome-dependent pathway (1). The active NF-B is then free for
translocation to the nucleus, where it binds the B sequences present in
the promoters of responsive genes.
IKK and IKK reside in a larger kinase complex (700–900 kDa),
called the IB kinase complex (IKK complex), that also contains the
essential regulatory subunit NEMO (also known as IKK) (13, 14).
Genetic studies suggest that NEMO/IKK is absolutely required for the
activation of IKKs and NF-B in response to different stimuli (13, 15).
NEMO/IKK contains several coiled-coil domains, a leucine zipper,
and a C-terminal zinc finger domain. These motifs are required for the
correct assembly of the IKK complex (13) and recruitment of upstream
signaling mediators (16). Numerous proteins have been demonstrated
to interact with NEMO/IKK, as the kinase RIP and the inhibitor of
NF-BA20 (17), the viral trans-activator TAX (18–20), and the adaptor
proteins CIKS/Act-1, TANK, and CARMA (21–23). Therefore,
NEMO/IKK represents the point where most NF-B signaling path-
ways converge. Despite this information, themolecularmechanism reg-
ulating IKK complex function is not fully understood.
Ubiquitin conjugation has been most prominently associated with
protein degradation through a proteasome-dependent pathway, but it is
becoming increasingly evident that ubiquitination plays a key role in the
signal transduction pathway leading to activation of NF-B (24, 25).
Recent reports show that lysine 63-linked ubiquitination of NEMO/
IKK is an important step for the activation of IKKs and NF-B follow-
ing various stimuli, such as TNF, lipopolysaccharide, and antigen recep-
tor (26–28). In contrast, the tumor suppressor CYLD is reported as a
negative regulator of NF-B by specific de-ubiquitination of NF-B sig-
naling molecules, such as TRAF2, TRAF6, and NEMO/IKK (29). Also
A20 functions as an inhibitor of the NF-B pathway by removing Lys63-
linked ubiquitin chains from RIP, an essential mediator of the proximal
TNF-Receptor-1 signaling complex. Then A20 targets RIP for Lys48-
linked polyubiquitination and proteasomal degradation (30). Further-
more, A20 terminates Toll-like receptor-induced NF-B signaling, by
cleaving ubiquitin chains from TRAF6 (27). The central role played by
A20 in terminatingNF-B activation is further demonstrated by the fact
thatA20/mice develop severe inflammation and cachexia, are hyper-
sensitive to both lipopolysaccharide and TNF, and die prematurely (27,
31). Here we used NEMO/IKK as bait in yeast two-hybrid screening,
and identified ABIN-1 (A20 binding inhibitor of NF-B) as a NEMO/
IKK-interacting protein.
EXPERIMENTAL PROCEDURES
Cell Culture and Biological Reagents—HEK293 cells were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with
10% fetal calf serum, 100 units/ml penicillin, 100mg/ml streptomycin, and
1% glutamine.
* This work was supported by grants from the Associazione Italiana Ricerca sul Cancro
(AIRC), MIUR-PRIN 2005051307, European Molecular Imaging Laboratory Network
Grant LSHC-2004-503569, and Fondazione Italiana Sclerosi Multipla (2003/R66). The
costs of publication of this article were defrayed in part by the payment of page
charges. This articlemust therefore be herebymarked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
This work is dedicated to the memory of Prof. Serafino Zappacosta.
□S The on-line version of this article (available at http://www.jbc.org) contains supple-
mental Fig. S1.
1 Both authors equally contributed to this work.
2 To whom correspondence should be addressed. Tel.: 39-081-7463606; Fax: 39-081-
7701016; E-mail: leonardi@unina.it.
3 The abbreviations used are: IKK, IB kinases; TNF, tumor necrosis factor; ABIN-1, A20
binding inhibitor of NF-B; HA, hemagglutinin; GST, glutathione S-transferase; siRNA,
small interfering RNA; CIKS, connection to IB kinase and SAPK.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 27, pp. 18482–18488, July 7, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
18482 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 27•JULY 7, 2006
Anti-ABIN-1 polyclonal antibodies were generated in rabbits, by
using a recombinant peptide encompassing amino acids 380–636 of
human ABIN-1. Other antibodies used for this study were: FLAG
epitope (Sigma), A20 (BD Pharmingen), HA epitope, NEMO/IKK,
IKK, IB, and tubulin (Santa Cruz Biotechnologies). Human TNF-
(Peprotech Inc.) was used at 2,000 units/ml.
Human ABIN-1 was amplified by PCR from a human liver c-DNA
library (Clontech) and cloned into pcDNA3.1-HA, -FLAG, and -His
vectors (Invitrogen) for expression in mammalian cells. A20, TAX, and
ubiquitin expression vectors were gifts from G. Natoli, T. K. Jeang, and
G. Courtois, respectively. NEMO/IKK, IKK, CIKS, and TRAF2
expression vectorswerepreviouslydescribed (21, 32).All deletionmutants
were prepared by conventional PCR and cloned into pcDNA3.1-HA or
-FLAG vectors. Point mutants of A20 (C103S and D100A/C103S) were
generated by the QuikChange Site-directed Mutagenesis kit (Stratagene),
according to the manufacturer’s protocol.
Yeast Two-hybrid Screening—The cDNA encoding the N-terminal
part of mouse NEMO/IKK (amino acids 1–311) was cloned in-frame
into the GAL-4 DNA-binding domain vector pGBKT7 (Clontech). The
resulting plasmid pGBKT7-NEMO/IKK was used as bait in a yeast
two-hybrid screen of a human liver cDNA library (Clontech) in Saccha-
romyces cerevisiae strain AH109. The NEMO/IKK deletion mutants
for two-hybrid mapping were made by conventional PCR and cloned
into the pGBKT7 vector.
Gel Filtration of Cellular Extracts—Gel filtration procedures were
performed as previously described (42). Fractions were analyzed by
Western blotting for ABIN-1, NEMO/IKK, and IKK.
In Vitro Translation and GST Pull-down Assays—In vitro transcrip-
tion and translation were carried out with 1 g of ABIN-1 constructs
according to the TNT Quick Coupled Transcription/Translation Sys-
tem protocol (Promega) in the presence of [35S]methionine.
GST-NEMO/IKK fusion protein was produced and purified as
described (33). GST pull-down assays were performed by incubating
an aliquot of GST-NEMO/IKK bound to glutathione-Sepharose
beads (Amersham Biosciences) together with 10 l of in vitro trans-
lated ABIN-1 protein in phosphate-buffered saline, 1% Triton X-100
buffer (including Complete Protease Inhibitor mixture (Roche)) for
2 h at 4 °C. Beads were then washed five times with the same buffer,
resuspended in Laemmli buffer, and run on a SDS-polyacrylamide
gel before autoradiography.
Transfection, Immunoprecipitation, and Luciferase Assay— Lipo-
fectamine-mediated transfectionswere performed according to themanu-
facturer’s instructions (Invitrogen). All transfections included supple-
mental empty vector to ensure that the total amount of transfected
DNA was kept constant in each dish culture.
For immunoprecipitation of transfected proteins, HEK293 cells (3
106) were transiently transfected and 24 h after transfection cells were
lysed in Triton X-100 lysis buffer (20 mM Hepes, pH 7.4, 150 mM NaCl,
10% glycerol, 1% Triton X-100, and Complete Protease Inhibitor mix-
ture). After an additional 15 min on ice, cell extracts were centrifuged
for 10min at 14,000 g at 4 °C and supernatants were incubated for 4 h
at 4 °C with anti-FLAG antibodies bound to agarose beads (M2, Sigma).
The immunoprecipitates were washed five times with Triton X-100
lysis buffer and subjected to SDS-PAGE.
For luciferase assay, HEK293 cells (4  105) were seeded in 6-well
plates. After 12 h cells were transfected with 0.5 g of Ig-B-luciferase
reporter plasmid and various combinations of expression plasmids. 24 h
after transfection, cells were stimulated with TNF- for 3 h or left
untreated. Cell extracts were prepared and reporter gene activity was
determined via the luciferase assay system (Promega). Expression of the
pRSV--galactosidase vector (0.2 g) was used to normalize transfec-
tion efficiencies.
FIGURE 1. Mapping of the ABIN-1 interaction
domain onNEMO/IKK. A, mapping of the NEMO/
IKK-ABIN interaction by yeast two-hybrid experi-
ments. TheNEMO/IKK constructs are schematically
represented. The interaction of theNEMO/IKK con-
structs with the clone isolated by yeast two-hybrid
screening (ABIN 380–636) is indicated by the plus
sign. B, in vivo mapping of the NEMO/IKK-ABIN
interaction. HEK293 cells were transfected with
the indicated combinations of expression con-
structs encoding HA-ABIN and either FLAG-
NEMO/IKK or FLAG-NEMON91. Cell extracts
were analyzed by immunoblotting either directly
or after immunoprecipitation with anti-FLAG anti-
bodies.C, chromatographic distribution of endog-
enous ABIN-1, NEMO/IKK, and IKK. Cytoplasmic
extracts were prepared from HEK293 treated with
TNF for 120 min or left unstimulated, and sub-
jected to chromatography on a Superdex S-200
column. Fractions were analyzed by Western blot
(WB) by using the indicated antibodies. Molecular
weight markers are indicated at the top of the
figure.
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In Vivo Ubiquitination and De-ubiquitination Assays— HEK293 cells
(3  106) were co-transfected with expression vectors containing
epitope-tagged ubiquitin (1 mg) and NEMO/IKK (200 ng), plus
various constructs encoding A20 or ABIN-1 proteins. 24 h after
transfection, cell lysates were prepared as above and analyzed for
polyubiquitination of NEMO/IKK either by Western blot anti-
NEMO/IKK (-FLAG) on total extracts or by immunoprecipitating
FLAG-NEMO/IKK with anti-FLAG beads followed by Western
blot anti-HA-ubiquitin.
ABIN-1 Small Interfering RNA (siRNA) Expression Vectors—
To knockdown ABIN-1 expression, we designed double-stranded oli-
gonucleotides containing sequences derived from the human ABIN-1
open reading frame (nucleotides 1136–1156 and 1685–1705) in forward
and reverse orientations separated by a 7-base pair spacer region (caagaga)
to allow the formation of the hairpin structure in the expressed siRNAs;
ABINi-370: sense strand, 5-aattcGAGGAGACCGACAAGGAGCAGca-
agagaCTGCTCCTTGTCGGTCTCCTCtttttc; antisense strand, 5-tcgag-
aaaaaGAGGAGACCGACAAGGAGCAGtctcttgCTGCTCCTTGTCG-
GTCTCCTCg;ABINi-560: sense strand, 5-aattcCCACACCATGGCTT-
CGAGGACcaagagaGTCCTCGAAGCCATGGTGTGGtttttc; antisense
strand, 5-tcgagaaaaaCCACACCATGGCTTCGAGGACtctcttgGTCCT-
CGAAGCCATGGTGTGGg. The resulting double-stranded oligonucleo-
tides were cloned into the pcRNAi vector that we derived from the
pcDNA3.1vector (Invitrogen)by replacing theviral promoter cassettewith
the H1 gene promoter that is specifically recognized by RNA polymerase
III. The plasmids used to knockdown A20 expression (pU6-A20i and the
pU6)were a kind gift ofDr. S. Yamaoka andhavebeenpreviously described
(43).
RESULTS
ABIN-1 Binds to NEMO/IKK—The regulatory subunit of the IKK
complex, NEMO/IKK, has an essential role in NF-B activation. To
gain insights into how NEMO/IKK modulates the activation of
NF-B, we screened a human liver cDNA library for NEMO/IKK
interacting proteins, via the yeast two-hybrid system. 25 clones were
identified that expressed NEMO/IKK-interacting proteins, includ-
ing IKK and CARMA (23). Three clones encoded for overlapping
fragments of ABIN-1, a protein previously identified as an A20-bind-
ing protein that mimics the NF-B inhibiting effects of A20 (34).
To define the region of NEMO/IKK that interacts with ABIN-1, we
tested various deletion mutants of NEMO/IKK for binding to the
ABIN-1 fragment (amino acids 380–636) in yeast. Data shown in Fig.
1A indicate that the region between amino acids 50 and 100 of NEMO/
IKK is required for interaction with ABIN-1. The binding was con-
firmed in mammalian cells (Fig. 1B). HA-ABIN-1 was transiently co-
expressed in HEK293 cells together with FLAG-NEMO/IKK or a
NEMO/IKK mutant lacking the first 91 amino acids (FLAG-
FIGURE 2. Mapping of the NEMO/IKK and the
A20 binding domains on ABIN-1. A and B, GST
pull-down assays: GST-NEMO/IKKwas incubated
with in vitro translated full-length (FL) or deletion
mutants of ABIN. Aliquots of in vitro translated
constructs and GST-NEMO/IKK stained by Coo-
massie Blue are shown. C, co-immunoprecipita-
tion of FLAG-A20withHA-ABINor ABIN407–431.
HEK293 cells were transfected with FLAG-A20 and
either HA-ABIN or ABIN407–431. Cell extracts
were immunoprecipitated with anti-FLAG anti-
bodies (A20) followed by Western blot (WB)
anti-HA (ABIN). The presence ofHA andFLAG
proteins in total extracts is shown.
FIGURE 3. ABIN-1 and A20 are inhibitors of NF-B. A and B, ABIN-1 and A20 inhibit
NF-Bat level of the IKK complex. Relative reporter activitywas evaluated inHEK293 cells
co-transfected with the Ig-B-luciferase plasmid and the indicated expression vectors.
24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as
indicated. Values shown in arbitrary units represent the mean  S.D. of three experi-
ments done in triplicate, normalized for -galactosidase expression of a co-transfected
pRSV--galactosidase plasmid.
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NEMON91). Immunoprecipitates of FLAG-NEMO/IKK contained
HA-ABIN-1 only if both proteins were co-expressed (Fig. 1B, compare
lanes 3 and 4). In agreement with the data obtained in yeast, ABIN-1 did
not co-immunoprecipitate withNEMON91 (lane 6, Fig. 1B).Wewere
unable to detect the association between endogenousNEMO/IKK and
ABIN-1, probably because of the transient nature of the association
and/or the high stringent conditions we used to perform co-immuno-
precipitation experiments. However, gel filtration experiments showed
that endogenous ABIN-1 was eluted from the column in the same frac-
tions containing endogenous NEMO/IKK and other components of
IKK complex (Fig. 1C).
Mapping of the NEMO/IKK and the A20 Binding Domains on
ABIN-1—To define the domain of ABIN-1 required for its interaction
with NEMO/IKK, we performed pull-down assays by using recombi-
nant GST-NEMO/IKK and in vitro translated [35S]ABIN-1 (Fig. 2A).
ABIN-1 binds to GST-NEMO/IKK, indicating a direct interaction
between the two proteins. Furthermore, amino acids 500–588 of
ABIN-1 represent the minimal region that binds to NEMO/IKK (Fig.
2A, upper panel). To confirm that the region between amino acids 500
and 588 of ABIN-1 was responsible for interaction with NEMO/IKK,
we generated an internal deletion mutant of ABIN-1 (500–588) and
evaluated its ability to interact with NEMO/IKK. As expected, the
internal deletion of 89 amino acids from ABIN-1 abolished the interac-
tion with NEMO/IKK (Fig. 2B). Because ABIN-1 was identified as an
A20-interacting protein (35), we confirmed that the region between
amino acids 407 and 431 of ABIN-1 is responsible for interaction with
A20 (Fig. 2C).
Both ABIN-1 and A20 Inhibit NF-B at the Level of the IKK Complex
byAssociating withNEMO/IKK—BothABIN-1 andA20 are inhibitors of
NF-B. It has been proposed that they interfere with a RIP and TRAF2-
mediated transactivation signal (34). The identification of the interaction
between ABIN-1 and NEMO/IKK prompted us to investigate if ABIN-1
was involved in controllingNF-B activation not only upstreambut also at
the level of the IKK complex. To this aim, we performed reporter assays by
transfectingHEK293cellswith the Ig-B-luciferaseplasmid in thepresence
of ABIN-1 and various activators of NF-B. ABIN-1 efficiently inhibited
TNF- and TRAF2-dependent activation of NF-B (Fig. 3A). ABIN-1 also
blockedNF-B activation induced by proteins acting at the level of the IKK
complex, suchasCIKSandTAX(18–21). In contrast,ABIN-1wasnot able
to inhibit the IKK-mediated activation of NF-B (Fig. 3A). Similarly, A20
inhibits NF-B activation mediated by TNF- or ectopic expression of
TRAF2, CIKS, andTAXbut not IKK (Fig. 3B). These results indicate that
both ABIN-1 andA20 interfere with activation of NF-B at the level of the
IKKcomplex, suggesting that theassociationofABIN-1withNEMO/IKK
could play an important role in the inhibition of NF-B.
Because ABIN-1 interacts with both NEMO/IKK and A20, we
tested whether theNEMO/IKK- andA20-binding domains of ABIN-1
were required for inhibition ofNF-B.ABIN-1 deletionmutants lacking
FIGURE 4. ABIN-1 interacts with NEMO/IKK and A20 to inhibit NF-B activity. A–C, the deletion mutant of ABIN-1 lacking both NEMO/IKK- and A20-binding domains
(ABIN407–431/500–588) does not blockNF-B activation (C ), in contrast to ABIN500–588 (A) andABIN407–431 (B). HEK293 cells were co-transfectedwith the Ig-B-luciferase
reporter plasmid and the indicated combinations of expression plasmids. 24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as indicated. Analysis was
done as in Fig. 3. Lower panels in A–C show relative expression levels of each of the transfected proteins. D, ABIN-1 forms a complex with NEMO/IKK and A20. HEK293 cells were
transfectedwith constructs encoding NEMO/IKK, A20, and a deletionmutant of ABIN lacking the NEMO/IKK-binding domain (ABIN500–588). Cell extracts were immunoprecipi-
tatedwith anti-FLAG antibodies (NEMO/IKK) andWestern blotted (WB) anti-HA to reveal the co-precipitation of A20 andABIN500–588. The presence ofHAandFLAGproteins
in total extracts is shown. E, ABIN-1promotes associationofA20withNEMO/IKK. HEK293 cellswere transiently transfectedwith constructs encoding FLAG-NEMO/IKK, HA-A20, and
an increasing amount of His-ABIN. Cell extractswere immunoprecipitatedwith anti-FLAG antibodies (NEMO/IKK) andWestern blotted anti-HA to reveal the co-precipitation of A20.
The presence of ABIN, NEMO/IKK, and A20 in the whole cell lysate is shown.
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either the NEMO/IKK binding domain (ABIN500–588) or the A20
binding domain (ABIN407–431) were still able to inhibit the activity
of a NF-B-driven luciferase reporter following different stimuli (Fig. 4,
A and B). In contrast, a mutant of ABIN-1 in which both the NEMO/
IKK- and the A20-binding domains were deleted (ABIN407–431/
500–588) lost the ability to block activation of NF-B (Fig. 4C). These
data were consistent with the hypothesis that ABIN-1 forms a complex
with bothNEMO/IKK andA20. To address this hypothesis, we immu-
noprecipitated FLAG-NEMO/IKK and monitored the co-precipita-
tion of the ABIN-1 mutant lacking the NEMO/IKK-binding domain
(HA-ABIN500–588) either in the presence or absence of A20 (Fig.
4D). ABIN500–588 co-immunoprecipitated with NEMO/IKK only
in the presence of A20 (Fig. 4D). To further support the idea that
ABIN-1 promotes association ofA20withNEMO/IKK, we transfected
A20 andNEMO/IKK in the presence of an increasing amount of over-
expressedABIN-1. As expected, the amount ofA20 co-immunoprecipi-
tating with NEMO/IKK increased in the presence of ABIN-1 (Fig. 4E).
Taken together, these data indicated that ABIN-1 interferes with acti-
vation of NF-B at the level of the IKK complex, and support the idea
that ABIN-1 promotes association of A20 with NEMO/IKK.
A20 Inhibits NF-B by De-ubiquitinating NEMO/IKK—To explore
themechanism by which the interactions of both A20 and ABIN-1 with
NEMO/IKK down-regulate NF-B signaling, we assessed the effect of
either A20 or ABIN-1 on NEMO/IKK ubiquitination. Transfection of
FLAG-NEMO/IKK in the presence of HA-ubiquitin results in the
polyubiquitination of NEMO/IKK (Fig. 5A, lane 3). Co-transfection of
A20 and NEMO/IKK resulted in a dose-dependent disappearance of
the ubiquitinated forms of NEMO/IKK (Fig. 5A, lanes 4 and 5). In
contrast, co-transfection of ABIN-1 did not affect NEMO/IKK ubiq-
uitination (Fig. 5A, lanes 6 and 7). We did not observe reduction in the
overall level of ubiquitinated cellular proteins in the presence of A20,
indicating that A20 does not have a global de-ubiquitinating activity in
FIGURE 5. A20 inhibits NF-B by de-ubiquitinat-
ingNEMO/IKK. A, A20 but not ABIN-1 de-ubiquiti-
nates NEMO/IKK. HEK293 cells were transfected
with FLAG-NEMO/IKK and HA-ubiquitin, plus
increasing amounts of either HA-A20 or HA-ABIN.
Cell extracts were immunoprecipitated with anti-
FLAG antibodies (NEMO/IKK) followed by West-
ern blot analysis with anti-HA antibodies to reveal
the polyubiquitinated forms of NEMO/IKK. West-
ern blot analyses with anti-FLAG, -HA, -A20, -ABIN,
and -tubulin antibodies were performed on total
extracts. B, A20 blocks the ubiquitination of
NEMO/IKK and the degradation of IB induced
by TNF-. HEK293 cells were transfected with
FLAG-NEMO/IKK, HA-ubiquitin, andHA-A20. 24 h
after transfection cellswere stimulatedwith TNF-
for 5 min or left untreated, as indicated. Cell
extractswere immunoprecipitatedwith anti-FLAG
antibodies (NEMO/IKK) andWesternblottedwith
anti-HA antibodies. Western blots of anti-NEMO/
IKK, -IB, -A20, and -tubulin are shown. C, a cat-
alytically inactive formofA20 (D100A/C103S) does
not de-ubiquitinate NEMO/IKK. Conditions were
similar to those in A, except for the plasmids
encoding HA-A20 C103S, or D100A/C103S. D, A20
D100A/C103S does not inhibit NF-B activation
dependent on TRAF2 in contrast to wild type A20.
Reporter assay was performed by co-transfection
of the Ig-B-luciferase plasmid with combinations
of TRAF2, plus A20-WT, or -D100A/C103S. Values
shown in arbitrary units represent themean S.D.
of three experiments done in triplicate, normal-
ized for -galactosidase expression of a co-trans-
fected pRSV--galactosidase plasmid.
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cultured cells (Fig. 5A). Importantly, A20 also blocks IB degradation
and NEMO/IKK ubiquitination induced by TNF- (Fig. 5B). To dem-
onstrate that the de-ubiquitinating activity of A20 was required for the
observed reduction in NEMO/IKK ubiquitination, we generated two
mutants in the OTU domain of A20, which is the domain responsible
for the de-ubiquitinating activity of A20 (36). We replaced the cysteine
residue of the DXXCmotif with serine (C103S), and both the aspartic
acid and the cysteine residues (D100A/C103S) with alanine and ser-
ine, respectively. The mutation C103S affected the ability of A20 to
de-ubiquitinate NEMO/IKK compared with wild type A20,
whereas the double mutant D100A/C103S resulted in the complete
loss of the de-ubiquitinating activity of A20 on NEMO/IKK (Fig.
5C). As expected, the D100A/C103S mutant was not able to block
the NF-B activity induced by different stimuli, such as TRAF2 (Fig.
5D and data not shown).
These findings strongly suggest that NEMO/IKK is a target of the
de-ubiquitinating activity of A20 and confirmed that the ubiquitination
ofNEMO/IKK is a crucial step in themechanisms ofNF-B activation.
ABIN-1 Mediates the De-ubiquitinating Activity of A20 on
NEMO/IKK—Next, we explored whether ABIN-1 was involved in the
A20-dependent de-ubiquitination ofNEMO/IKK. To this purpose, we
transfected HEK293 cells with a suboptimal amount of A20 and an
increasing amount of ABIN-1 and checked for NEMO/IKK ubiquiti-
nation. We found that ABIN-1 increases the ability of A20 to de-ubiq-
uitinate NEMO/IKK (Fig. 6A). To demonstrate a role for ABIN-1 in
the A20-mediated de-ubiquitination of NEMO/IKK, we generated
siRNA constructs targeting ABIN-1 (ABINi-370 and i-560). Fig. 6B
shows that the construct i-370 knocked-down ABIN-1 expression,
whereas the i-560 construct did not. Then, we evaluated whether inter-
ference of ABIN-1 impairs the de-ubiquitinating activity of A20 on
NEMO/IKK. We co-transfected HEK293 cells with FLAG-NEMO/
IKK and HA-ubiquitin and assessed the de-ubiquitinating activity of
A20 alone or in the presence of either i-370 or i-560 constructs. The
A20-dependent de-ubiquitination of NEMO/IKK decreased only in
the presence of the i-370 construct (Fig. 6C). The i-370 construct led to
a 2-fold increase of both basal and induced (TRAF2 and CIKS) NF-B
activity compared with the empty vector or the i-560 construct, which
we used as controls (Fig. 6D). Accordingly with the data shown in Fig.
3A, interferenceofABIN-1didnot influence theactivationof theNF-B-
dependent transfected IKK. Also in this case, NF-B activity corre-
lated with the levels of NEMO/IKK ubiquitination. In fact, transfected
i-370 increased the ubiquitination of NEMO/IKKwith respect to both
empty vector and i-560 (data not shown). From these experiments, we
concluded that reduced levels of the ABIN-1 protein affect the ability of
FIGURE 6. ABIN-1 participates to the A20-dependent de-ubiquitination of NEMO/IKK. A, ABIN-1 increases the effects of A20 on NEMO/IKK ubiquitination. HEK293 cells were
transfected with FLAG-NEMO/IKK, HA-ubiquitin, suboptimal amounts of HA-A20, and increasing amounts of HA-ABIN. Cell extracts were immunoprecipitated with anti-FLAG
antibodies (NEMO/IKK) and analyzed by Western blot for anti-HA. Western blots of anti-FLAG, -A20, -ABIN, and -tubulin are shown. B, RNA interference of ABIN-1. HEK293
cells were transiently transfected with siRNAs targeting ABIN (ABINi-370 or -560). ABIN expression was analyzed by immunoblotting with antibodies against ABIN. Equiva-
lency of protein loading is shown in the tubulin and NEMO/IKK blots. C, ABIN-1 siRNAs impairs the A20-dependent de-ubiquitination of NEMO/IKK. HEK293 cells were co-
transfectedwith FLAG-NEMO/IKK, HA-ubiquitin, and -A20, plus eitherABINi-370or -560. Cell extractswere immunoprecipitatedwith anti-FLAGantibodies andWesternblottedwith
anti-HA. Western blots of anti-FLAG, -A20, and -tubulin were performed on total extracts. D, ABIN-1 siRNAs increase NF-B activation by TRAF2 and CIKS. HEK293 cells were
co-transfected with TRAF2, CIKS, or IKK, plus Ig-B-luciferase reporter and either ABINi-370 or -570. 24 h after transfection cells were stimulated with TNF for 3 h or left untreated.
Analysis was done as in Fig. 5D. E, RNA interference of A20 impairs the ABIN-1-mediated inhibition of NF-B. Relative reporter activity was evaluated in HEK293 cells co-transfected
with the Ig-B-luciferase reporter, TRAF2, and either A20i or CTLi plasmids. 24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as indicated. Analysis of
luciferase activity was done as above.
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A20 to de-ubiquitinate NEMO/IKK and, consequently the A20-medi-
ated inhibition of NF-B. To further support the functional interplay
between ABIN-1 and A20, we knocked-down A20 (43) and evaluated
the ability of ABIN-1 to interfere with NF-B activation. As shown in
Fig. 6E, ABIN-1 requires A20 to efficiently block NF-B activation
induced by TNF and TRAF2.
DISCUSSION
In the present study, we have performed experiments in yeast, in vitro
and in transfected cells demonstrating that ABIN-1 physically associ-
ates with NEMO/IKK. The functional consequence of this interaction
is that overexpression of ABIN-1 blocks not only activation of NF-B
upstream of the IKK complex, but also NF-B activation mediated by
proteins directly contacting the IKK complex, such as CIKS and TAX.
Indeed, activation of NF-B mediated by overexpression of IKK,
which may be considered functionally downstream of NEMO/IKK, is
not affected by ABIN-1. ABIN-1 has been identified as an A20-binding
protein and its overexpression mimics the inhibitory effect of A20, sug-
gesting that ABIN-1, at least partially, mediates the inhibitory function
of A20. A20 is a TNF- responsive gene that inhibits NF-B-dependent
gene transcription in response to TNF- and other stimuli (37–39).
Given that A20 expression itself is regulated byNF-B, it is possible that
A20 and ABIN-1 participate in a negative feedback regulation of NF-B
activation (40, 41). However, the mechanism by which ABIN-1 partici-
pates in this process is not clear. We provide evidence that ABIN-1 and
A20 co-operate to promote de-ubiquitination of NEMO/IKK, which
results in functional inactivation of NF-B. In fact, recent studies have
indicated ubiquitination as a key event in the regulation of NF-B acti-
vation. For example, A20 modifies the ubiquitination profile of RIP in a
two-step model, by removing the Lys63-linked ubiquitin chain and by
the subsequent ligation of the Lys48-linked ubiquitin chain (30). Simi-
larly, A20 inhibits Toll-like receptor signaling by removing the Lys63-
linked ubiquitin chain from TRAF6 (27). In this context our data dem-
onstrate that NEMO/IKK is an additional target of the
de-ubiquitinating activity of A20. Currently, it is not clear if A20 directly
de-ubiquitinates NEMO/IKK, or it affects the activity of other pro-
tein(s) regulating NEMO/IKK ubiquitination. However, we have now
shown that in cells knocked-down for ABIN-1, we observed a decrease
in the ability of A20 to de-ubiquitinate NEMO/IKK, and that in cells
knocked-down for A20, the inhibitory function of ABIN-1 is impaired.
Altogether our data strongly suggest that ABIN-1 functionally connects
A20 and NEMO/IKK.
In summary, we have identified a previously not reported association
between ABIN-1 and NEMO/IKK and we provide evidence that
ABIN-1 co-operateswithA20 in inhibitingNF-B at the level of the IKK
complex. In addition, we propose that this association could target A20
on NEMO/IKK and interfere with NEMO/IKK ubiquitination, to
negatively regulate NF-B activation.
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Summary. Background: Inﬂammation plays a pivotal role in
atherothrombosis. Recent data indicate that serum levels of
neopterin, a marker of inﬂammation and immune modulator
secreted by monocytes/macrophages, are elevated in patients
with acute coronary syndromes and seem to be a prognostic
marker for major cardiovascular events. The aim of the present
study was to determine whether neopterin might aﬀect the
thrombotic and atherosclerotic characteristics of human cor-
onary artery endothelial cells (HCAECs).Methods and results:
In HCAECs, neopterin induced TF-mRNA transcription as
demonstrated by real time polymerase chain reaction and
expression of functionally active tissue factor (TF) as demon-
strated by procoagulant activity assay, and of cellular adhesion
molecules (CAMs) as demonstrated by FACS analysis, in a
dose-dependent fashion. These neopterin eﬀects were prevented
by lovastatin, a HMG-CoA reductase inhibitor. Neopterin-
inducedTFandCAMs expressionwasmediatedby oxygen free
radicals through the activation of the transcription factor,
nuclear factor-kappa B (NF-jB), as demonstrated by elec-
trophoretic mobility shift assay and by suppression of CAMs
and TF expression by superoxide dismutase and by NF-jB
inhibitor, pyrrolidine-dithio-carbamate ammonium. Con
clusions: These data indicate that neopterin exerts direct eﬀects
on HCAECs by promoting CAMs and TF expression and
support the hypothesis that neopterin, besides representing a
marker of inﬂammation, might be an eﬀector molecule able to
induce a pro-atherothrombotic phenotype in cells of the
coronary circulation.
Keywords: adhesion molecules, atherosclerosis, inﬂammation,
thrombosis, tissue factor.
Introduction
Increasing evidence has assigned a central role to inﬂamma-
tion in both the initiation, and progression of atherosclerosis
linking it to the clinical occurrence of acute coronary
syndromes; in the last few years, it has been demonstrated
that selected markers of inﬂammation might play an active
role in modulating these phenomena [1–3]. In recent years,
some epidemiological studies have pointed out the associ-
ation existing between increased plasma levels of neopterin, a
marker of inﬂammation released by activated macrophages,
and coronary artery disease and acute coronary syndromes
[4–8]. However, despite these clinical data, to date the
possible pathophysiological links existing between increased
plasma levels of neopterin and the occurrence of major
cardiovascular events are still unknown.
Increasing evidence suggest an important role for adhe-
sion molecules (CAMs) in the early stages and in the
progression of atherosclerosis, thus triggering the develop-
ment of atherosclerotic complications as acute coronary
syndromes [9,10].
Tissue factor (TF) plays a pivotal role in the pathophys-
iology of acute coronary syndromes by triggering the
formation of intracoronary thrombi following endothelial
injury [11–12]. In this respect, endothelial cells, being
normally exposed to the blood stream, express TF on their
membrane only when activated after exposure to speciﬁc
stimuli [13–14].
In the present study, we provide support in vitro for the
hypothesis that neopterin, another marker of vascular or
systemic inﬂammation, might play an active role in the
pathophysiology of coronary events by induction of CAMs
and TF, thus promoting both pro-atherosclerotic and pro-
thrombotic state in human coronary endothelial cells.
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Methods
The investigation conforms with theGuide for the Care and Use
of Laboratory Animals published by the US National Institutes
of Health.
Experiments were performed using human coronary artery
endothelial cells (HCAECs; Cambrex Bio Science, Walkers-
ville, MD, USA). Cells were grown in EGM 2 medium
(Cambrex Bio Science) with endothelial cell growth supplement
and 10% fetal serum. Cells were used at passages 2–5.
Neopterin (Sigma Chemical Co., St Louis, MO, USA) was
used in all studies described.Given the concern surrounding the
potential contamination of neopterin with endotoxin, we
analyzed our substance and found endotoxin level to
be < 0.125 EU mL)1 (< 12.5 pg mL)1) by Limulus assay
(BioWhittaker, Walkersville, MD, USA). All media, and water
were also tested and endotoxin level found to
be < 0.125 EU mL)1.
Effects of neopterin on TF transcription
Preliminary dose–response effects of neopterin on TF-mRNA
transcription were evaluated by semi-quantitative polymerase
chain reaction (PCR). Then, the effect of neopterin on TF-
mRNA was investigated by real-time reverse transcription
(RT) analysis as previously described [15]. HCAECs were
incubated with neopterin (20 nM, concentration chosen on the
basis of semi-quantitative results). Thirty minutes after the
addition of neopterin, cells were washed with phosphate
buffered saline (PBS) and then fresh medium (EGM 2
containing 0.1% serum) was added. Total mRNA was
extracted at baseline, 30, 60, and 120 min after neopterin
stimulation and TF mRNA levels were examined by RT and
PCR by LightCycler (Roche Diagnostics, Basel, Switzerland).
In positive control experiments, HCAECs were incubated for
30 minwith lipopolysaccharide (LPS) (50 lg mL)1) for 30 min
and then mRNA was extracted at 60 min.
Dose–response effects of neopterin on TF activity
HCAECs were incubated with increasing concentration of
neopterin (10, 20, 50, 100 nM) for 6 h. TF activity was
determined by a two-step colorimetric assay, based on the
ability of TF to promote generation of coagulation factor Xa,
as previously described [15].
To evaluate whether neopterin-induced expression of TF
resulted from de novo synthesis of this protein, in another set
of experiments cells were preincubated with cycloheximide
(CE) (10 lg mL)1), an inhibitor of protein synthesis, or with
5, 6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB,
10 lg mL)1), an inhibitor ofDNA transcription, before adding
neopterin (20 nM). Additional control experiments included
cells preincubated with a mouse monoclonal antibody against
human TF (American Diagnostica Inc, Greenwich, CT, USA).
Moreover, in additional experiments we have investigated the
effect of lovastatin on neopterin-induced TF expression.
HCAECs were cultivated in medium enriched with increasing
lovastatin concentrations (0.1, 1, 5, and 10 lM) for 24 h, then
stimulated with neopterin (20 nM) for 6 h and ﬁnally processed
as above to evaluate TF activity.
As it has been documented that promotion of oxidative
stress is a fundamental principle of neopterin’s mode of
operation [16], in another set of experiments, TF activity was
evaluated as above, but in HCAECs preincubated for 30 min
in the presence of the free radical scavenger superoxide
dismutase (SOD; 500 U mL)1). Finally, because neopterin is
able to induce nitric oxide (NO) synthase gene in vascular cells
[17], it has been investigated whether NO might play a role in
neopterin-induced TF activity. Thus, TF activity has been
evaluated in HCAECs preincubated with non-selective NO
synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME,
0.1, 1, and 10 lM).
Positive control experiments included cells incubated for 6 h
with LPS (50 lg mL)1). Six different experiments were
performed for each experimental condition.
Effects of neopterin on adhesion molecules expression
HCAECs were incubated with different doses of neopterin (10,
20, 50, and 100 nM) or with LPS (50 lg mL)1) for 12 h. Cells
were then detached with 10 mmol L)1 EDTA in PBS (without
trypsin) and stained withR-phycoerythrin–labeled monoclonal
antibodies (Pharmingen, Franklin Lakes, NJ, USA) against
VCAM-1 (CD106) or ICAM-1 (CD54), or with the appropri-
ate isotype IgG (phycoerythrin or FITC) as control. Fluores-
cence intensity of 9000 cells for each sample was quantiﬁed by a
FACSCalibur analyzer (Becton-Dickinson, Franklin Lakes,
NJ, USA). Moreover, in additional experiments we have
investigated the effect of lovastatin on neopterin-induced
CAMs expression. HCAECs were cultivated in medium
enriched with increasing lovastatin concentrations (0.1, 1, 5,
and 10 lM) for 24 h, then stimulated with neopterin (20 nM)
for 12 h and ﬁnally processed as above to evaluate VCAM-1
and ICAM-1 expression.
Finally, as described above, CAMs expression has been
evaluated in HCAECs cultivated in the presence of the free
radical scavenger SOD (500 U mL)1), and in cells preincubat-
ed with non-selective NO synthase inhibitor L-NAME (0.1, 1,
and 10 lM). All experiments were performed in triplicate.
Effects of neopterin on nuclear factor-kappa B (NF-jB)
activation
To elucidate the intracellular mechanisms by which neopterin
induced TF, ICAM-1, and VCAM-1 on endothelial cells, in
another set of experiments, we tested the hypothesis that
NF-jB might be involved in mediating this phenomenon.
The levels of NF-jB proteins in nuclear extracts from the
cells were analyzed by electrophoretic mobility shift assay
(EMSA).HCAECs starved in serum-freemediumwere washed
and incubated with different doses of neopterin (10, 20, 50, and
100 nM) for 30 min. Cells incubated with 50 lg mL)1 of LPS
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served as positive control. Moreover, to elucidate whether
lovastatin could modulate NF-jB activity induced by neo-
pterin, in another set of experiments HCAECs were cultivated
in medium enriched with lovastatin (10 lM) for 24 h and then
stimulated with neopterin (20 nM) for 30 min. Finally, in an
additional set of experiments, NF-jB activity was measured in
cells preincubated with SOD (500 U mL)1) or in the presence
of L-NAME, (1 lM), before adding neopterin (20 nM for
30 min). Control experiments included cells preincubated
with pyrrolidine dithio carbamate ammonium (PDTC,
100 lmol L)1), an inhibitor of NF-jB activation, for 60 min
before stimulation with neopterin as described above. Nuclear
proteins from these cells were isolated as previously described
[18] and were subjected to EMSA using 32P-labeled NF-jB
double-strand oligonucleotide (5¢-ACTTGAGGGGACTTT-
CCCAGGC-3¢). Nuclear proteins were incubated with oligo-
nucleotide for 30 min, subjected to gel electrophoresis and
ﬁnally autoradiographed.
In additional experiments, the protein levels of IjB-a were
determined by Western blot. A total of 20 lg of cytoplasmatic
proteins was separated on a 15% SDS–PAGE and transferred
to a PVDFmembrane. The membrane was blocked in washing
solution with 5% non-fat dried milk for 30 min at 37 C, then
it was incubated ﬁrst with 1 lg mL)1 of primary antibody
overnight at 4 C and then with a peroxidase-conjugated
secondary antibody for 30 min at 37 C. The bands were
detected by colorimetry. All experiments were performed in
triplicate.
Statistical analysis
Data are presented as mean ± SD. Differences between
groups were determined by a one-way ANOVA followed by a
Student’s t-test with Bonferroni’s correction. AP-value < 0.05
was considered statistically signiﬁcant.
Results
Effects of neopterin on TF transcription
TF mRNA was undetectable in unstimulated endothelial
cells as expected [19]. Incubation with neopterin, caused a
progressive, time-dependent, increase in TF mRNA levels,
as compared to unstimulated cells. The peak of TF mRNA
levels was observed after 60 min of neopterin incubation,
while at 120 min, TF mRNA levels started decreasing
(Fig. 1).
Dose–response effects of neopterin on TF expression
TF antigen was not expressed on HCAEC at baseline, and,
when they were exposed to neopterin, the antigen levels
evaluated by FACS analysis, increased (data not shown).
Endothelial cells showed undetectable TF activity at baseline,
and exposure to neopterin induced a signiﬁcant increase in TF
activity (Fig. 2A).
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Fig. 1. Eﬀects of neopterin on tissue factor (TF) transcription in human
coronary artery endothelial cells (HCAECs) assessed by real time quan-
titative polymerase chain reaction. TF mRNA was undetectable at base-
line (Base) in unstimulated HCAECs. Incubation with neopterin, caused a
progressive, time-dependent, increase in TFmRNA levels, as compared to
unstimulated cells. The peak of TF mRNA levels was observed after
60 min of neopterin incubation while at 120 min, TFmRNA levels started
decreasing. Each bar represents the mean ± SD of three diﬀerent
experiments.
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Fig. 2. Dose-response eﬀects of neopterin (10, 20, 50, and 100 nM for 6 h)
on tissue factor (TF) activity in human coronary artery endothelial cells
(HCAECs), determined by a two-step colorimetric assay based on the
ability of TF/factor (F) VIIa to promote generation of coagulation FXa.
Neopterin induced a dose-response increase in TF activity (A). Control
experiments performed by preincubating endothelial cells with cyclohexi-
mide or with 6-dichloro-1-b-D-ribofuranosylbenzimidazole (B), showed
that neopterin-induced TF expression required de novo mRNA tran-
scription and protein synthesis. Pretreatment of endothelial cells with
superoxide dismutase (SOD), an oxygen free radicals scavenger, or with
pyrrolidine dithio carbamate ammonium (PDTC), an inhibitor of nuclear
factor-kappa B (NF-jB) activation, decreased the expression of TF (B).
Each bar represents the mean ± SD of six diﬀerent experiments. * ¼
P < 0.05 vs. corresponding value at baseline.
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Control experiments, performed by preincubating HCAECs
with a mouse monoclonal antibody directed against human
TF, conﬁrmed that the procoagulant activity measured was
actually due to TF expression on cell surface after neopterin
induction (data not shown).
In additional experiments, preincubation with CE, an
inhibitor of protein synthesis, or with DRB, an inhibitor of
DNA transcription, completely inhibited TF expression
(Fig. 2B). These data suggest that neopterin is able to induce
de novo synthesis of TF, and these new TF molecules are then
expressed in an active form on the cell surface.
Moreover, different concentrations of lovastatin had similar
effects in prevent signiﬁcantly neopterin-induced TF expression
(Fig. 3A). Interestingly, in cells preincubated with the free
radical scavenger SOD, neopterin failed to induce TF expres-
sion, suggesting that these high reactive oxygen derived
molecules play an important role in mediating neopterin effects
(Fig. 2B). Vice versa, inhibition of NO synthesis by L-NAME
did not interfere with neopterin-induced TF expression,
suggesting that NO is not involved in mediating the neopterin
effects on TF expression (Fig. 3A).
To investigate whether lovastatin concentrations used in our
experiments exerted toxic effects on HCAECs, trypan blue
exclusion assays were performed at conclusion of the experi-
ments with increasing lovastatin concentrations and demon-
strated > 95% viability with no differences between control
and statin-treated group (data not shown).
Effects of neopterin on adhesion molecules
HCAECs expressed low basal levels of ICAM-1 and VCAM-1.
Incubation with neopterin induced expression of both adhesion
molecules on cell surface. Conversely, pretreatment of endot-
helial cells with lovastatin as well as with SOD decreased the
expression of ICAM-1 as well as of VCAM-1 (Figs 3B and 4).
Inhibition of NO synthesis with L-NAME had no effect on
neopterin-induced CAMs expression (Fig. 3B).
Neopterin and activation of NF-jB
To investigate whether expression of TF, ICAM-1 and
VCAM-1 induced by neopterin involved activation of the
NF-jB pathway, we employed EMSA on nuclear extracts
Fig. 3. Eﬀects of Lovastatin and of N-nitro-L-arginine methyl ester
(L-NAME) on neopterin-induced expression of tissue factor (TF) and
cellular adhesion molecules (CAMs). Neopterin-induced TF expression
was prevented by lovastatin at diﬀerent concentrations (A). Inhibition of
nitric oxide (NO) synthesis by L-NAME did not interfere with neopterin-
induced TF expression (A). Similarly, lovastatin prevented neopterin-in-
duced CAMs expression (B) and inhibition of NO synthesis by L-NAME
did not interfere with neopterin-induced expression of the adhesion
molecules (B).
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Fig. 4. Dose–response eﬀects of neopterin (10, 20, 50 and 100 nM for
12 h) on adhesion molecules expression in human coronary endothelial
cells, determined by FACS analysis. Neopterin induced expression of
ICAM-1 and VCAM-1 on cell surface. Conversely, pretreatment of
endothelial cells with superoxide dismutase (SOD) or with pyrrolidine
dithio carbamate ammonium (PDTC) an inhibitor of NF-jB activation,
decreased the expression of ICAM-1 as well as of VCAM-1. Each bar
represents the mean ± SD of six experiments. * ¼ P < 0.05 vs. corre-
sponding value at baseline. #P < 0.05 vs. neopterin (20 and 50 nM).
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obtained from cells stimulated with it. As shown in Fig. 5,
NF-jB was activated after incubation with the macrophage
derivative substance. In fact, neopterin was able to induce a
distinct shifted band in stimulated cells, while no shift could be
observed in unstimulated, control cells. Preincubation of cells
with lovastatin and with SOD diminished NF-jB activation
induced by neopterin (Figs 5 and 6). Moreover, in cells
incubated with the inhibitor of NO synthesis, NF-jB was
activated anyway by neopterin stimulation (Fig. 6). Interest-
ingly, pretreatment of cells with PDTC, signiﬁcantly reduced
TF activity, and CAMs expression (Figs 2B and 4).
To investigate the correlation of NF-jB activation with
changes of the expression of IjB, levels of this factor were
determined by Western blot analysis. Elevated levels of IjB-a
were detected at baseline, in unstimulated cells, as expected.
Conversely, IjB-a levels decreased after neopterin stimulation.
Similarly, IjB-a levels decreased after neopterin stimulation in
cells preincubated with L-NAME, while any change in IjB-a
levels were observed after cell pretreatment with SOD or with
lovastatin, (Fig. 7). These changes in IjB-a levels were time
coincided with changes of NF-jB levels described above.
Discussion
The main ﬁndings of the present study are: (i) exposure of
HCAECs to neopterin, a pteridine compound released by
activated macrophages and known as marker of inﬂammation,
induces expression of adhesionmolecules; (ii) neopterin induces
TF-mRNA transcription and de novo synthesis of functionally
active TF; and (iii) these phenomenon appear to be regulated
by oxygen free radicals through activation of NF-jB pathway.
Over the past few years it has become clear that inﬂamma-
tion plays an important pathophysiological role not only in
initiating the pathogenesis of atherosclerosis, but also in
developing its complications, such as the occurrence of acute
coronary syndromes [1–3]. More recently, it has been reported
an association between a marker of inﬂammation, neopterin,
and coronary artery disease. In particular, Scumacher et al. [4]
have shown that neopterin levels are increased in patients with
chronic and acute coronary syndromes, while another report
has demonstrated that serum levels of this substance are
associated with the presence of complex vulnerable coronary
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Fig. 5. Eﬀects of neopterin on nuclear translocation of NF-jB. Nuclear
extracts were prepared from untreated endothelial cells (Base) or cells
treated with increasing concentrations of neopterin (10, 20, 50, and
100 nM, for 30 min) or lipopolysaccharide as a positive control. The
NF-jB activation was determined by electrophoretic mobility shift assay.
Neopterin was able to induce a distinct shifted band in stimulated cells,
while no shift could be observed in unstimulated, control cells. Pre-
incubation of cells with lovastatin (10 lM) diminished NF-jB activation
induced by neopterin (20 nM). Data are representative of three separate
experiments. Top, result of a representative experiment, bottom, summary
of data from three separate experiments (mean ± SD).
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Fig. 6. Eﬀects of superoxide dismutase (SOD) and of N-nitro-L-arginine
methyl ester (L-NAME) on the activation of NF-jB by Neopterin. Pre-
incubation of human coronary artery endothelial cells (HCAECs) with
SOD prevented neopterin activation of the transcription factor NF-jB.
Vice versa, L-NAME did not prevent NF-jB activation. Top, result of a
representative experiment, bottom, summary of data from three separate
experiments (mean ± SD).
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Fig. 7. Activation of IjB. Cellular extracts were prepared from untreated
endothelial cells (Base) or cells treated with neopterin (Neo, 10 nM, for
30 min). In additional experiments endothelial cells were preincubated
with superoxide dismutase (SOD), N-nitro-L-arginine methyl ester (L-
NAME) or with Lovastatin (Lova) and then stimulated with Neopterin as
above. Elevated levels of IjB were detected at baseline, in unstimulated
cells (Base). Conversely, IjB levels decreased after neopterin stimulation
and in cells preincubated with L-NAME. Any change in IjB-a levels were
observed after cell pretreatment with SOD or with Lova. Data are rep-
resentative of three separate experiments. Top, result of a
representative experiment, bottom, summary of data from three separate
experiments (mean ± SD).
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lesions in patients with unstable angina [5]. Moreover,
Zouridakis et al. [6] have demonstrated that increased levels
of serum neopterin are associated with a rapid CAD progres-
sion. Finally a recent report by Avanzas et al. [7] has shown
that high neopterin levels are an independent predictor of
major adverse coronary events in patients with CAD. Despite
these growing clinical observations, the literature about neo-
pterin and coronary artery disease is still scanty and our
understanding of the possible underlying mechanisms of the
pathophysiological links between increased neopterin serum
levels and the occurrence of acute coronary syndromes still
remains largely incomplete.
In the present study we have demonstrated, using a cell
culture model, that neopterin induces TF expression in
HCAECs in a dose-dependent fashion and that this pheno-
menon appears to be mainly related to the synthesis of new TF
molecules, as CE and DRB, an inhibitor of protein synthesis
and mRNA transcription, respectively, completely inhibited
the neopterin effects on TF expression.
Of particular pathophysiological interest was the ﬁnding that
these newly formed TF molecules were functionally active, as
demonstrated by the parallel increase in TF-procoagulant
activity, which was detectable on the surface of stimulated cells.
This observation might have important pathophysiological
consequences, considering that endothelial cells are at the
interface between the vessel wall and circulating blood coagu-
lation factors; thus, neopterin seems to be able to induce a
procoagulant phenotype in endothelial cells.
Moreover, we have demonstrated that neopterin causes the
up-regulation of expression of CAMs such as ICAM 1 and
VCAM 1 on endothelial cell surface. These CAMs are
responsible of attachment and transendothelial migration of
leukocytes [20], and are known to be directly involved in the
pathogenesis of atherosclerosis mediating many of the stages of
the disease progression [20]. In addition, serum concentration
of CAMs are strongly correlated with CAD [21] and with the
risk of cardiovascular events [22].
Studies dealing with the potential effects of neopterin
provided evidence that promotion of oxidative stress is a
fundamental principle of neopterin’s mode of action [16]. In
line with these previous observations, we have demonstrated
that neopterin-induced TF and CAM expression in endothelial
cells is mediated by oxygen free radicals and that the
transcription factor NF-jB is the potential link in modulating
these phenomena. Indeed SOD, a scavenger for oxygen-free
radicals, signiﬁcantly reduced NF-jB activation as well as TF
and CAM expression. In addition, neopterin effects on TF and
CAM expression were signiﬁcantly reduced by PDTC, a
selective NF-jB inhibitor.
Several lines of evidence indicate that the activation of NF-
jBmay be controlled by the redox status of cells [23]. NF-jB is
present but inactive in the cytoplasm of many cells such as
lymphocytes, monocytes, endothelial and smooth muscle cells.
It seems to be activated by several stimuli during the
atherosclerotic process and it is responsible of the expression
of inﬂammatory proteins that actively participate in this
process and might lead to plaque disruption and acute
coronary events [24]. In particular, activation of NF-jB
stimulates the promoter for TF [25], for CAMs [26] as well as
for NO genes [27]. Previous evidence has already suggested that
neopterin induces NF-jB activation in smooth muscle cells,
and consequently promotes NOS gene expression [17,28].
However, in the present study we have demonstrated for the
ﬁrst time that activation of the NF-jB pathway by neopterin
causes expression of TF and of ICAM-1 and VCAM-1. These
proteins are actively involved in the pathophysiology of
atherosclerosis and its complication. Again, neopterin effects
on TF and CAMs expression seem not correlated to neopterin-
induced NO synthesis as NO inhibitor L-NAME did not
reduce TF and CAMs levels in neopterin-stimulated HCAECs.
Considering that NF-jB has been demonstrated to be
activated in the peripheral monocytes [29], as well as within the
unstable plaques of patients with acute coronary syndromes
[30], the ﬁnding observed in our study that neopterin induces
TF and CAM expression via activation of NF-jB might
explain, at least in part, why patients with CAD and elevated
neopterin serum levels have a worse clinical outcome than
patients with normal serum levels.
Importantly, we demonstrated that the effects of neopterin
on endothelial cell activation and on expression of TF and
CAMs can be prevented by HMG-CoA reductase inhibition.
In particular, we wanted to study whether a lipid-lowering
agent, lovastatin possessed anti-inﬂammatory proprieties inde-
pendently of its lipid-lowering action, and so we have
investigated its effects on neopterin-induced NF-jB activation.
Previous reports have shown that statins exert protective effects
on endothelial cells, allowing restoration of their functions [31].
Speciﬁcally, Ortego et al. [32] have shown that atorvastatin can
reduce the expression of some chemokines and cytokines with
pro-inﬂammatory effects in several cell types through inhibition
of NF-jB pathway, while Lin et al. [33] have recently
demonstrated that lovastatin reduces the effects induced by
C-reactive protein in human vascular endothelial cells. In the
present study, lovastatin signiﬁcantly diminished NF-jB acti-
vation induced by neopterin, thus preventing the effects of this
marker of inﬂammation on endothelial cells in vitro, avoiding
their dysfunction.
Potential limitations of the present study
The present study, although in vitro, describes a potential new
link between inﬂammation (as reﬂected by high neopterin
levels) and atherothrombosis. The evidence that neopterin
exerts direct effects on coronary artery endothelial cells, leading
to TF and CAM expression on their surface, might explain, at
least in part, why patients with increased plasma levels of
neopterin have a worse clinical outcome than patients with
normal neopterin levels, via a broad activation of the coronary
endothelial cells ultimately increasing the risk to develop new
coronary events. These ﬁndings clearly indicate a direct effect
of neopterin in promoting atherothrombosis, but the clinical
relevance of this pathophysiological mechanism might appear
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questionable, considering that some of the experiments
performed in the present study employed high neopterin
concentrations. Plasma neopterin concentrations in healthy
controls range between 1.0 and 9.0 nM [34], and increase to
about 15.0 nM in patients with coronary artery disease [7].
Thus, this discrepancy is only apparent, as it should be
emphasized that the transcription factor NF-jB was activated
at neopterin concentrations as low as 10 nM, which are well
within the range observed in patients with increased cardio-
vascular risk. Moreover, it should be kept in mind that plasma
neopterin concentrations might only loosely reﬂect tissue
neopterin levels and that locally, that is, within the arterial
wall, neopterin might be present in amounts sufﬁciently high to
exert relevant cellular effects. Indeed, coronary plaques of
patients with acute coronary syndromes have more extensive
macrophage-rich areas that those with stable angina [35].
Again, vulnerable plaques reﬂect increased numbers of macro-
phages and activated lymphocytes [36]. Thus, it is very
probably that, at the site of vulnerable plaque, local neopterin
concentrations are signiﬁcantly higher than that measured in
peripheral blood. Therefore, we might speculate that activated
monocytes/macrophages in atherosclerotic lesions signiﬁcantly
increase local neopterin levels; thus, they induce expression of
ICAM-1 and VCAM-1 on endothelial cells in coronary
circulation. Increased expression of CAMs may result in
increase binding of T lymphocytes, platelets and other mono-
cytes (that, once activated, further increase local neopterin
concentration), key players in the atherosclerotic process. The
endothelial activation causes expression of TF, promoting an
endothelial pro-thrombotic phenotype, and ﬁnally leading to
the occurrence of acute coronary syndromes.
In conclusion, the present study, although in vitro, describes
the close relationship between inﬂammation and athero-
thrombosis, providing for the ﬁrst time support to the view
that neopterin might be not only a risk marker but it may
indeed be a participant and culprit in atherogenesis and
thrombosis. Further studies are warranted to clarify whether
these mechanisms are also important in the clinical setting.
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